U.S. patent application number 13/642790 was filed with the patent office on 2013-08-15 for lysosomal storage disease enzymes.
This patent application is currently assigned to SYNAGEVA BIOPHARMA CORP.. The applicant listed for this patent is Alex J. Harvey, Anthony Quinn. Invention is credited to Alex J. Harvey, Anthony Quinn.
Application Number | 20130209436 13/642790 |
Document ID | / |
Family ID | 44834852 |
Filed Date | 2013-08-15 |
United States Patent
Application |
20130209436 |
Kind Code |
A1 |
Quinn; Anthony ; et
al. |
August 15, 2013 |
LYSOSOMAL STORAGE DISEASE ENZYMES
Abstract
The present invention provides compositions of recombinant human
lysosomal acid lipase having particular glycosylation patterns for
internalization into target cells, a vector containing the nucleic
acid encoding human lysosomal acid lipase, a host cell transformed
with the vector, pharmaceutical compositions comprising the
recombinant human lysosomal acid lipase and method of treating
conditions associated with lysosomal acid lipase deficiency.
Inventors: |
Quinn; Anthony; (Chestnut
Hill, MA) ; Harvey; Alex J.; (Athens, GA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Quinn; Anthony
Harvey; Alex J. |
Chestnut Hill
Athens |
MA
GA |
US
US |
|
|
Assignee: |
SYNAGEVA BIOPHARMA CORP.
Lexington
MA
|
Family ID: |
44834852 |
Appl. No.: |
13/642790 |
Filed: |
April 23, 2011 |
PCT Filed: |
April 23, 2011 |
PCT NO: |
PCT/US2011/033699 |
371 Date: |
April 30, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61343177 |
Apr 23, 2010 |
|
|
|
61396376 |
May 26, 2010 |
|
|
|
61403011 |
Sep 9, 2010 |
|
|
|
61456014 |
Oct 29, 2010 |
|
|
|
61432372 |
Jan 13, 2011 |
|
|
|
Current U.S.
Class: |
424/94.6 ;
435/198; 800/19 |
Current CPC
Class: |
A01K 2267/01 20130101;
A61P 9/00 20180101; A61P 43/00 20180101; A61K 38/465 20130101; A61P
3/06 20180101; A61K 31/194 20130101; C12N 2740/10041 20130101; A01K
2217/052 20130101; C12Y 301/01013 20130101; A01K 2227/30 20130101;
A61K 38/385 20130101; A01K 67/0278 20130101; A61P 35/04 20180101;
A61P 3/00 20180101; A61P 1/00 20180101; A61P 1/16 20180101; C12N
9/20 20130101 |
Class at
Publication: |
424/94.6 ;
435/198; 800/19 |
International
Class: |
C12N 9/20 20060101
C12N009/20; A61K 38/38 20060101 A61K038/38; A61K 31/194 20060101
A61K031/194; A61K 38/46 20060101 A61K038/46 |
Claims
1.-72. (canceled)
73. A composition comprising an isolated human recombinant
lysosomal acid lipase (rhLAL) comprising one or more N-glycan
structures, wherein the rhLAL is N-linked glycosylated at
Asn.sup.15, Asn.sup.80, Asn.sup.140, Asn.sup.252 and Asn.sup.300 of
SEQ ID NO:2.
74. The composition of claim 73, wherein the LAL comprises a
N-glycan structure comprising a phosphorylated mannose at
Asn.sup.80, Asn.sup.140 or Asn.sup.252 of SEQ ID NO:2.
75. The composition of claim 74, wherein the LAL comprises an
N-glycan structure comprising a phosphorylated mannose at
Asn.sup.80.
76. The composition of claim 75, wherein at least 30% of N-glycan
structures associated with Asn.sup.80 have a phosphorylated
mannose.
77. The composition of claim 74, wherein the LAL comprises an
N-glycan structure comprising a bisphosphorylated mannose at
Asn.sup.80.
78. The composition of claim 74, wherein the LAL comprises an
N-glycan structure comprising a phosphorylated mannose (M6P) at
Asn.sup.140.
79. The composition of claim 78, wherein between about 10% and
about 50% of N-glycan structures associated with Asn.sup.140
comprise a M6P.
80. The composition of claim 74, wherein the LAL comprises an
N-glycan structure comprising a phosphorylated mannose (M6P) at
Asn.sup.252.
81. The composition of claim 80, wherein at least 50% of the
N-glycan structures at Asn.sup.252 comprise a M6P.
82. The composition of claim 73, wherein the LAL comprises an
N-glycan structure comprising a high-mannose group at Asn.sup.80 or
Asn.sup.252.
83. The composition of claim 82, wherein the high mannose-group
comprises 6, 7, 8, 9 or 10 mannose.
84. The composition of claim 83, wherein the LAL comprises an
N-glycan structure comprising 7, 8 or 9 mannose at Asn.sup.80.
85. The composition of claim 83, wherein the LAL comprises an
N-glycan structure comprising 7, 8 or 9 mannose at Asn.sup.252.
86. The composition of claim 73, wherein the LAL comprises an
N-glycan structure comprising a terminal galactose at Asn.sup.15,
Asn.sup.140 or Asn.sup.300.
87. The composition of claim 86, wherein about 2% to about 10% of
N-glycan structures associated with Asn.sup.15 comprise a terminal
galactose.
88. The composition of claim 87, wherein less than 5% of N-glycan
structures associated with Asn.sup.140 comprise a terminal
galactose.
89. The composition of claim 88, wherein the LAL comprises a
terminal galactose at Asn.sup.300.
90. The composition of claim 73, wherein Asn.sup.51 of the LAL is
unglycosylated.
91. The composition of claim 73, wherein the LAL comprises N-glycan
structures having no xylose and less than 15% of the N-glycan
structures contain sialic acid.
92. The composition of claim 91, wherein the LAL comprises N-glycan
structures having no xylose and less than 10% of the N-glycan
structures contain sialic acid.
93. The composition of claim 92, wherein the LAL comprises N-glycan
structures having no xylose and less than 5% of the N-glycan
structures contain sialic acid.
94. The composition of claim 73, wherein the LAL contains no sialic
acid and no xylose.
95. The composition of claim 73, wherein the LAL contains no
fucose.
96. The composition of claim 73, wherein the LAL comprises a
N-linked glycosylation profile as follows: a) at Asn.sup.15,
GlcNAc4Man3GlcNAc2, or Gal1GlcNAc4Man3GlcNAc2; b) at Asn.sup.80,
Phos2Man7GlcNAc2; c) at Asn.sup.140, Phos1Man6GlcNAc2,
GlcNAc1Phos1Man6GlcNAc2; Man3GlcNAc2; GlcNAc2Man3GlcNAc2;
GlcNAc3Man3GlcNAc2; GlcNAc4Man3GlcNAc2, or Gal1GlcNAc4Man3GlcNAc2;
d) at Asn.sup.252, Man7GlcNAc2, Man8GlcNAc2, Man9GlcNAc2,
Phos1Man8GlcNAc2, or Phos1Man9GlcNAc2; and e) at Asn.sup.300,
GlcNAc2Man3GlcNAc2, GlcNAc3Man3GlcNAc2, GlcNAc4Man3GlcNAc2,
Gal1GlcNAc4Man3GlcNAc2, GlcNAc5Man3GlcNAc2, Gal1GlcNAc5Man3GlcNAc2,
GlcNAc6Man3GlcNAc2, or Gal1GlcNAc6Man3GlcNAc2, wherein Man=mannose,
GlcNAc=N-Acetyl Glucosamine Phos=phosphate Gal=galactose.
97. The composition of claim 73, wherein the LAL is produced in a
germ-line transgenic avian.
98. The composition of claim 97, wherein the LAL is produced from
an oviduct cell of the germ-line transgenic avian.
99. The composition of claim 98, wherein the avian is a
chicken.
100. A composition comprising a mixture of recombinant human
lysosomal acid lipase (LAL), the mixture comprising at least two
human LAL selected from the group consisting of SEQ ID NO:2, SEQ ID
NO:3, SEQ ID NO:4 and SEQ ID NO:19.
101. The composition of claim 100, wherein the mixture of human LAL
comprises N-glycans selected from the following structures:
##STR00006## ##STR00007## ##STR00008## ##STR00009##
102. A method of producing glycosylated human lysosomal acid lipase
(LAL), comprising creating a germ-line transgenic avian which
contains a transgene encoding human LAL operably linked to a
promoter and expresses the human LAL in an oviduct cell, wherein
the LAL is glycosylated in the oviduct cell and deposited into a
hard shell egg laid by the transgenic avian; and obtaining the LAL
from egg white of the egg.
103. A transgenic avian which produces glycosylated human lysosomal
acid lipase (LAL) according to claim 73 or claim 100.
104. An egg laid by a transgenic avian according to claim 103.
105. A pharmaceutical formulation comprising a composition
according to claim 73 or claim 100 in combination with a
pharmaceutically acceptable carrier, diluent or excipient.
106. The pharmaceutical formulation of claim 105, wherein the
formulation comprises at least one agent selected from the group
consisting of trisodium citrate dehydrate, citric acid and human
serum albumin.
107. The pharmaceutical formulation of claim 105, wherein the
formulation is provided in an aqueous solution maintained at pH
between about 5.6 and about 6.2.
Description
RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional
Application No. 61/343,177, filed on Apr. 23, 2010, U.S.
Provisional Application No. 61/396,376, filed on May 26, 2010, U.S.
Provisional Application No. 61/403,011, filed on Sep. 9, 2010, U.S.
Provisional Application No. 61/456,014, filed on Oct. 29, 2010,
U.S. Provisional Application No. 61/432,372, filed on Jan. 13,
2011. The entire teachings of the above applications are
incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] Lysosomal Acid Lipase (LAL) deficiency is a very rare
lysosomal storage disease (LSD) characterized by a failure to
breakdown cholesteryl esters (CE) and triglycerides (TAG) in
lysosomes due to a deficiency of the enzyme. LAL deficiency
resembles other lysosomal storage disorders with the accumulation
of substrate in a number of tissues and cell types. In LAL
deficiency substrate accumulation is most marked in cells of the
reticuloendothelial system including Kupffer cells in the liver,
histiocytes in the spleen and in the lamina propria of the small
intestine. Reticuloendothelial cells express the macrophage
mannose/N-acetylglucosamine receptor (also known as macrophage
mannose receptor or MMR, CD206), which mediates binding, cell
uptake and lysosomal internalization of proteins with GlcNAc or
mannose terminated N-glycans, and provides a pathway for the
potential correction of the enzyme deficiency in these key cell
types.
[0003] LAL deficiency is a multi-system disease that most commonly
manifests with gastrointestinal, liver and cardiovascular
complications and is associated with significant morbidity and
mortality. The clinical effects of LAL deficiency are due to a
massive accumulation of lipid material in the lysosomes in a number
of tissues and a profound disturbance in cholesterol and lipid
homeostatic mechanisms, including substantial increases in hepatic
cholesterol synthesis. LAL deficiency presents of at least two
phenotypes, Wolman Disease (WD) and Cholesteryl Ester Storage
Disease (CESD).
[0004] Wolman Disease is the most aggressive presentation of LAL
deficiency. This phenotype is characterized by gastrointestinal and
hepatic manifestations including growth failure, malabsorption,
steatorrhea, profound weight loss and hepatomegaly. Wolman Disease
is rapidly progressive and fatal usually within the first year of
life. Case report review indicates survival beyond 12 months of age
is highly unusual for patients who present with growth failure due
to LAL deficiency in the first year of life. In this most
aggressive form, growth failure is the predominant clinical feature
and is a key contributor to the early mortality. Hepatic
involvement as evidenced by liver enlargement and elevation of
transaminases is also common in infants. Physical findings include
abdominal distention with hepatomegaly and splenomegaly, and
radiographic examination often reveals calcification of the adrenal
glands. Laboratory evaluations typically reveal elevated levels of
serum transaminases and absent or markedly reduced LAL enzyme
activity. Elevated blood levels of cholesterol and triglycerides
are also seen in patients.
[0005] Current treatment options for Wolman Disease are extremely
limited. Antibiotics are administered to infants with pyrexia
and/or evidence of infection. Steroid replacement therapy for
adrenal insufficiency and specialized nutritional support may be
prescribed and while there is no evidence that these interventions
prevents death, it is also unclear at present if they have an
impact on short term survival. In a series of four patients with
LAL deficiency treated with bone marrow transplantation, all four
patients died due to complications of the procedure within months
of transplantation.
[0006] Patients with LAL deficiency can also present later in life
with predominant liver and cardiovascular involvement and this is
often called Cholesteryl Ester Storage Disease (CESD). In CESD, the
liver is severely affected with marked hepatomegaly, hepatocyte
necrosis, elevation of transaminases, cirrhosis and fibrosis. Due
to the increased levels of CE and TG, hyperlipidemia and
accelerated atherosclerosis are also seen in LAL deficiency.
Particularly, an accumulation of fatty deposits on the artery walls
is described early in life. The deposits narrow the arterial lumen
and can lead to vessel occlusion increasing the risk of significant
cardiovascular events including myocardial infarction and strokes.
The presentation of CESD is highly variable with some patients
going undiagnosed until complications manifest in late adulthood,
while others can have liver dysfunction presenting in early
childhood. CESD is associated with shortened lifespan and
significant ill health; the life expectancy of those with CESD
depends on the severity of the associated complications.
[0007] Current treatment options for the CESD phenotype are focused
on controlling lipid accumulation through diet that excludes foods
rich in cholesterol and triglycerides and suppression of
cholesterol synthesis and apolipoprotein B production through
administration of cholesterol lowering drugs. Although some
clinical improvement may be seen, the underlying disease
manifestations persist and disease progression still occurs.
[0008] In most cases, therapy for LAL deficiencies requires
life-long treatment. In addition, due to the high cost of protein
therapeutics, it is desirable to administer a minimum effective
amount of therapeutic to treat LAL deficiency. However, to date,
there is no effective therapy for treating LAL deficiency,
particularly the patients suffering from Wolman Disease and CESD.
Therefore, there is a strong need for an effective therapy with a
minimized frequency of administration in order to improve the
quality of life for patients. There is also a need for a high
expressing and robust protein production platform which can produce
LAL proteins that are stable and efficiently targeted to the
lysosomal compartment in the affected tissue cells in patients.
SUMMARY OF THE INVENTION
[0009] Disclosed herein are compositions of LAL which are
particularly suited for use in therapy, for example, for treatment
of conditions associated with LAL deficiency. The LAL molecules
described herein contain particular glycan structures which afford
efficient and rapid uptake into lysosomes of cells when
administered into a subject, for example, a human subject.
[0010] In one aspect, the compositions disclosed herein comprise
human LAL wherein a substantial percentage of the human LAL contain
at least one mannose-6-phosphate glycan moiety, which can serve as
a ligand for internalization by the mannose-6-phosphate receptor on
the surface of cells found, for example, on hepatocytes. In one
embodiment, 30% or more, for example, at least 30%, at least 40%,
at least 50%, at least 60%, at least 70%, at least 80%, at least
90%, at least 95%, at least 97%, or at least 99%, of the LAL
contained in the composition contains at least one
mannose-6-phosphate moiety. The mannose-6-phosphate moiety can be
found, for example, on an N-glycan structure located at one or more
residues selected from the group consisting of Asn.sup.15,
Asn.sup.51, Asn.sup.80, Asn.sup.140, Asn.sup.252 and Asn.sup.300 of
SEQ ID NO:2.
[0011] In another aspect, the compositions disclosed herein
comprise human LAL wherein a substantial percentage of the human
LAL does not contain a sialic acid moiety in any of its N-glycan
structures, which can sometimes interfere with internalization of
the enzyme into cells. In one embodiment, 15% or less, for example,
10% or less, 5% or less, 2% or less, 1% or less, or essentially
none, of the LAL contained in the composition contains a sialic
acid moiety in any of its N-glycan structures.
[0012] In another aspect, the compositions disclosed herein
comprise human LAL wherein a substantial percentage of the human
LAL does not contain a fucose moiety in any of its N-glycan
structures. In one embodiment, 50% or less, for example, 50% or
less, 40% or less, 30% or less, 20% or less, 10% or less, 5% or
less, 2% or less, 1% or less, or essentially none, of the LAL
contained in the composition contains a fucose moiety in any of its
N-glycan structures.
[0013] In yet another aspect, vectors, host cells, expression
systems and associated methods suitable for producing the
LAL-containing compositions are described.
[0014] Typically, the LAL of the invention discussed and disclosed
herein is human LAL. In one embodiment, the composition comprising
LAL includes the mature LAL having the amino acid sequence of:
TABLE-US-00001 (SEQ ID NO: 2)
SGGKLTAVDPETNMNVSEIISYWGFPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPVVFLQHGL
LADSSNWVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQDEFWAFSYDEMAKYDLPAS
INFILNKTGQEQVYYVGHSQGTTIGFIAFSQIPELAKRIKMFFALGPVASVAFCTSPMAKLGRLPDH
LIKDLFGDKEFLPQSAFLKWLGTHVCTHVILKELCGNLCFLLCGFNERNLNMSRVDVYTTHSPAGTS
VQNMLHWSQAVKFQKFQAFDWGSSAKNYFHYNQSYPPTYNVKDMLVPTAVWSGGHDWLADVYDVNIL
LTQITNLVFHESIPEWEHLDFIWGLDAPWRLYNKIINLMRKYQ.
[0015] In another embodiment, the mature LAL has the amino acid
sequence of:
TABLE-US-00002 (SEQ ID NO: 3)
GKLTAVDPETNMNVSEIISYWGFPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPVVFLQHGLLA
DSSNWVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQDEFWAFSYDEMAKYDLPASIN
FILNKTGQEQVYYVGHSQGTTIGFIAFSQIPELAKRIKMFFALGPVASVAFCTSPMAKLGRLPDHLI
KDLFGDKEFLPQSAFLKWLGTHVCTHVILKELCGNLCFLLCGFNERNLNMSRVDVYTTHSPAGTSVQ
NMLHWSQAVKFQKFQAFDWGSSAKNYFHYNQSYPPTYNVKDMLVPTAVWSGGHDWLADVYDVNILLT
QITNLVFHESIPEWEHLDFIWGLDAPWRLYNKIINLMRKYQ.
[0016] In another embodiment, the mature LAL has the amino acid
sequence of:
TABLE-US-00003 (SEQ ID NO: 4)
TAVDPETNMNVSEIISYWGFPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPVVFLQHGLLADSS
NWVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQDEFWAFSYDEMAKYDLPASINFIL
NKTGQEQVYYVGHSQGTTIGFIAFSQIPELAKRIKMFFALGPVASVAFCTSPMAKLGRLPDHLIKDL
FGDKEFLPQSAFLKWLGTHVCTHVILKELCGNLCFLLCGFNERNLNMSRVDVYTTHSPAGTSVQNML
HWSQAVKFQKFQAFDWGSSAKNYFHYNQSYPPTYNVKDMLVPTAVWSGGHDWLADVYDVNILLTQIT
NLVFHESIPEWEHLDFIWGLDAPWRLYNKIINLMRKYQ.
[0017] In another embodiment, the mature LAL has the amino acid
sequence of:
TABLE-US-00004 (SEQ ID NO: 19)
AVDPETNMNVSEIISYWGFPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPVVFLQHGLLADSSN
WVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQDEFWAFSYDEMAKYDLPASINFILN
KTGQEQVYYVGHSQGTTIGFIAFSQIPELAKRIKMFFALGPVASVAFCTSPMAKLGRLPDHLIKDLF
GDKEFLPQSAFLKWLGTHVCTHVILKELCGNLCFLLCGFNERNLNMSRVDVYTTHSPAGTSVQNMLH
WSQAVKFQKFQAFDWGSSAKNYFHYNQSYPPTYNVKDMLVPTAVWSGGHDWLADVYDVNILLTQITN
LVFHESIPEWEHLDFIWGLDAPWRLYNKIINLMRKYQ.
[0018] In another embodiment, the mature LAL is a mixture of at
least two polypeptides selected from the group consisting of: SEQ
ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:19.
[0019] The invention also provides for compositions which contain
isolated mixtures of an individual type of useful protein molecule,
such as those proteins disclosed herein, where one or more of the
protein molecules contained in the mixture has a specific
oligosaccharide structure attached, in particular an
oligosaccharide structure disclosed herein. For example, the
invention provides for isolated mixtures of LAL molecules, for
example, human LAL molecules which contain an LAL molecule
glycosylated with one or more of the following structures A-n to
O-n:
##STR00001## ##STR00002## ##STR00003## ##STR00004##
##STR00005##
[0020] According to one aspect of the present invention, a
composition comprises any isolated individual or combination of the
polypeptides described above. In one embodiment, the composition
can be a pharmaceutical composition, for example, a formulation
that further comprises pharmaceutically acceptable carriers, such
that the composition is, for example, suitable for administration
into a subject (e.g., a human, particularly a patient suffering
from or diagnosed with a condition). The composition can be
administered any number of ways, including by intravenous
administration. In another embodiment, the composition can further
comprise a second agent. Such an agent can be a medicament, or an
agent which can influence or modify a biological process when
administered into a subject. For example, the second agent can be
an immunomodulatory agent. Such immunomodulatory agents can include
any agent which, when administered together (i.e., administered at
the same time as, or shortly before or after) with any of the LAL
compositions described herein, may have the effect of reducing the
immunogenicity of the LAL composition in the subject (e.g.,
Rituximab, or any other B-cell depleting antibody).
[0021] In a final aspect, methods and compositions for the
treatment of symptoms associated with LAL deficiency are
disclosed.
[0022] Additional objects and aspects of the present invention will
become more apparent upon review of the detailed description set
forth below when taken in conjunction with the accompanying figures
and sequences.
BRIEF DESCRIPTION OF THE DRAWINGS
[0023] FIG. 1 depicts the amino acid sequences of human LAL. The
amino acid sequence of the recombinant hLAL shows 100% homologous
to that of natural human LAL. The mature form of hLAL is
underlined.
[0024] FIG. 2 depicts the nucleotide sequence of recombinant hLAL,
the rhLAL transgene of pALVIN-OVR1-I-hLAL-dSA.
[0025] FIGS. 3A and 3B depict diagrams of pALVIN-OVR1-I-hLAL-dSA
and its proviral region. FIG. 3A depicts a diagram of human LAL
retrovirus expression vector used in the production of transducing
particles is diagrammed (the DNA sequence of the plasmid is located
in Appendix A). FIG. 3A depicts pALVIN-OVR1-I-hLAL-dSA proviral
region that has been integrated into the genome. SIN LTR,
self-inactivating long terminal repeat; OV DHSIII enhancer, DNase
hypersensitive site III of the ovalbumin gene; OV Intron; ovalbumin
5' untranslated region and intron 1; hLAL, human LAL cDNA; OV 3'
UTR, ovalbumin gene 3' untranslated region; partial gag, partial
gag gene; LTR, long terminal repeat.
[0026] FIG. 4 depicts a nucleotide sequence of
pALVIN-OVR1-I-hLAL-dSA.
[0027] FIG. 5 depicts a nucleotide sequence of
pALVIN-OVR1-I-hLAL-dSA proviral region that has been integrated
into the genome.
[0028] FIG. 6 depicts a nucleotide sequence of pALVIN-OV-1.1-I
vector.
[0029] FIG. 7 depicts a nucleotide sequence of rhLAL adaptor.
[0030] FIG. 8 depicts a nucleotide sequence of rhLAL including the
partial ovalbumin promoter.
[0031] FIG. 9 depicts a nucleotide sequence of OVR1 promoter.
[0032] FIG. 10 depicts schematics of the steps used to construct
the pALVIN-OVR1-I-hLAL-dSA vector.
[0033] FIG. 11 depicts a real-time PCR analysis of blood DNA
samples from a hemizygous transgenic G1 offspring of XLL109. The
signals from duplicate DNA samples of hemizygous G1 progeny,
1LL7466, are indicated by the curves that initiate an increase in
Delta Rn before cycle 22. The curves for two non-transgenic progeny
are shown; these curves stay at or near baseline through at least
34 cycles.
[0034] FIGS. 12A-D depict Southern analysis of G1 chickens carrying
the ALVIN-OVR1-I-hLAL-dSA transgene. FIG. 12A illustrates schematic
of the integrated transgene and flanking genomic regions is shown
with the known position of the transgene BlpI site and predicted
position of the flanking genomic BlpI sites. The position of the OV
promoter probe and the hLAL coding sequence probe (hLAL probe) are
indicated by the black bars. The positions of the 4.3 kb and 10.6
kb bands detected in the Southern analysis are shown as well as the
predicted sizes of the genomic and transgene portions of the 4.3 kb
and 10.6 kb bands. FIG. 12B illustrates a Southern blot of genomic
DNA digested with BlpI and probed with the OV probe. WT CTRL is
genomic DNA isolated from a non-transgenic chicken. The ID numbers
of the G1 transgenics are indicated above the lanes. The position
and size (kb) of the molecular weight markers are shown to the left
of the blot. The position and size of the detected transgene
fragment (4.3 kb) and endogenous ovalbumin gene (4.1 kb) are shown
to the right of the blot. FIG. 12C depicts a Southern blot was
probed with the hLAL probe. The position and size of the detected
transgene fragment (10.6 kb) is shown to the right of the blot.
FIG. 12D depicts a section of the image shown in FIG. 12B at a
larger scale to demonstrate the presence of the 4.1 and 4.3 kb
bands.
[0035] FIG. 13A depicts schematic of the ALVIN-OVR1-I-hLAL-dSA
transgene. The size of ApaLI bands predicted to be detected by the
OV probe and hLAL probe are also shown. FIG. 13B depicts schematic
of a Southern blot analysis of the ALVIN-OVR1-I-hLAL-dSA transgene
for confirmation of transgene size. Southern blot of genomic DNA
digested with ApaLI and probed with either the OV probe (left
panel) or hLAL probe (right panel). WT CTRL is genomic DNA isolated
from a non-transgenic chicken. The ID number of the G1s is
indicated above each lane. The position and size (kb) of the
molecular weight markers are shown to the left of the blots. The
position and size of the detected transgene fragments (OV promoter
probe, 3.6 kb; hLAL probe, 3.8 kb) and endogenous ovalbumin gene
(7.7 kb) are shown to the right of the blots.
[0036] FIG. 14 depicts a lineage of transgenic chickens. Shown for
each chicken are the generation number (G0, G1 or G2),
identification number, gender and hatch date. Other G1 chickens are
those of other lineages.
[0037] FIG. 15 depicts the purification steps of hLAL from egg
white.
[0038] FIG. 16 depicts N-glycans found as an N-linked Glycosylation
structure in LAL produced in accordance with the invention. Square,
N-Acetyl glucosamine; Filled square, mannose-6-phosphate; circle,
mannose; filled circle; galactose; and filled triangle, fucose.
[0039] FIG. 17 depicts the relative position of predicted N-glycan
sites indicated on the LAL polypeptide (arrow) set forth in SEQ ID
NO:1. N-glycans that are structurally representative of those
detected at each site are shown. Square, N-Acetyl glucosamine;
Filled square, mannose-6-phosphate; circle, mannose; filled circle;
galactose; and filled triangle, fucose.
[0040] FIG. 18 depicts phosphorylated N-glycans released by PNGase
and analyzed by MALDI-TOF. Structures are shown.
[0041] FIG. 19 depicts the effect of dephosphorylation of LAL on
HPAEC-PAD retention time of N-glycans. LAL produced in accordance
with the invention was dephosphorylated with bacterial alkaline
phosphatase (upper panel) or left untreated (lower panel). Released
N-glycans were analyzed by HPAEC-PAD.
[0042] FIG. 20 depicts the co-localization of recombinant human
LAL(SBC-102) and lysosomal marker in the lysosomes of these cells
examined by confocal fluorescence microscopy using a sequential
scanning mode.
[0043] FIG. 21 depicts the binding specificity of recombinant human
LAL (SBC-102) to the GlcNAc/mannose receptor assessed by
competitive binding assays using the macrophage cell line,
NR8383.
[0044] FIG. 22 depicts the activity of recombinant human LAL in
cells in normal and LAL-deficient cells in vitro.
[0045] FIG. 23 depicts the effect of recombinant human LAL
(SBC-102) treatment on internal organs mass of LAL deficient rats.
Organ size is represented as percent of body weight determined at 8
weeks of age, in LAL.sup.-/- rats and LAL.sup.+/+ rats after weekly
administration of vehicle or SBC-102 at 5 mg/kg for 4 weeks.
[0046] FIG. 24 depicts body weight in wild type and LAL-deficient
rats after weekly administration of vehicle or SBC-102 at 5
mgkg.sup.-1 for 4 weeks. Dose administration is highlighted on
X-axis by diamonds starting at 4 week.
[0047] FIG. 25 shows liver cholesterol, cholesteryl ester and
triglyceride levels determined at 8 weeks of age in WT and LAL
deficient rats after weekly administration of vehicle or
recombinant human LAL (SBC-102) at 5 mgkg.sup.-1 for 4 weeks.
[0048] FIG. 26 depicts percent increase in body weight in
LAL-deficient rats after 4 weeks administration recombinant human
LAL (SBC-102) at the indicated levels and schedules, determined at
8 weeks of age.
[0049] FIG. 27 shows liver weight, as a percent of body weight, in
LAL-deficient rats after 4 weeks administration SBC-102 at the
indicated levels and schedules, determined at 8 weeks of age.
[0050] FIG. 28 shows tissue cholesteryl ester levels in
LAL-deficient rats after 4 weeks administration SBC-102 at the
indicated levels and schedules, determined at 8 weeks of age.
[0051] FIG. 29 shows the daily progress in weight gain of rats
which were administered either 1 mg/kg of LAL per week or 5 mg/kg
of LAL per week or 5 mg/kg of LAL per two weeks.
[0052] FIG. 30 depicts the gross pathological examination of
treated animals showing a substantial normalization in liver size
and color as can be seen in the dissection at the top panels and
histopathology of liver tissue from LAL of treated rats showing
normal liver histology in marked contrast to the substantial
accumulation of foamy macrophages in the placebo-treated animals at
the bottom panels.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0053] Certain definitions are set forth herein to illustrate and
define the meaning and scope of the various terms used to describe
the invention herein.
[0054] As used herein, the term "acceptable" with respect to a
formulation, composition or ingredient, as used herein, means
having no persistent detrimental effect on the general health of
the subject being treated.
[0055] As used herein, the term "administration" or "administering"
refers to providing a recombinant human lysosomal acid lipase of
the invention to a subject in need of treatment.
[0056] A "nucleic acid or polynucleotide sequence" includes, but is
not limited to, eukaryotic mRNA, cDNA, genomic DNA, and synthetic
DNA and RNA sequences, comprising the natural nucleoside bases
adenine, guanine, cytosine, thymidine, and uracil. The term also
encompasses sequences having one or more modified bases.
[0057] The term "avian" as used herein refers to any species,
subspecies or race of organism of the taxonomic class ava, such as,
but not limited to chicken, turkey, duck, goose, quail, pheasants,
parrots, finches, hawks, crows and ratites including ostrich, emu
and cassowary. The term includes the various known strains of
Gallus gallus, or chickens, (for example, White Leghorn, Brown
Leghorn, Barred-Rock, Sussex, New Hampshire, Rhode Island,
Australorp, Minorca, Amrox, California Gray), as well as strains of
turkeys, pheasants, quails, duck, ostriches and other poultry
commonly bred in commercial quantities. It also includes an
individual avian organism in all stages of development, including
embryonic and fetal stages.
[0058] "Therapeutic proteins" or "pharmaceutical proteins" include
an amino acid sequence which in whole or in part makes up a
drug.
[0059] A "coding sequence" or "open reading frame" refers to a
polynucleotide or nucleic acid sequence which can be transcribed
and translated (in the case of DNA) or translated (in the case of
mRNA) into a polypeptide in vitro or in vivo when placed under the
control of appropriate regulatory sequences. The boundaries of the
coding sequence are determined by a translation start codon at the
5' (amino) terminus and a translation stop codon at the 3'
(carboxy) terminus. A transcription termination sequence is usually
located 3' to the coding sequence. A coding sequence may be flanked
on the 5' and/or 3' ends by untranslated regions.
[0060] "Exon" refers to that part of a gene which, when transcribed
into a nuclear transcript, is "expressed" in the cytoplasmic mRNA
after removal of the introns or intervening sequences by nuclear
splicing.
[0061] Nucleic acid "control sequences" or "regulatory sequences"
refer to promoter sequences, translational start and stop codons,
ribosome binding sites, polyadenylation signals, transcription
termination sequences, upstream regulatory domains, enhancers, and
the like, as necessary and sufficient for the transcription and
translation of a given coding sequence in a defined host cell.
Examples of control sequences suitable for eukaryotic cells are
promoters, polyadenylation signals, and enhancers. All of these
control sequences need not be present in a recombinant vector so
long as those necessary and sufficient for the transcription and
translation of the desired gene are present.
[0062] "Operably or operatively linked" refers to the configuration
of the coding and control sequences so as to perform the desired
function. Thus, control sequences operably linked to a coding
sequence are capable of effecting the expression of the coding
sequence. A coding sequence is operably linked to or under the
control of transcriptional regulatory regions in a cell when DNA
polymerase binds the promoter sequence and transcribes the coding
sequence into mRNA that can be translated into the encoded protein.
The control sequences need not be contiguous with the coding
sequence, so long as they function to direct the expression
thereof. Thus, for example, intervening untranslated yet
transcribed sequences can be present between a promoter sequence
and the coding sequence and the promoter sequence can still be
considered "operably linked" to the coding sequence.
[0063] The terms "heterologous" and "exogenous" as they relate to
nucleic acid sequences such as coding sequences and control
sequences, denote sequences that are not normally associated with a
region of a recombinant construct or with a particular chromosomal
locus, and/or are not normally associated with a particular cell.
Thus, an "exogenous" region of a nucleic acid construct is an
identifiable segment of nucleic acid within or attached to another
nucleic acid molecule that is not found in association with the
other molecule in nature. For example, an exogenous region of a
construct could include a coding sequence flanked by sequences not
found in association with the coding sequence in nature. Another
example of an exogenous coding sequence is a construct where the
coding sequence itself is not found in nature (e.g., synthetic
sequences having codons different from the native gene). Similarly,
a host cell transformed with a construct or nucleic acid which is
not normally present in the host cell would be considered exogenous
for purposes of this invention.
[0064] As used herein the terms "N-glycan," "oligosaccharide,"
"oligosaccharide structure," "glycosylation pattern,"
"glycosylation profile" and "glycosylation structure" have
essentially the same meaning and each refer to one or more
structures which are formed from sugar residues and are attached to
glycosylated proteins.
[0065] "Exogenous protein" as used herein refers to a protein not
naturally present in a particular tissue or cell, a protein that is
the expression product of an exogenous expression construct or
transgene, or a protein not naturally present in a given quantity
in a particular tissue or cell. A protein that is exogenous to an
egg is a protein that is not normally found in the egg. For
example, a protein exogenous to an egg may be a protein that is
present in the egg as a result of the expression of a coding
sequence present in a transgene of the animal laying the egg.
[0066] "Endogenous gene" refers to a naturally occurring gene or
fragment thereof normally associated with a particular cell.
[0067] "LAL" means "human lysosomal acid lipase," "SBC-102" or
"human lysosomal acid lipase molecule" and these terms are used
interchangeably throughout the specification.
[0068] The expression products described herein may consist of
proteinaceous material having a defined chemical structure.
However, the precise structure depends on a number of factors,
particularly chemical modifications common to proteins. For
example, since all proteins contain ionizable amino and carboxyl
groups, the protein may be obtained in acidic or basic salt form,
or in neutral form. The primary amino acid sequence may be
derivatized using sugar molecules (glycosylation) or by other
chemical derivatizations involving covalent or ionic attachment
with, for example, lipids, phosphate, acetyl groups and the like,
often occurring through association with saccharides. These
modifications may occur in vitro or in vivo, the latter being
performed by a host cell through post-translational processing
systems. Such modifications may increase or decrease the biological
activity of the molecule, and such chemically modified molecules
are also intended to come within the scope of the invention.
[0069] Alternative methods of cloning, amplification, expression,
and purification will be apparent to the skilled artisan.
Representative methods are disclosed in Sambrook, Fritsch, and
Maniatis, Molecular Cloning, a Laboratory Manual, 2nd Ed., Cold
Spring Harbor Laboratory (1989).
[0070] "Vector" means a polynucleotide comprised of single strand,
double strand, circular, or supercoiled DNA or RNA. A typical
vector may be comprised of the following elements operatively
linked at appropriate distances for allowing functional gene
expression: replication origin, promoter, enhancer, 5' mRNA leader
sequence, ribosomal binding site, nucleic acid cassette,
termination and polyadenylation sites, and selectable marker
sequences. One or more of these elements may be omitted in specific
applications. The nucleic acid cassette can include a restriction
site for insertion of the nucleic acid sequence to be expressed. In
a functional vector the nucleic acid cassette contains the nucleic
acid sequence to be expressed including translation initiation and
termination sites. An intron optionally may be included in the
construct, for example, 5' to the coding sequence. A vector is
constructed so that the particular coding sequence is located in
the vector with the appropriate regulatory sequences, the
positioning and orientation of the coding sequence with respect to
the control sequences being such that the coding sequence is
transcribed under the "control" of the control or regulatory
sequences. Modification of the sequences encoding the particular
protein of interest may be desirable to achieve this end. For
example, in some cases it may be necessary to modify the sequence
so that it may be attached to the control sequences with the
appropriate orientation; or to maintain the reading frame. The
control sequences and other regulatory sequences may be ligated to
the coding sequence prior to insertion into a vector.
Alternatively, the coding sequence can be cloned directly into an
expression vector which already contains the control sequences and
an appropriate restriction site which is in reading frame with and
under regulatory control of the control sequences.
[0071] A "promoter" is a site on the DNA to which RNA polymerase
binds to initiate transcription of a gene. In some embodiments the
promoter can be modified by the addition or deletion of sequences,
or replaced with alternative sequences, including natural and
synthetic sequences as well as sequences which may be a combination
of synthetic and natural sequences. Many eukaryotic promoters
contain two types of recognition sequences: the TATA box and the
upstream promoter elements. The former, located upstream of the
transcription initiation site, is involved in directing RNA
polymerase to initiate transcription at the correct site, while the
latter appears to determine the rate of transcription and is
upstream of the TATA box. Enhancer elements can also stimulate
transcription from linked promoters, but many function exclusively
in a particular cell type. Many enhancer/promoter elements derived
from viruses, e.g., the SV40 promoter, the cytomegalovirus (CMV)
promoter, the rous-sarcoma virus (RSV) promoter, and the murine
leukemia virus (MLV) promoter are all active in a wide array of
cell types, and are termed "ubiquitous." Alternatively,
non-constitutive promoters such as the mouse mammary tumor virus
(MMTV) promoter may also be used in the present invention. The
nucleic acid sequence inserted in the cloning site may have any
open reading frame encoding a polypeptide of interest, with the
proviso that where the coding sequence encodes a polypeptide of
interest, it should lack cryptic splice sites which can block
production of appropriate mRNA molecules and/or produce aberrantly
spliced or abnormal mRNA molecules.
[0072] As used herein, the term "pharmaceutical composition" refers
to a mixture of a compound described herein with other chemical
components, such as carriers, stabilizers, diluents, dispersing
agents, suspending agents, thickening agents, and/or
excipients.
[0073] The term "poultry derived" or "avian derived" refers to a
composition or substance produced by or obtained from poultry.
"Poultry" refers to avians that can be kept as livestock, including
but not limited to, chickens, duck, turkey, quail and ratites. For
example, "poultry derived" may refer to chicken derived, turkey
derived and/or quail derived.
[0074] A "retroviral particle," "transducing particle," or
"transduction particle" refers to a replication-defective or
replication-competent virus capable of transducing non-viral DNA or
RNA into a cell. In one particularly useful embodiment, retroviral
particles used to produce transgenic avians in accordance with the
invention are made as disclosed in U.S. Pat. No. 7,524,626, issued
Apr. 28, 2009, the disclosure of which is incorporated in its
entirety herein by reference.
[0075] The terms "transformation," "transduction" and
"transfection" all denote the introduction of a polynucleotide into
an avian blastodermal cell. "Magnum" is that part of the oviduct
between the infundibulum and the isthmus containing tubular gland
cells that synthesize and secrete the egg white proteins of the
egg.
[0076] The term "transgene" refers to heterologous nucleotide
sequence inserted into an avian genome in accordance with the
invention. "Transgene" can specifically refer to an exogenous
coding sequence, an exogenous coding sequence linked to an
exogenous promoter or other regulatory sequence, all nucleotide
sequence between two retoroviral LTRs and/or retroviral LTRs and
nucleotide sequence between the LTRs wherein the LTRs are of a
retrovirus used to introduce the transgene.
[0077] The term "optimized" is used in the context of "optimized
coding sequence", wherein the most frequently used codons for each
particular amino acid found in the egg white proteins ovalbumin,
lysozyme, ovomucoid, and ovotransferrin are used in the design of
the optimized human interferon-.alpha. 2b (IFN-.alpha. 2b)
polynucleotide sequence that is inserted into vectors of the
present invention. More specifically, the DNA sequence for
optimized human IFN-.alpha. 2b is based on the hen oviduct
optimized codon usage and is created using the BACKTRANSLATE
program of the Wisconsin Package, Version 9.1 (Genetics Computer
Group Inc., Madison, Wis.) with a codon usage table compiled from
the chicken (Gallus gallus) ovalbumin, lysozyme, ovomucoid, and
ovotransferrin proteins. For example, the percent usage for the
four codons of the amino acid alanine in the four egg white
proteins is 34% for GCU, 31% for GCC, 26% for GCA, and 8% for GCG.
Therefore, GCU is used as the codon for the majority of alanines in
an optimized coding sequence. The vectors containing the gene for
the optimized human protein are used to produce transgenic avians
that express transgenic poultry derived protein in their tissues
and eggs.
[0078] As used herein, the term "subject" encompasses mammals and
non-mammals. Examples of mammals include, but are not limited to,
humans, chimpanzees, apes monkeys, cattle, horses, sheep, goats,
swine; rabbits, dogs, cats, rats, mice, guinea pigs, and the
like.
[0079] As used herein, the term "therapeutically effective amount"
refers to any amount of a compound which, as compared to a
corresponding subject who has not received such amount, results in
improved treatment, healing, prevention, or amelioration of a
disease, disorder, or side effect, or a decrease in the rate of
advancement of a disease or disorder. The term also includes within
its scope amounts effective to enhance normal physiological
function.
[0080] The term "treat," "treating" or "treatment" refers to
methods of alleviating, abating or ameliorating a disease or
condition symptoms, preventing additional symptoms, ameliorating or
preventing the underlying causes of symptoms, inhibiting the
disease or condition, arresting the development of the disease or
condition, relieving the disease or condition, causing regression
of the disease or condition, relieving a condition caused by the
disease or condition, or stopping the symptoms of the disease or
condition either prophylactically and/or therapeutically.
LAL Compositions
[0081] The invention is generally drawn to compositions comprising
enzymes useful for therapy, for example, in the treatment of
lysosomal storage diseases. In one aspect, the invention is drawn
to lysosomal storage disease enzymes such as LAL with a
glycosylation pattern that renders the molecule amenable for
internalization by certain cell types. Also included in the
invention are recombinant human proteins including LAL in isolated
or purified form. The isolation of the lysosomal storage disease
enzymes (such as LAL) can be accomplished by methodologies readily
apparent to a practitioner skilled in the art of protein
purification.
[0082] In one embodiment, the invention is directed to lysosomal
storage disease enzymes including, but not limited to LAL, having
an N-linked glycosylation pattern described herein.
[0083] In one aspect, the compositions disclosed herein comprise
human LAL wherein a substantial percentage of the human LAL contain
a mannose-6-phosphate glycan moiety, which can serve as a ligand
for internalization by the mannose-6-phosphate receptor on the
surface of cells found, for example, on hepatocytes. In one
embodiment, 30% or more, for example, at least 30%, at least 40%,
at least 50%, at least 60%, at least 70%, at least 80%, at least
90%, at least 95%, at least 97%, or at least 99%, of the LAL
contained in the composition contains at least one
mannose-6-phosphate moiety. The mannose-6-phosphate moiety can be
found, for example, on an N-glycan structure located at one or more
residues selected from the group consisting of Asn.sup.15,
Asn.sup.51, Asn.sup.80, Asn.sup.140, Asn.sup.252 and Asn.sup.300 of
SEQ ID NO:2. Glycan structures containing mannose-6-phosphate
moieties include, for example, G-n and H-n shown in FIG. 16.
[0084] The recombinant human LAL according to the present invention
contains multiple N-linked carbohydrate chains (e.g., about 5 or 6
carbohydrate chains). N-linked glycosylation structures at each of
the five or six sites can be selected from one of A-n, B-n, C-n,
D-n, E-n, F-n, G-n, H-n, I-n, J-n, K-n, L-n, M-n, N-n and O-n as
shown in FIG. 16
[0085] Also described herein are a mixture of LAL molecules (e.g.,
more than one LAL molecule can be present in a mixture such as the
LAL molecules set forth in SEQ ID NOs: 2, 3, 4 and 19) wherein some
or all of the LAL molecules have one or more glycosylation
structures selected from Structure A-n, Structure B-n, Structure
C-n, Structure D-n, Structure E-n, Structure F-n, Structure G-n,
Structure H-n, Structure I-n, Structure J-n, Structure K-n,
Structure L-n, Structure M-n, Structure N-n and Structure O-n (FIG.
16). In one embodiment, the mixture of lysosomal acid lipase
molecules is purified or isolated, for example, isolated from an
egg or purified or isolated from egg white produced in a transgenic
avian.
[0086] The invention also includes an individual LAL molecule
comprising a Structure A-n. The invention also includes an
individual LAL molecule comprising a Structure B-n. The invention
also includes an individual LAL molecule comprising a Structure
C-n. The invention also includes an individual LAL molecule
comprising a Structure D-n. The invention also includes an
individual LAL molecule comprising a Structure E-n. The invention
also includes an individual LAL molecule comprising a Structure
F-n. The invention also includes an individual LAL molecule
comprising a Structure G-n. The invention also includes an
individual LAL molecule comprising a Structure H-n. The invention
also includes an individual LAL molecule comprising a Structure
I-n. The invention also includes an individual LAL molecule
comprising a Structure J-n. The invention also includes an
individual LAL molecule comprising a Structure K-n. The invention
also includes an individual LAL molecule comprising a Structure
L-n. The invention also includes an individual lysosomal acid
lipase molecule comprising a Structure M-n. The invention also
includes an individual LAL molecule comprising a Structure N-n. The
invention also includes an individual LAL molecule comprising a
Structure O-n.
[0087] N-linked oligosaccharides attached to human LAL according to
the present invention have a paucity of terminal sialic acid and
galactose residues. That is, only minor amounts of the N-linked
oligosaccharide structures are terminally sialylated and few
galactose residues are present as well. Further, terminal N-Acetyl
Glucosamine (GlcNAc) is present extensively on the N-linked
oligosaccharide structures of the LAL described herein. As such,
LAL produced in accordance with the invention can be targeted to
cells such as monocyte macrophages and Kupffer cells.
[0088] One aspect of the invention provides compositions of LAL
having essentially no sialic acid. In another aspect, the
compositions disclosed herein comprise recombinant human LAL
wherein a substantial percentage of the human LAL does not contain
a sialic acid moiety in any of its N-glycan structures, which can
interfere with internalization of the enzyme into cells. In one
embodiment, 15% or less, for example, 10% or less, 5% or less, 2%
or less, 1% or less, or essentially none, of the LAL contained in
the composition contains a sialic acid moiety in any of its
N-glycan structures.
[0089] In another embodiment, about 95% or more of the N-linked
oligosaccharides present on the individual LAL molecule of the
invention do not contain sialic acid. In another embodiment, about
90% or more of the N-linked oligosaccharides present on the
individual LAL molecule of the invention do not contain sialic
acid. In another embodiment, about 80% or more of the N-linked
oligosaccharides present on the individual LAL molecule of the
invention do not contain sialic acid. In another embodiment, more
than about 70% or more of the N-linked oligosaccharides present on
the individual LAL molecule of the invention do not contain sialic
acid.
[0090] In still another embodiment, essentially none of the
N-linked oligosaccharides structure types present on the LAL
molecules of the invention contain sialic acid. In another
embodiment, about 90% or more of the N-linked oligosaccharides
structure types found to be associated with the LAL molecules of
the invention do not contain sialic acid. For example, if there are
20 oligosaccharide structure types, then 18 or more of the
structure types do not contain sialic acid. In another embodiment,
about 80% or more of the N-linked oligosaccharides structure types
found to be associated with the LAL molecules of the invention do
not contain sialic acid. In another embodiment, about 70% or more
of the N-linked oligosaccharides structure types found to be
associated with the LAL molecules of the invention do not contain
sialic acid. In another embodiment, about 60% or more of the
N-linked oligosaccharides structure types found to be associated
with the LAL molecules of the invention do not contain sialic acid.
In another embodiment, about 50% or more of the N-linked
oligosaccharides structure types found to be associated with the
LAL molecules of the invention do not contain sialic acid.
[0091] According to one aspect of the invention, LAL as described
herein contain high levels of terminal N-Acetyl Glucosamine. In one
aspect, about 95% or more of the N-linked oligosaccharides present
on the individual LAL molecule of the invention contain a terminal
N-Acetyl Glucosamine. In another embodiment, about 90% or more of
the N-linked oligosaccharides present on the individual LAL
molecule of the invention contain a terminal N-Acetyl Glucosamine.
In another embodiment, about 80% or more of the N-linked
oligosaccharides present on the individual LAL molecule of the
invention contain a terminal N-Acetyl Glucosamine. In another
embodiment, about 70% or more of the N-linked oligosaccharides
present on the individual LAL molecule of the invention contain a
terminal N-Acetyl Glucosamine. In another embodiment, about 60% or
more of the N-linked oligosaccharides present on the individual LAL
molecule of the invention contain a terminal N-Acetyl Glucosamine.
In another embodiment, about 50% or more of the N-linked
oligosaccharides present on the individual LAL molecule of the
invention contain a terminal N-Acetyl Glucosamine.
[0092] In one embodiment, all of the N-linked oligosaccharides
structure types present on the LAL molecules of the invention
contain a terminal N-Acetyl Glucosamine. In another embodiment,
about 90% or more of the N-linked oligosaccharides structure types
present on the LAL molecules of the invention contain a terminal
N-Acetyl Glucosamine. For example, if there are 20 oligosaccharide
structure types, then 18 or more of the structure types do not
contain a terminal N-Acetyl Glucosamine. In another embodiment,
about 80% or more of the N-linked oligosaccharides structure types
present on the LAL molecules of the invention contain a terminal
N-Acetyl Glucosamine. In another embodiment, about 70% or more of
the N-linked oligosaccharides structure types present on the LAL
molecules of the invention contain a terminal N-Acetyl Glucosamine.
In another embodiment, about 60% or more of the N-linked
oligosaccharides structure types present on the LAL molecules of
the invention contain a terminal N-Acetyl Glucosamine. In another
embodiment, about 50% or more of the N-linked oligosaccharides
structure types present on the LAL molecules of the invention
contain a terminal N-Acetyl Glucosamine.
[0093] In another aspect of the invention, the compositions
disclosed herein comprise human LAL wherein a substantial
percentage of the human LAL does not contain a fucose moiety in any
of its N-glycan structure. In one embodiment, 50% or less, for
example, 50% or less, 40% or less, 30% or less, 20% or less, 10% or
less, 5% or less, 2% or less, 1% or less, or essentially none, of
the LAL contained in the composition contains a fucose moiety in
any of its N-glycan structure.
[0094] In one embodiment, fucose is essentially not present on the
N-linked oligosaccharide structures of the LAL produced in
accordance of the invention. In another embodiment, about 95% or
more of the N-linked oligosaccharides present on the individual LAL
molecule of the invention do not contain fucose. In another
embodiment, about 90% or more of the N-linked oligosaccharides
present on the individual LAL molecule of the invention do not
contain fucose. In another embodiment, about 85% or more of the
N-linked oligosaccharides present on the individual LAL molecule of
the invention do not contain fucose. In another embodiment, about
80% or more of the N-linked oligosaccharides present on the
individual LAL molecule of the invention do not contain fucose. In
another embodiment, about 70% or more of the N-linked
oligosaccharides present on the individual LAL molecule of the
invention do not contain fucose. In another embodiment, about 60%
or more of the N-linked oligosaccharides present on the individual
LAL molecule of the invention do not contain fucose. In another
embodiment, about 50% or more of the N-linked oligosaccharides
present on the LAL of the invention do not contain fucose.
[0095] In one embodiment, essentially none of the N-linked
oligosaccharides structure types present on the LAL molecules of
the invention contain fucose. In another embodiment, about 95% or
more of the N-linked oligosaccharides structure types present on
the LAL molecules of the invention do not contain fucose. For
example, if there are 20 oligosaccharide structure types, then 19
or more of the structure types do not contain fucose. In another
embodiment, about 90% or more of the N-linked oligosaccharides
structure types present on the LAL molecules of the invention do
not contain fucose. In another embodiment, about 85% or more of the
N-linked oligosaccharides structure types present on the LAL
molecules of the invention do not contain fucose. In another
embodiment, about 80% or more of the N-linked oligosaccharides
structure types present on the LAL molecules of the invention do
not contain fucose. In another embodiment, about 70% or more of the
N-linked oligosaccharides structure types present on the LAL
molecules of the invention do not contain fucose.
[0096] As discussed above, certain monosaccharides are abundantly
present in LAL molecules produced in accordance with the present
invention. The total monosaccharide species analyzed includes
fucose, N-acetyl galactosamine, N-acetyl glucosamine, galactose,
glucose, mannose, mannose-6-phosphate, N-acetyl neuraminic acid and
N-glycolyl neuraminic acid. Fucose can be present between about 0%
and about 1% of the total monosaccharide composition. N-acetyl
galactosamine can be present between about 0% and about 1% of the
total monosaccharide composition. N-acetyl glucosamine can be
present between about 35% and about 50% of the total monosaccharide
composition. Galactose can be present between about 1-10% of the
total monosaccharide composition. Glucose is present at 0% of the
total monosaccharide composition. Mannose is present between about
32% and about 50% of the total monosaccharide composition.
Mannose-6-phosphate is present between about 1% and about 11% of
the total monosaccharide composition.
[0097] In one embodiment, LAL produced in accordance with the
present invention do not contain any xylose. In addition, because
there is essentially no N-acetylgalactosamine (GalNac) in LAL
produced in accordance with the invention, one aspect of the
invention includes a composition of LAL having no O-linked
glycosylation.
[0098] LAL has 6 potential sites in its amino acid sequence for
N-linked glycosylation, for example Asn.sup.36, Asn.sup.72,
Asn.sup.101, Asn.sup.161, Asn.sup.273, and Asn.sup.321 as in SEQ ID
NO:1. Five of these, Asn.sup.36, Asn.sup.101 Asn.sup.161,
Asn.sup.273 and Asn.sup.321 are glycosylated while Asn.sup.72 can
be unglycosylated or substantially unglycosylated (substantially
unglycosylated means in a mixture of LAL molecules, fewer
Asn.sup.72 are glycosylated than any of Asn.sup.36, Asn.sup.101,
Asn.sup.161, Asn.sup.273 and Asn.sup.321) (see FIG. 17).
Accordingly, one aspect of the invention is a composition of LAL
which is unglycosylated and/or substantially unglycosylated at
Asn.sup.72. LAL having a glycosylated Asn.sup.72 is within the
scope of the invention. The positions of Asn described herein are
based on the LAL amino acid sequence set forth in SEQ ID NO:1. It
will be apparent to those skilled in the art that the numbering of
Asn (i.e., the position of asparagine) can vary depending on
individual LAL molecule and be readily determined in other LAL
molecules such as those whose amino acid sequences are set forth in
SEQ ID NOs:2, 3, 4 and 19.
[0099] The LAL molecules produced in accordance with the present
invention contain N-glycan structures comprising a mixture of bi-,
tri- and tetraantennary structures with N-acetylglucosamine,
mannose and mannose-6-phosphate (M6P) as the major sugars (FIGS. 16
and 17). According to one aspect of the invention, M6P-modified
N-glycans reside at least at Asn.sup.101, Asn.sup.161 and
Asn.sup.273. Thus, one embodiment of the present invention includes
a composition of LAL having M6P-modified N-glycans residing at any
one of Asn.sup.101, Asn.sup.161 or Asn.sup.273. In yet another
embodiment, the present invention includes a composition of LAL
having M6P-modified N-glycans residing at Asn.sup.273. In another
embodiment, the present invention includes a composition of LAL
having monophosphorylated N-glycans (M6P) residing at any one of
Asn.sup.101, Asn.sup.161 or Asn.sup.273. In yet another embodiment,
the present invention includes a composition of LAL having
monophosphorylated N-glycans residing at Asn.sup.161 and
Asn.sup.273. In yet another embodiment, the present invention
includes a composition of LAL having monophosphorylated N-glycans
residing at Asn.sup.101 and Asn.sup.273. In one specific
embodiment, a LAL produced in accordance with the present invention
can contain bisphosphorylated mannose (bis-M6P) at Ase.sup.101.
[0100] The LAL molecules produced in accordance with the present
invention contain reduced levels of galactose (e.g., "Gal"). One
aspect of the present invention includes a composition of LAL
having terminal galactose at any one of Asn.sup.36, Asn.sup.161 or
Asn.sup.321. In yet another embodiment, the present invention
includes a composition of LAL having terminal galactose at
Asn.sup.36 and Asn.sup.161. In yet another embodiment, the present
invention includes a composition of LAL having terminal galactose
at Asn.sup.161 and Asn.sup.321. In yet another embodiment, the
present invention includes a composition of LAL having terminal
galactose at Asn.sup.36 and Asn.sup.321. In yet another embodiment,
the present invention includes a composition of LAL having terminal
galactose at Asn.sup.36, Asn.sup.161 and Asn.sup.321. In yet
another embodiment, the present invention includes a composition of
LAL having no terminal galactose.
[0101] Various types of N-glycans were found in LAL at different
N-linked glycosylation sites. The N-glycan structures include a
mixture of bi-, tri- and tetraantennary structures with
N-acetylglucosamine, mannose and mannose-6-phosphate (M6P) as the
major sugars. Specifically, in one embodiment of the present
invention, LAL contains an N-glycan structure selected from
GlcNAc4Man3GlcNAc2 or Gal1GlcNAc4Man3GlcNAc2 at the first N-linked
glycosylation site (e.g., Asn.sup.36 as in SEQ ID NO:1). In another
embodiment, LAL contains no glycosylation or is substantially
unglycosylated at the second N-linked glycosylation site (e.g.,
Asn.sup.72 as in SEQ ID NO:1). In yet another embodiment, LAL
contains Phos2Man7GlcNAc2 at its third N-linked glycosylation site
(e.g., Asn.sup.101 as in SEQ ID NO:1). In yet another embodiment,
LAL contains a N-glycan structure selected from Phos1Man6GlcNAc2,
GlcNAc1Phos1Man6GlcNAc2, Man3GlcNAc2, GlcNAc2Man3GlcNAc2,
GlcNAc3Man3GlcNAc2, GlcNAc4Man3GlcNAc2, or Gal1GlcNAc4Man3GlcNAc2
at its fourth N-linked glycosylation site (e.g., Asn.sup.161 as in
SEQ ID NO:1). In yet another embodiment, LAL contains a N-glycan
structure selected from Man7GlcNAc2, Man8GlcNAc2, Man9GlcNAc2,
Phos1Man8GlcNAc2, or Phos1Man9GlcNAc2 at its fifth N-linked
glycosylation site (e.g., Asn.sup.273 as in SEQ ID NO:1). In yet
another embodiment, LAL contains a N-glycan structure selected from
GlcNAc2Man3GlcNAc2, GlcNAc3Man3GlcNAc2, GlcNAc4Man3GlcNAc2,
Gal1GlcNAc4Man3GlcNAc2, GlcNAc5Man3GlcNAc2, Gal1GlcNAc5Man3GlcNAc2,
GlcNAc6Man3GlcNAc2, or Gal1GlcNAc6Man3GlcNAc2 at its sixth N-linked
glycosylation site (e.g., Asn.sup.321 as in SEQ ID NO:1).
[0102] According to certain aspects of the invention, compositions
of LAL include LAL glycosylated at Asn.sup.36, Asn.sup.72,
Asn.sup.101 Asn.sup.161, Asn.sup.273 and Asn.sup.321 of SEQ ID NO:1
(or corresponding Asparagine residues within SEQ ID NOs: 2, 3, 4,
and 19) with one N-glycan at the designated Asn position as shown
below:
[0103] a) at Asn.sup.36, GlcNAc4Man3GlcNAc2, or [0104]
Gal1GlcNAc4Man3 GlcNAc2;
[0105] b) at Asn.sup.72, no glycosylation;
[0106] c) at Asn.sup.101, Phos2Man7GlcNAc2;
[0107] d) at Asn.sup.161, Phos1Man6GlcNAc2, [0108]
GlcNAc1Phos1Man6GlcNAc2; [0109] Man3 GlcNAc2; [0110] GlcNAc2Man3
GlcNAc2; [0111] GlcNAc3Man3GlcNAc2; [0112] GlcNAc4Man3GlcNAc2, or
[0113] Gal1GlcNAc4Man3 GlcNAc2;
[0114] e) at Asn.sup.273, Man7GlcNAc2, [0115] Man8GlcNAc2, [0116]
Man9GlcNAc2, [0117] Phos1Man8GlcNAc2, or [0118] Phos1Man9GlcNAc2;
and
[0119] f) at Asn.sup.321, GlcNAc2Man3GlcNAc2, [0120]
GlcNAc3Man3GlcNAc2, [0121] GlcNAc4Man3GlcNAc2, [0122]
Gal1GlcNAc4Man3 GlcNAc2, [0123] GlcNAc5Man3GlcNAc2, [0124]
Gal1GlcNAc5Man3 GlcNAc2, [0125] GlcNAc6Man3GlcNAc2, or [0126]
Gal1GlcNAc6Man3 GlcNAc2, where Man=mannose,
[0127] GlcNAc=N-Acetyl Glucosamine,
[0128] Phos=phosphate, and
[0129] Gal=galactose.
[0130] In one embodiment, Gal1GlcNAc4Man3GlcNAc2 can be found as a
glycan component at any one of Asn.sup.36, Asn.sup.161 or
Asn.sup.321 in LAL produced in accordance with the invention. In
one specific embodiment, Gal1GlcNAc4Man3GlcNAc2 can be found as a
glycan component of Asn.sup.36, Asn.sup.161 and Asn.sup.321.
[0131] In the LAL of the present invention, Asn.sup.101 and
Asn.sup.273 display the high-mannose-type having about 6 to about
10 mannose molecules (MAN6-MAN10 as described herein) as a major
component. Accordingly, one aspect of the present invention
includes a composition of LAL having a high mannose structure at
Asn.sup.101 or Asn.sup.273. In another embodiment, a composition of
LAL of the invention can comprise a N-glycan structure having at
least 6 mannose at Asn.sup.101 or Asn.sup.273. In another
embodiment, a composition of LAL contains a N-glycan having 7, 8 or
9 mannose at Asn.sup.101 or Asn.sup.273. In yet another embodiment,
the present invention includes a composition of LAL having 7, 8 or
9 mannose at Asn.sup.101 and Asn.sup.273. In yet another
embodiment, the present invention includes a composition of LAL
having 7, 8 or 9 mannose at Asn.sup.101 and/or Asn.sup.273 and at
least one of the mannose is phosphorylated.
[0132] It is to be understood that the glycosylation sites and the
numbers associated with Asn described above is based on the amino
acid sequence of LAL set forth in SEQ ID NO:1 and that the
glycosylation profiles described above in context of SEQ ID NO:1
also apply to LAL molecules set forth in SEQ ID NOs: 2, 3, 4 and 19
though the numbering of corresponding Asn may vary depending on LAL
molecule. For example, Asn.sup.36 in SEQ ID NO:1 corresponds to
Asn.sup.15 in SEQ ID NO:2, Asn.sup.13 in SEQ ID NO:3, Asn.sup.10 in
SEQ ID NO:4 and Asn.sup.9 in SEQ ID NO:19. Asn.sup.72 in SEQ ID
NO:1 corresponds to Asn.sup.51 in SEQ ID NO:2, Asn.sup.49 in SEQ ID
NO:3, Asn.sup.46 in SEQ ID NO:4 and Asn.sup.45 in SEQ ID NO:19.
Asn.sup.101 in SEQ ID NO:1 corresponds to Asn.sup.80 in SEQ ID
NO:2, Asn.sup.78 in SEQ ID NO:3, Asn.sup.75 in SEQ ID NO:4 and
Asn.sup.74 in SEQ ID NO:19. Asn.sup.161 in SEQ ID NO:1 corresponds
to Asn.sup.140 in SEQ ID NO:2, Asn.sup.138 in SEQ ID NO:3,
Asn.sup.135 in SEQ ID NO:4 and Asn.sup.134 in SEQ ID NO:19.
Asn.sup.273 of SEQ ID NO:1 corresponds to Asn.sup.252 in SEQ ID
NO:2, Asn.sup.250 in SEQ ID NO:3, Asn.sup.247 in SEQ ID NO:4 and
Asn.sup.246 in SEQ ID NO:19. Asn.sup.321 of SEQ ID NO:1 corresponds
to Asn.sup.300 in SEQ ID NO:2, Asn.sup.298 in SEQ ID NO:3,
Asn.sup.295 in SEQ ID NO:4 and Asn.sup.294 in SEQ ID NO:19.
[0133] For example, in one embodiment, the LAL is N-linked
glycosylated at least at one position selected from the group
consisting of Asn.sup.15, Asn.sup.51, Asn.sup.80, Asn.sup.140,
Asn.sup.252 and Asn.sup.300 of SEQ ID NO:2. In another embodiment,
the LAL is N-linked glycosylated at Asn.sup.15, Asn.sup.80,
Asn.sup.140, Asn.sup.252 and Asn.sup.300 of SEQ ID NO:2. In yet
another embodiment, N-glycan structures of LAL of SEQ ID NO:2 have
no xylose while less than 15%, 10%, 5%, or 1% of N-glycan
structures contain sialic acid; less than 50%, 40%, 30%, 20%, 10%,
5% or 1% of N-glycan structures contain fucose; and at least 30%,
50%, 60%, 70%, 80%, 90% and 95% of N-glycan structures contain
phosphorylated mannose (M6P). S
[0134] In one embodiment, the LAL is N-linked glycosylated at least
at one position selected from the group consisting of Asn.sup.13,
Asn.sup.49, Asn.sup.78, Asn.sup.138, Asn.sup.250 and Asn.sup.298 of
SEQ ID NO:3. In another embodiment, the LAL is N-linked
glycosylated at Asn.sup.13, Asn.sup.78, Asn.sup.138, Asn.sup.250
and Asn.sup.298 of SEQ ID NO:3. In yet another embodiment, N-glycan
structures of LAL of SEQ ID NO:3 have no xylose while less than
15%, 10%, 5%, or 1% of N-glycan structures contain sialic acid;
less than 50%, 40%, 30%, 20%, 10%, 5% or 1% of N-glycan structures
contain fucose; and at least 30%, 50%, 60%, 70%, 80%, 90% and 95%
of N-glycan structures contain phosphorylated mannose (M6P).
[0135] In one embodiment, the LAL is N-linked glycosylated at least
at one position selected from the group consisting of Asn.sup.10,
Asn.sup.46, Asn.sup.75, Asn.sup.135, Asn.sup.247 and Asn.sup.295 of
SEQ ID NO:4. In another embodiment, the LAL is N-linked
glycosylated at Asn.sup.10, Asn.sup.75, Asn.sup.135, Asn.sup.247
and Asn.sup.295 of SEQ ID NO:4. In yet another embodiment, N-glycan
structures of LAL of SEQ ID NO:4 have no xylose while less than
15%, 10%, 5%, or 1% of N-glycan structures contain sialic acid;
less than 50%, 40%, 30%, 20%, 10%, 5% or 1% of N-glycan structures
contain fucose; and at least 30%, 50%, 60%, 70%, 80%, 90% and 95%
of N-glycan structures contain phosphorylated mannose (M6P).
[0136] In one embodiment, the LAL is N-linked glycosylated at least
at one position selected from the group consisting of Asn.sup.9,
Asn.sup.45, Asn.sup.74, Asn.sup.134, Asn.sup.246 and Asn.sup.294 of
SEQ ID NO:19. In another embodiment, the LAL is N-linked
glycosylated at Asn.sup.9, Asn.sup.74, Asn.sup.134, Asn.sup.246 and
Asn.sup.294 of SEQ ID NO:19. In yet another embodiment, N-glycan
structures of LAL of SEQ ID NO:4 have no xylose while less than
15%, 10%, 5%, or 1% of N-glycan structures contain sialic acid;
less than 50%, 40%, 30%, 20%, 10%, 5% or 1% of N-glycan structures
contain fucose; and at least 30%, 50%, 60%, 70%, 80%, 90% and 95%
of N-glycan structures contain phosphorylated mannose (M6P).
[0137] The composition according to the present invention can be
produced a number of ways, including by use of transgenic avians,
transgenic fish, transgenic mammals, for example, transgenic goats
or in transgenic plants, such as tobacco and duck weed (Lemna
minor) and certain types of cell culture.
[0138] The present invention also contemplates compositions
comprising PEGylated LAL. LAL enzyme as described herein can be
PEGylated as disclosed, for example, in U.S. Patent publication No.
20070092486, published Apr. 26, 2007, the disclosure of which is
incorporated it its entirety herein by reference.
[0139] In one embodiment, the derived glycosylation pattern is
obtained through expression specialized expression systems, for
example, from avian oviduct cells, for example, tubular gland
cells. For example, glycosylation patterns disclosed herein have
been demonstrated to be present on lysosomal storage disease
enzymes produced in oviduct cells of an avian such as a chicken in
accordance with the present invention.
[0140] Proteins produced in accordance with the invention can be
purified from egg white by any useful procedure such as those
apparent to a practitioner of ordinary skill in the art of protein
purification. For example, the human LAL (hLAL) produced in
transgenic avians in accordance with the invention can be purified
from egg white by methods apparent to practitioners of ordinary
skill in the art of protein purification. An example of a
purification protocol for LAL present in egg white is described in
the Examples.
[0141] The invention includes the eggs and egg white and the avians
(e.g., chicken turkey and quail) that lay the eggs and produce the
egg white containing lysosomal acid lipase molecules of the
invention comprising one or more of the glycosylation structures
disclosed herein.
Expression of LAL in Avians
[0142] Disclosed herein are vectors and methods for the stable
introduction of exogenous nucleic acid sequences into the genome of
avians to express desired proteins such as those which benefit
(e.g., attain an increased efficacy) from the addition of
mannose-6-phospahate such as lysosomal enzymes including, without
limitation, lysosomal acid lipase (LAL) and other proteins such as
those specifically disclosed herein. In particular, transgenic
avians are produced which express exogenous sequences in their
oviducts and which deposit exogenous proteins, such as
pharmaceutical proteins, into their eggs. Avian eggs that contain
such exogenous proteins are also described herein. Also disclosed
herein are novel forms of LAL which are efficiently expressed in
the oviduct of transgenic avians and deposited into avian eggs.
[0143] One aspect of the invention relates to compositions
containing LAL, i.e., LAL molecules produced in accordance with the
invention. In a particularly useful embodiment, the LAL is purified
or isolated. For example, the LAL has been removed from the
contents of a hard shell egg laid by a transgenic avian. In one
particularly useful embodiment, the LAL is human LAL. In one
embodiment, the LAL of the invention has a glycosylation pattern
resulting from the LAL being produced in an oviduct cell of an
avian. For example, the compositions can contain a mixture of LAL
molecules produced in avians, for example, chickens, in accordance
with the invention and isolated from egg white. In one useful
embodiment, the LAL containing compositions are pharmaceutical
formulations.
[0144] In one aspect, the invention is drawn to compositions
containing isolated LAL molecules, for example, human LAL
molecules, wherein the LAL is produced in an avian which contains a
transgene encoding the LAL. In one embodiment, the LAL is produced
in an oviduct cell (e.g., a tubular gland cell) of a transgenic
avian (e.g., transgenic chicken) and the LAL is isolated from egg
white of the transgenic avian. In one embodiment, the LAL is
glycosylated in the oviduct cell (e.g., tubular gland cell) of the
bird, for example, a chicken.
[0145] In another aspect, methods for producing exogenous proteins
such as lysosomal storage disease enzymes, for example, LAL, in
specific tissues of avians, are provided. Such exogenous proteins
may be expressed in the oviduct, blood and/or other cells and
tissues of the avian. In one embodiment, transgenes are introduced
into embryonic blastodermal cells, for example, near stage X, to
produce a transgenic avian, such that the protein of interest is
expressed in the tubular gland cells of the magnum of the oviduct,
secreted into the lumen, and deposited into the egg white of a hard
shell egg. A transgenic avian so produced can carry the transgene
in its germ line providing transmission of the exogenous transgene
to the avian's offspring stably in a Mendelian fashion.
[0146] The present invention encompasses methods of producing
exogenous protein such as LAL in an avian oviduct. The methods may
include a first step of providing a vector that contains a coding
sequence and a promoter operably linked to the coding sequence, so
that the promoter can effect expression of the nucleic acid in the
avian oviduct. Transgenic cells and/or tissues can be produced,
wherein the vector is introduced into avian embryonic blastodermal
cells, either freshly isolated, in culture, or in an embryo, so
that the vector sequence is inserted into the avian genome. A
mature transgenic avian which expresses the exogenous protein such
as LAL in its oviduct can be derived from the transgenic cells
and/or tissue.
[0147] In one aspect of the invention, production of a transgenic
avian is accomplished by transduction of embryonic blastodermal
cells with replication-defective or replication-competent
retroviral particles carrying the transgene between the 5' and 3'
LTRs of the retroviral rector. For instance, an avian leukosis
virus (ALV) retroviral vector or a murine leukemia virus (MLV)
retroviral vector may be used which comprises a modified pNLB
plasmid containing an exogenous gene that is inserted downstream of
a segment of a promoter region. An RNA copy of the modified
retroviral vector, packaged into viral particles, can be used to
infect embryonic blastoderms which develop into transgenic
avians.
[0148] Another aspect of the invention provides a vector which
includes a coding sequence and a promoter in operational and
positional relationship such that the coding sequence is expressed
in an avian oviduct. Such vectors include, but are not limited to,
an avian leukosis virus (ALV) retroviral vector, a murine leukemia
virus (MLV) retroviral vector, and a lentivirus vector. In
addition, the vector may be a nucleic acid sequence which includes
an LTR of an avian leukosis virus (ALV) retroviral vector, a murine
leukemia virus (MLV) retroviral vector, or a lentivirus vector. The
promoter is sufficient for effecting expression of the coding
sequence in the avian oviduct. The coding sequence codes for an
exogenous protein which is deposited into the egg white of a hard
shell egg. As such, the coding sequence codes for exogenous
proteins such as transgenic poultry derived proteins such as
transgenic poultry derived lysosomal acid lipase (TPD LAL).
[0149] In one embodiment, vectors used in the methods of the
invention contain a promoter which is particularly suited for
expression of exogenous proteins in avians and their eggs. As such,
expression of the exogenous coding sequence may occur in the
oviduct and blood of the transgenic avian and in the egg white of
its avian egg. The promoters include, but are not limited to, a
cytomegalovirus (CMV) promoter, a rous-sarcoma virus (RSV)
promoter, a .beta.-actin promoter (e.g., a chicken .beta.-actin
promoter), a murine leukemia virus (MLV) promoter, a mouse mammary
tumor virus (MMTV) promoter, an ovalbumin promoter, a lysozyme
promoter, a conalbumin promoter, an ovomucoid promoter, an ovomucin
promoter, and an ovotransferrin promoter. Optionally, the promoter
may be a segment of at least one promoter region, such as a segment
of the ovalbumin, lysozyme, conalbumin, ovomucoid, ovomucin, and
ovotransferrin promoter region. In one embodiment, the promoter is
a combination or a fusion of one or more promoters or a fusion of a
portion of one or more promoters such as ovalbumin, lysozyme,
conalbumin, ovomucoid, ovomucin, and ovotransferrin promoters.
[0150] In one embodiment, the vector includes a signal peptide
coding sequence which is operably linked to the coding sequence, so
that upon translation in a cell, the signal peptide directs
secretion of the exogenous protein expressed by the vector, such as
human LAL, into the egg white of a hard shell egg.
[0151] One aspect of the invention provides for coding sequences
for exogenous proteins produced as disclosed herein wherein the
coding sequence is codon optimized for expression in an avian, for
example, in a chicken. Codon optimization may be determined from
the codon usage of at least one, and preferably more than one,
protein expressed in an avian cell (e.g., a chicken cell). For
example, the codon usage may be determined from the nucleic acid
sequences encoding the proteins ovalbumin, lysozyme, ovomucin and
ovotransferrin of chicken. For example, the DNA coding sequence for
the exogenous protein may be codon optimized using the
BACKTRANSLATE.RTM. program of the Wisconsin Package, version 9.1
(Genetics Computer Group, Inc., Madison, Wis.) with a codon usage
table compiled from the chicken (Gallus gallus) ovalbumin,
lysozyme, ovomucoid, and ovotransferrin proteins.
[0152] One important aspect of the present invention relates to
avian hard shell eggs (e.g., chicken hard shell eggs) which contain
an exogenous peptide or protein including, but not limited to, a
human LAL. The exogenous peptide or protein such as human LAL may
be encoded by a transgene of a transgenic avian. Often, the
exogenous peptide or protein (e.g., LAL) is glycosylated. The
protein may be present in any useful amount. In one embodiment, the
protein is present in an amount in a range of between about 0.01
.mu.g per hard-shell egg and about 1 gram per hard-shell egg. In
another embodiment, the protein is present in an amount in a range
of between about 1 .mu.g per hard-shell egg and about 1 gram per
hard-shell egg. For example, the protein may be present in an
amount in a range of between about 10 .mu.g per hard-shell egg and
about 1 gram per hard-shell egg (e.g., a range of between about 10
.mu.g per hard-shell egg and about 400 milligrams per hard-shell
egg).
[0153] In one embodiment, the exogenous protein of the invention is
present in the egg white of the egg. In one embodiment, the protein
is present in an amount in a range of between about 1 ng per
milliliter of egg white and about 0.2 gram per milliliter of egg
white. For example, the protein may be present in an amount in a
range of between about 0.1 .mu.g per milliliter of egg white and
about 0.2 gram per milliliter of egg white (e.g., the protein may
be present in an amount in a range of between about 1 .mu.g per
milliliter of egg white and about 100 milligrams per milliliter of
egg white. In one embodiment, the protein is present in an amount
in a range of between about 1 .mu.g per milliliter of egg white and
about 50 milligrams per milliliter of egg white. For example, the
protein may be present in an amount in a range of about 1 .mu.g per
milliliter of egg white and about 10 milligrams per milliliter of
egg white (e.g., the protein may be present in an amount in a range
of between about 1 .mu.g per milliliter of egg white and about 1
milligrams per milliliter of egg white). In one embodiment, the
protein is present in an amount of more than 0.1 .mu.g per
milliliter of egg white. In one embodiment, the protein is present
in an amount of more than 0.5 .mu.g per milliliter of egg white. In
one embodiment, the protein is present in an amount of more than 1
.mu.g per milliliter of egg white. In one embodiment, the protein
is present in an amount of more than 1.5 .mu.g per milliliter of
egg white.
[0154] The avians of the invention which produce exogenous proteins
disclosed herein (e.g., LAL) which are developed from the
blastodermal cells into which the vector has been introduced are
the G0 generation and can be referred to as "founders." Founder
birds are typically chimeric for each inserted transgene. That is,
only some of the cells of the G0 transgenic bird contain the
transgene(s). The G0 generation typically is also hemizygous for
the transgene(s). The G0 generation may be bred to non-transgenic
animals to give rise to G1 transgenic offspring which are also
hemizygous for the transgene and contain the transgene(s) in
essentially all of the bird's cells. The G1 hemizygous offspring
may be bred to non-transgenic animals giving rise to G2 hemizygous
offspring or may be bred together to give rise to G2 offspring
homozygous for the transgene. Substantially all of the cells of
birds which are positive for the transgene that are derived from G1
offspring contain the transgene(s). In one embodiment, hemizygotic
G2 offspring from the same line can be bred to produce G3 offspring
homozygous for the transgene. In one embodiment, hemizygous G0 or
G1 animals, for example, are bred together to give rise to
homozygous G1 offspring containing two copies of the transgene(s)
in each cell of the animal. These are merely examples of certain
useful breeding methods and the present invention contemplates the
employment of any useful breeding method such as those known to
individuals of ordinary skill in the art.
[0155] In one embodiment, the invention provides for the LAL to be
isolated. That is, the LAL contained in the composition may be an
isolated LAL. For example, the LAL may be isolated from egg white.
The isolated LAL may be LAL molecules having a variety of
glycosylation structures among the LAL molecules.
[0156] By the methods of the present invention, transgenes can be
introduced into avian embryonic blastodermal cells to produce a
transgenic chicken, transgenic turkey, transgenic quail and other
avian species, that carry the transgene in the genetic material of
its germ-line tissue in order to produce proteins of the invention.
The blastodermal cells are typically stage VII-XII cells, or the
equivalent thereof, and in one embodiment are near stage X.
[0157] Some vectors useful in carrying out the methods of the
present invention are described herein. In one embodiment, the
coding sequence and the promoter of the vector are both positioned
between 5' and 3' LTRs before introduction into blastodermal cells.
In one embodiment, the vector is retroviral and the coding sequence
and the promoter are both positioned between the 5' and 3' LTRs of
the retroviral vector. In one useful embodiment, the LTRs or
retroviral vector is derived from the avian leukosis virus (ALV),
murine leukemia virus (MLV), or lentivirus.
[0158] In one embodiment, vectors are used for transfecting
blastodermal cells and generating stable integration into the avian
genome contain a coding sequence and a promoter in operational and
positional relationship to express the coding sequence in the
tubular gland cell of the magnum of the avian oviduct, wherein the
exogenous protein such as an lysosomal enzyme (e.g., LAL) is
deposited in the egg white of a hard shell egg.
[0159] The promoter may optionally be a segment of the ovalbumin
promoter region which is sufficiently large to direct expression of
the coding sequence in the tubular gland cells. Truncating the
ovalbumin promoter and/or condensing the critical regulatory
elements of the ovalbumin promoter so that it retains sequences
required for expression in the tubular gland cells of the magnum of
the oviduct, while being small enough that it can be readily
incorporated into vectors is included within the scope of the
invention. In one embodiment, a segment of the ovalbumin promoter
region may be used. This segment comprises the 5'-flanking region
of the ovalbumin gene.
[0160] The promoter may also be a promoter that is largely, but not
entirely, specific to the magnum, such as the lysozyme promoter.
The promoter may also be a mouse mammary tumor virus (MMTV)
promoter. Alternatively, the promoter may be a constitutive
promoter (e.g., a cytomegalovirus (CMV) promoter, a rous-sarcoma
virus (RSV) promoter, a murine leukemia virus (MLV) promoter,
etc.). In one embodiment, the promoter is a cytomegalovirus (CMV)
promoter, a MDOT promoter, a rous-sarcoma virus (RSV) promoter, a
murine leukemia virus (MLV) promoter, a mouse mammary tumor virus
(MMTV) promoter, an ovalbumin promoter, a lysozyme promoter, a
conalbumin promoter, an ovomucoid promoter, an ovomucin promoter
and/or an ovotransferrin promoter. Optionally, the promoter may be
at least one segment of a promoter region, such as a segment of the
ovalbumin, lysozyme, conalbumin, ovomucoid, ovomucin, and
ovotransferrin promoter region.
[0161] In one method of transfecting blastodermal cells, a packaged
retroviral-based vector is used to deliver the vector into
embryonic blastodermal cells so that the vector is integrated into
the avian genome.
[0162] Useful retrovirus for randomly introducing a transgene into
the avian genome is the replication-deficient avian leucosis virus
(ALV), the replication-deficient murine leukemia virus (MLV), or
the lentivirus. In one embodiment, a pNLB vector is modified by
inserting a region of the ovalbumin promoter and one or more
exogenous genes between the 5' and 3' long terminal repeats (LTRs)
of the retrovirus genome. The invention contemplates that any
coding sequence placed downstream of a promoter that is active in
tubular gland cells can be expressed in the tubular gland cells.
For example, the ovalbumin promoter can be expressed in the tubular
gland cells of the oviduct magnum because the ovalbumin promoter
drives the expression of the ovalbumin protein and is active in the
oviduct tubular gland cells.
[0163] Any of the vectors described herein can also optionally
include a coding sequence encoding a signal peptide that directs
secretion of the protein expressed by the vector's coding sequence
from the tubular gland cells of the oviduct. This aspect
effectively broadens the spectrum of exogenous proteins that may be
deposited in avian eggs using the methods described herein. Where
an exogenous protein would not otherwise be secreted, the vector
containing the coding sequence is modified to comprise a DNA
sequence comprising about 60 bp encoding a signal peptide from the
lysozyme gene. The DNA sequence encoding the signal peptide is
inserted in the vector such that it is located at the N-terminus of
the protein encoded by the DNA.
[0164] Another aspect of the invention involves the use of internal
ribosome entry site (IRES) elements in any of the vectors of the
present invention to allow the translation of two or more proteins
from a dicistronic or polycistronic mRNA. The IRES units are fused
to 5' ends of one or more additional coding sequences which are
then inserted into the vectors at the end of the original coding
sequence, so that the coding sequences are separated from one
another by an IRES.
[0165] In one embodiment when using an IRES, post-translational
modification of the product is facilitated because one coding
sequence can encode an enzyme capable of modifying the other coding
sequence product. For example, the first coding sequence may encode
collagen which would be hydroxylated and made active by the enzyme
encoded by the second coding sequence wherein an IRES is employed
as is understood in the art.
[0166] In another aspect, the coding sequences of vectors used in
any of the methods of the present invention are provided with a 3'
untranslated region (3' UTR) to confer stability to the RNA
produced. When a 3' UTR is added to a retroviral vector, the
orientation of the promoter, gene X and the 3' UTR must be reversed
in the construct, so that the addition of the 3' UTR does not
interfere with transcription of the full-length genomic RNA. In one
embodiment, the 3' UTR may be that of the ovalbumin or lysozyme
genes, or any 3' UTR that is functional in a magnum cell, i.e., the
SV40 late region.
[0167] In one embodiment, a constitutive promoter is used to
express the coding sequence of a transgene in the avian. In this
case, expression is not limited to the magnum; expression also
occurs in other tissues within the avian (e.g., blood). The use of
such a transgene, which includes a constitutive promoter and a
coding sequence, is particularly suitable for effecting or driving
the expression of a protein in the oviduct and the subsequent
secretion of the protein into the egg.
[0168] Transducing particles (i.e., transduction particles) are
produced for the vector and titered to determine the appropriate
concentration that can be used to inject embryos. Avian eggs are
windowed according to the Speksnijder procedure (U.S. Pat. No.
5,897,998, the disclosure of which is incorporated in its entirety
herein by reference), and eggs are injected with transducing
particles. Eggs hatch about 21 days after injection and male birds
are selected for breeding. In order to screen for G0 roosters which
contain the transgene in their sperm, DNA is extracted from rooster
sperm samples. The G0 roosters with the highest levels of the
transgene in their sperm samples are bred to nontransgenic hens by
artificial insemination. Blood DNA samples are screened for the
presence of the transgene. The serum of transgenic roosters is
tested for the presence of exogenous protein. If the exogenous
protein is confirmed, the sperm of the transgenic roosters is used
for artificial insemination of nontransgenic hens. A certain
percent of the offspring then contains the transgene (e.g., more
than 50%). When exogenous protein is present in eggs produced in
accordance with the present invention the protein may be isolated.
The protein may also be tested for biological activity.
[0169] The methods of the invention which provide for the
production of exogenous protein in the avian oviduct and the
production of eggs which contain exogenous protein involve an
additional step subsequent to providing a suitable vector and
introducing the vector into embryonic blastodermal cells so that
the vector is integrated into the avian genome. The subsequent step
involves deriving a mature transgenic avian from the transgenic
blastodermal cells produced in the previous steps. Mature
transgenic avians can be obtained from the cells of a blastodermal
embryo which has been transfected or transduced with the vector
directly within the embryo. The resulting embryo is allowed to
develop and the chick allowed to mature.
[0170] The transgenic avian produced from blastodermal cells is
known as a founder. Some founders will carry the transgene in
tubular gland cells in the magnum of their oviducts. These avians
will express the exogenous protein encoded by the transgene in
their oviducts. The exogenous protein may also be expressed in
other tissues (e.g., blood) in addition to the oviduct. If the
exogenous protein contains the appropriate signal sequence(s), it
will be secreted into the lumen of the oviduct and into the egg
white of the egg.
[0171] Some founders are germ-line founders. A germ-line founder is
a founder that carries the transgene in genetic material of its
germ-line tissue, and may also carry the transgene in oviduct
magnum tubular gland cells that express the exogenous protein.
Therefore, in accordance with the invention, the transgenic avian
may have tubular gland cells expressing the exogenous protein, and
the offspring of the transgenic avian may also have oviduct magnum
tubular gland cells that express the exogenous protein.
Alternatively, the offspring express a phenotype determined by
expression of the exogenous gene in specific tissue(s) of the
avian. In one embodiment, the transgenic avian is a chicken or a
turkey.
Pharmaceutical Compositions & Therapeutic Methods
[0172] While it is possible that, for use in therapy, therapeutic
proteins produced as described herein may be administered in raw
form, it is preferable to administer the therapeutic proteins as
part of a pharmaceutical formulation. Therefore, further provided
are pharmaceutical formulations comprising poultry derived
glycosylated therapeutic proteins such as LAL or a pharmaceutically
acceptable derivative thereof together with one or more
pharmaceutically acceptable carriers thereof and, optionally, other
therapeutic and/or prophylactic ingredients and methods of
administering such pharmaceutical formulations. The carrier(s) must
be "acceptable" in the sense of being compatible with the other
ingredients of the formulation and not deleterious to the recipient
thereof. Methods of treating a patient (e.g., quantity of
pharmaceutical protein administered, frequency of administration
and duration of treatment period) using pharmaceutical compositions
of the invention can be determined using standard methodologies
known to physicians of skill in the art.
[0173] Compositions comprising carriers, including composite
molecules, are formulated by well-known conventional methods (see,
for example, Remington's Pharmaceutical Sciences, 14th Ed., Mack
Publishing Co., Easton, Pa.), the entire teachings of which are
incorporated herein by reference. The carrier may comprise a
diluent. In one embodiment, the pharmaceutical carrier can be a
liquid and the recombinant human LAL can be in the form of a
solution. The pharmaceutical carrier can be wax, fat, or alcohol.
In one embodiment, the wax- or fat-based carrier does not contain
ester. In another embodiment, the pharmaceutically acceptable
carrier may be a solid in the form of a powder, a lyophilized
powder, or a tablet. In one embodiment, the carrier may comprise a
liposome or a microcapsule.
[0174] The pharmaceutical formulations include those suitable for
administration by injection including intramuscular, sub-cutaneous
and intravenous administration. Pharmaceutical formulations include
those suitable for oral, rectal, nasal, topical (including buccal
and sub-lingual), vaginal or parenteral. The pharmaceutical
formulations also include those for administration by inhalation or
insufflation. The formulations may, where appropriate, be
conveniently presented in discrete dosage units and may be prepared
by any of the methods well known in the art of pharmacy. The
methods of producing the pharmaceutical formulations typically
include the step of bringing the therapeutic protein into
association with liquid carriers or finely divided solid carriers
or both and then, if necessary, shaping the product into the
desired formulation.
[0175] Pharmaceutical formulations suitable for oral administration
may conveniently be presented as discrete units such as capsules,
cachets or tablets each containing a predetermined amount of the
active ingredient; as a powder or granules; as a solution; as a
suspension; or as an emulsion. The active ingredient may also be
presented as a bolus, electuary or paste. Tablets and capsules for
oral administration may contain conventional excipients such as
binding agents, fillers, lubricants, disintegrants, or wetting
agents. The tablets may be coated according to methods well known
in the art. Oral liquid preparations may be in the form of, for
example, aqueous or oily suspensions, solutions, emulsions, syrups
or elixirs, or may be presented as a dry product for constitution
with water or other suitable vehicle before use. Such liquid
preparations may contain conventional additives such as suspending
agents, emulsifying agents, non-aqueous vehicles (which may include
edible oils) or preservatives.
[0176] LAL may also be formulated for parenteral administration
(e.g., by injection, for example, bolus injection or continuous
infusion) and may be presented in unit dose form in ampoules,
pre-filled syringes, small volume infusion or in multi-dose
containers with an added preservative. The therapeutic proteins can
be injected by, for example, subcutaneous injections, intramuscular
injections, and intravenous infusions or injections.
[0177] The LAL may take such forms as suspensions, solutions, or
emulsions in oily or aqueous vehicles, and may contain formulatory
agents such as suspending, stabilizing and/or dispersing agents. It
is also contemplated that the therapeutic protein may be in powder
form, obtained by aseptic isolation of sterile solid or by
lyophilization from solution, for constitution with a suitable
vehicle, e.g., sterile, pyrogen-free water, before use.
[0178] For intravenous infusions or injection, the LAL produced in
accordance of the invention can be formulated as an aqueous
supension or solution. Excipients suitable for the formulation for
intravenous infusion or injection can include one of the following:
trisodium citrate dehydrate, citric acid and human serum albumin.
The pharmaceutical formulation can also include other suitable
excipients well known in the art used for other products for
lysosomal storage disorders. The pH of LAL produced in accordance
with the invention is maintained between about 5.6 and about 6.2.
Preferably, the pH of the LAL formulation is maintained at
5.9.+-.0.2.
[0179] For topical administration to the epidermis, the therapeutic
proteins of the invention produced according to the invention may
be formulated as ointments, creams or lotions, or as a transdermal
patch. Ointments and creams may, for example, be formulated with an
aqueous or oily base with the addition of suitable thickening
and/or gelling agents. Lotions can be formulated with an aqueous or
oily base and can also contain one or more emulsifying agents,
stabilizing agents, dispersing agents, suspending agents,
thickening agents or coloring agents.
[0180] Formulations suitable for topical administration in the
mouth include lozenges comprising active ingredient in a flavored
base, usually sucrose and acacia or tragacanth; pastilles
comprising the active ingredient in an inert base such as gelatin
and glycerin or sucrose and acacia; and mouthwashes comprising the
active ingredient in a suitable liquid carrier.
[0181] Pharmaceutical formulations suitable for rectal
administration wherein the carrier is a solid are most preferably
represented as unit dose suppositories. Suitable carriers include
cocoa butter and other materials commonly used in the art, and the
suppositories may be conveniently formed by a mixture of the active
compound with the softened or melted carrier(s) followed by
chilling and shaping in molds.
[0182] Formulations suitable for vaginal administration may be
presented as pessaries, tampons, creams, gels, pastes, foams or
sprays containing in addition to the active ingredient, such
carriers as are known in the art to be appropriate.
[0183] For intra-nasal administration the therapeutic proteins of
the invention may be used as a liquid spray or dispersible powder
or in the form of drops. Drops may be formulated with an aqueous or
non-aqueous base also comprising one or more dispersing agents,
solubilizing agents or suspending agents. Liquid sprays are
conveniently delivered from pressurized packs.
[0184] For administration by inhalation, therapeutic proteins
according to the invention may be conveniently delivered from an
insufflator, nebulizer or a pressurized pack or other convenient
means of delivering an aerosol spray. Pressurized packs may
comprise a suitable propellant such as dichlorodifluoromethane,
trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide
or other suitable gas. In the case of a pressurized aerosol, the
dosage unit may be determined by providing a valve to deliver a
metered amount.
[0185] For administration by inhalation or insufflation, the
therapeutic proteins according to the invention may take the form
of a dry powder composition, for example, a powder mix of the
compound and a suitable powder base such as lactose or starch. The
powder composition may be presented in unit dosage form in, for
example, capsules or cartridges or, e.g., gelatin or blister packs
from which the powder may be administered with the aid of an
inhalator or insufflator.
[0186] When desired, the above described formulations adapted to
give sustained release of the active ingredient, may be
employed.
[0187] The pharmaceutical compositions described herein may also
contain other active ingredients such as antimicrobial agents, or
preservatives.
[0188] In addition, it is contemplated that the therapeutic
proteins disclosed herein may be used in combination with other
therapeutic agents. For example, the invention provides methods for
pretreatment with a pharmaceutically effective dose of an
antihistamine to minimize or prevent potential infusion-related
anaphylactic reactions. For example, the antihistamine may be any
pharmaceutically acceptable antihistamine (e.g. diphenhydramine) as
disclosed herein and as known in the art. In one embodiment, the
antihistamine is administered in a dose between about 1 mg and
about 10 mg per kilogram of body weight. For example, the
antihistamine may be administered in a dose of about 5 mg per
kilogram. In one embodiment, the antihistamine is administered
between about 10 minutes and about 90 minutes, for example, about
30 minutes to about 60 minutes, prior to administration of
lysosomal acid lipase using an ambulatory system connected to the
vascular access port. In one embodiment, the dose of
diphenhydramine effectively counteracts potential anaphylactic
infusion reactions.
[0189] Immunosuppresants such as antihistamines, corticosteroids,
sirolimus, voclosporin, ciclosporin, methotrexate, IL-2 receptor
directed antibodies, T-cell receptor directed antibodies,
TNF-.alpha. directed antibodies or fusion proteins (infliximab,
etanercept or adalimumab), CTLA4-Ig (e.g., abatacept), anti-OX-40
antibodies can also be administered before, during or after LAL
administration if an anaphylactic reaction or adverse immune
response is experienced by the patient.
[0190] The invention also contemplates therapy involving
administration of LAL-containing compositions in combination with
one or more cholesterol lowering agents (e.g., HMG-CoA reductase
inhibitors). Non-limiting examples of such agents include:
atorvastatin (Lipitor.RTM. and Torvast.RTM.), fluvastatin
(Lescol.RTM.), lovastatin (Mevacor.RTM., Altocor.RTM.,
Altoprev.RTM.), pitavastatin (Livalo.RTM., Pitava.RTM.),
pravastatin (Pravachol.RTM., Selektine.RTM., Lipostat.RTM.),
rosuvastatin (Crestor.RTM.) and simvastatin (Zocor.RTM.,
Lipex.RTM.).
[0191] Compositions or proteins described herein can be used to
treat a variety of conditions. For example, there are conditions
for which treatment therapies are known to practitioners of skill
in the art. The present invention contemplates that the therapeutic
proteins (e.g., LAL) produced in an avian system containing a
poultry derived glycosylation pattern can be employed to treat such
conditions. That is, the treatment of conditions known to be
treatable by conventionally produced therapeutic proteins by using
therapeutic proteins produced as described herein is also
contemplated. For example, LAL produced as described herein can be
used to treat conditions resulting from or associated with LAL
deficiency or insufficiency (collectively, "LAL deficiency"), such
as Wolman disease and cholesteryl ester storage disease (CESD). As
described herein, LAL deficiency also contemplates conditions in
which expression of LAL is reduced due to a condition (e.g., a
genetic mutation), physiological or environmental factors which
leads to a reduction or deficiency of LAL produced in the body. LAL
produced as described herein can also be used to treat other
conditions such as atherosclerosis, fatty liver disease,
non-alcoholic fatty liver disease, nonalcoholic steatohepatitis
(NASH) and cirrhosis. LAL produced as described herein can also be
used to treat other conditions such as those disclosed in U.S. Pat.
No. 6,849,257, issued Feb. 1, 2005, the disclosure of which is
incorporated in its entirety herein by reference, U.S. publication
No. 2009/0297496, published Dec. 3, 2009; US publication No.
2004/0223960, published Nov. 11, 2004; US publication No.
2007/0264249, published Nov. 15, 2009, the disclosures of which
(i.e., the disclosures of each of these four patent publications)
are incorporated in their entirety herein by reference.
[0192] It is also contemplated that LAL produced as disclosed
herein can be used to treat certain specific conditions including
pancreatitis, for example, chronic pancreatitis and/or acute
pancreatitis as well as alcohol induced pancreatic injury such as
alcohol induced pancreatitis.
[0193] LAL produced by any useful method, such as the ones
disclosed herein, is contemplated for use to treat diseases due to
alcohol induced cell injury including, but not limited to, those
alcohol induced cell injuries that result in accumulation of lipid
esters in body tissue such as, but not limited to, liver, spleen,
gut and cardiovascular tissue. The invention also contemplates the
treating of malabsorption by administering LAL.
[0194] One aspect of the invention is drawn to methods of treating
a patient comprising administering to a patient a therapeutically
effective amount of a composition comprising recombinant human LAL
as described herein. The patient can be suffering or diagnosed with
any number of conditions, including those associated with LAL
deficiency. In one embodiment, the therapeutically effective amount
is an amount that increases the red blood cell count in a patient
by a desired amount. It is contemplated that LAL produced in
accordance with the invention can be used to treat chronic kidney
disease, for example, where tissues fail to sustain production of
lysosomal acid lipase.
[0195] It is also contemplated that LAL produced by any useful
method may be useful for the treatment of patients with Tangier
disease and familial hypoalphalipoproteinemia. Tangier
disease/familial hypoalphalipoproteinemia is associated with the
accumulation of cholesterol esters in macrophages accompanied by
hepatosplenomegaly and/or lymphadenopathy along with low levels of
high-density lipoproteins (HDL) which can be treated by the
administration of LAL. For example, without wishing to limit the
invention to any particular theory or mechanism of operation, it is
believed that impaired LAL activity decreases ABCA1 expression and
conversely an increased LAL activity obtained by the administration
of LAL to a patient with Tangier disease/familial
hypoalphalipoproteinemia will increase ABCA1 expression to overcome
the effects of an ABCA1 gene with a reduced functional activity as
a result of polymorphism.
[0196] For the treatment of a condition, generally, the dosage
administered can vary depending upon known factors such as age,
health and weight of the recipient, type of concurrent treatment,
frequency of treatment, and the like. Usually, a dosage of active
ingredient can be between about 0.0001 and about 10 milligrams per
kilogram of body weight. Precise dosage, frequency of
administration and time span of treatment can be determined by a
physician skilled in the art of administration of the respective
therapeutic protein.
[0197] In addition, it has been discovered that dosages of 1 mg/kg
and less can be effective in treating LAL deficiencies. The present
invention provides methods of treating conditions comprising
administering to a mammal (e.g. a patient, preferably a human
patient) a therapeutically effective dose of lysosomal acid lipase
between one time every 5 days and one time every 25 days, for
example, between one time every 7 days and one time every 14 days.
In one embodiment, the dose of lysosomal acid lipase administered
is between about 0.1 mg and about 50 mg per kilogram of body
weight, for example, the dose may be between about 1 mg and 5 mg
per kilogram.
[0198] In one particularly useful embodiment, the invention
provides methods of treating a condition by administering a dose of
lysosomal acid lipase of between about 0.1 mg and 1.0 mg per
kilogram of body weight in accordance with any therapeutically
effective dosage regime such as those described herein.
[0199] The invention provides methods for treating any complication
of LAL deficiency which may benefit from administering a
therapeutically effective dose of LAL. In one embodiment,
malabsorption and growth failure may be treated in accordance with
the methods described herein. In another embodiment, complications
seen in LAL deficiency patients including but not restricted to
hepatomegaly and liver dysfunction may be treated using the methods
provided herein.
[0200] The invention provides for treatment with recombinant LAL
(e.g. recombinant human LAL) that can be produced by any useful
protein expression system, for example, transgenic mammals and
avians as is understood in the art. Other protein expression
systems may include, but are not limited to, cell culture,
bacteria, and plant systems.
[0201] The invention encompasses the administration of recombinant
LAL as a part of a pharmaceutically acceptable composition by any
route which may achieve the intended therapeutic effect, as
determined by a physician skilled in the art. In one embodiment,
the LAL may be administered by intravenous infusion over a period
of about five hours. For example, the infusion may be facilitated
by an ambulatory infusion pump connected to a vascular access port
(e.g. a Port-a-Cath).
[0202] The invention also includes monitoring clinical and
pathological presentation of the conditions, for example, Wolman
Disease and CESD, in the mammal (e.g. the human patient). In one
embodiment, the assessments consist of but are not limited to:
lipid analysis, chest x-ray, liver function tests, stool chart,
plasma mevalonic acid, immunogenicity, plasma lysosomal acid
lipase, chitotriosidase, PARC, portal hypertension, anthropometry,
volume and characterization of the liver, spleen, and
gastrointestinal tract using, for example, imaging technology. For
example, the aforementioned imaging technology may consist of
ultrasound, magnetic resonance imaging, and nuclear magnetic
resonance spectroscopy.
EXAMPLES
[0203] The present invention is further exemplified by the
following examples. The examples are for illustrative purpose only
and are not intended, nor should they be construed as limiting the
invention in any manner.
Example 1
Construction of Vector (pALVIN-OVR1-I-hLAL-dSA) Carrying
Recombinant Human Lysosomal Acid Lipase (rhLAL) Coding Sequence
[0204] The nucleotide sequence of the hLAL gene in the
pALVIN-OVR1-I-hLAL-dSA vector encodes a protein that is identical
to the amino acid sequence of the protein produced by the human
lysosomal acid lipase gene (GenBank Accession, NP.sub.--000226)
(FIG. 1). Transcription of this sequence and subsequent translation
of the resultant mRNA produces a 399 amino acid precursor protein,
which is processed to a mature 378 amino acid protein identical to
human LAL (GenBank Accession, NP.sub.--000226) (FIG. 1) as set
forth in SEQ ID NO:1. Expression of the hLAL gene (see FIG. 2 for
the cDNA sequence) in this Example is controlled by non-coding
elements derived from the ovalbumin gene including enhancer,
promoter, intronic, and 5' and 3' untranslated sequences. The
ovalbumin gene produces ovalbumin, the major protein constituent of
egg white. Activity of the chicken ovalbumin promoter is very
specific to the cells within the chicken oviduct that produce egg
white; expression in other tissues is minimal.
[0205] The plasmid vector pALVIN-OVR1-I-hLAL-dSA (FIG. 3A; the
nucleotide sequence of which is shown in FIG. 4) was used to
produce a replication-deficient retrovirus (RDR) that stably
integrated the hLAL transgene into the genome of the founder
(XLL109). This plasmid vector includes retroviral nucleotide
sequences required for viral RNA packaging, reverse transcription
and integration, but does not contain the intact sequences for the
viral gag, pol and env genes. The methods used to generate the
retroviral vector and their use in subsequent transgenesis
procedures are described herein.
[0206] The retroviral portion of pALVIN-OVR1-I-hLAL-dSA is based on
the ALV vector, pNLB. pNLB was modified such that the LTRs would be
self-inactivating (SIN) (FIG. 3B). To accomplish this, 273 bp of
the 3' LTR was deleted, which includes the enhancer and CAAT box of
the U3 region. Because the inactivated U3 region at the 3' end of
the retroviral sequence serves as a template for a new U3 region
present at the 5' end of an integrated provirus, 5' LTR is normally
also inactivated. The deletion of LTR sequences in the SIN
construct decreases promoter interference on the internal promoter
from the LTR, and minimizes the possibility for recombination of
sequences to form a replication competent retrovirus. The new
vector is termed pALVIN for ALV inactivation vector.
[0207] Downstream of the 5' LTR are the partial gag and env coding
sequences, which were carried over from the pNLB vector. In
pALVIN-OVR1-I-hLAL-dSA, a small portion (12%) of the gag protein
precursor sequence remains (55% of the p19 mature peptide sequence)
and a small portion (1.7%) of the env precursor sequence of RAV2
remains (GenBank Accession, AF033808). These truncated gag and env
regions are unable to produce functional proteins needed to create
replication competent retrovirus (Cosset, 1991).
[0208] Transcriptional and translational control elements of the
chicken ovalbumin gene were inserted into pALVIN to create
pALVIN-OV-1.1-I (sequence of which is shown in FIG. 6; SEQ ID NO:
8). The first section of pALVIN-OV-1.1-I is composed of a
contiguous section of the chicken ovalbumin gene which includes the
1.1 kb proximal promoter region, the first exon, first intron and
part of the 2.sup.nd exon. The next section is a stuffer insert
fragment that takes the place of the ovalbumin protein coding
sequences. The stuffer is followed by the 3' untranslated region
(UTR) of the chicken ovalbumin gene, which includes sequences that
facilitate proper processing of the mRNA, including
polyadenylation. In general, the stuffer fragment is replaced by
DNA fragments encoding the desired protein, in this case hLAL. The
result is a vector that has specific elements that promote
regulated transcriptional expression and translation of an mRNA in
the oviduct of transgenic chickens, that closely mimics regulation
of the endogenous ovalbumin mRNA, and that allows high expression
of the protein of interest in egg white.
[0209] The pALVIN-OV-1.1-I vector includes the first intron of the
ovalbumin gene. Because the intron is susceptible to splicing
during the production and packaging of the retroviral RNA genome,
we inserted the expression cassette in the opposite orientation
relative to the LTRs. In this way the intron is not recognizable in
the retroviral RNA and is packaged without splicing. For
convenience all maps in this document are drawn with the LTRs in
the opposite orientation and the expression cassette in the forward
or clockwise orientation.
[0210] pALVIN-OV-1.1-I is the base vector into which the coding
sequence (CDS) of hLAL was inserted. Two DNA fragments, hLAL
adaptor and Syn hLAL, which make up the hLAL CDS and sequences
required for compatibility with pALVIN-OV-1.1-I, were synthesized
at Integrated DNA Technologies, Coralville, Iowa, (see FIGS. 7 and
8; SEQ ID NOs: 9 and 10). A 229 bp HpaI/BamHI fragment of hLAL
adaptor and a 1113 bp BamHI/BstBI fragment of Syn hLAL were
inserted into the 7882 HpaI/BstBI fragment of pALVIN-OV-1.1-I,
thereby replacing the stuffer region with the hLAL CDS and creating
pALVIN-OV-1.1-1-hLAL.
[0211] It was discovered that there was a cryptic splice site in
the antisense strand of the hLAL CDS which prevented packaging of
intact retroviral RNA. The cryptic splice site was removed by
alteration of the DNA sequence without changing the amino acid
sequence of hLAL. This change was performed by polymerase chain
amplification of region 232 to 534 of pALVIN-OV-1.1-I-hLAL with
primer 5'-AGAAACTGAGAGTGTCTTAT-3' (SEQ ID NO: 12) and primer
5'-TGACAGCTGTGGATCCAGAAACAAACATG-3' (SEQ ID NO: 13), creating a 329
bp amplicon. This amplicon was digested with BamHI and SexAI and
ligated with the 8940 bp BamHI/SexAI fragment of
pALVIN-OV-1.1-I-hLAL to create pALVIN-OV-1.1-I-hLAL-dSA.
[0212] A putative promoter enhancer which contains DNase
hypersensitive site III (DHSIII) of the chicken ovalbumin gene
(-3819 to -2169 relative to the OV promoter start site) (Kaye,
Bellard et al. 1984) was inserted into pALVIN-OV-1.1-I-hLAL-dSA to
create pALVIN-OVR1-I-hLAL-dSA. This was performed as follows: a DNA
fragment which included the DHSIII enhancer and 1.1 kb proximal OV
promoter termed OVR1 promoter (see FIG. 9; and SEQ ID NO: 11 for
sequence) was isolated by digestion with XhoI and BlpI. To
facilitate subcloning, an adaptor fragment, PCR of pSIN-OV-1.1-1
was generated by PCR amplification of region 6752 to 7974 of
pALVIN-OV-1.1-I with primers 5'-GCCGCTCGAGCGAGGAATATAAAAAAATT-3'
(SEQ ID NO: 14) and 5'-TCCGCGCACATTTCCCCGAA-3'(SEQ ID NO: 15)
followed by digestion with NgoMI and XhoI. The 2772 bp XhoI/BlpI
fragment of OVR1 promoter and 1067 bp NgoMI/XhoI fragment of PCR of
pSIN-OV-1.1-I were inserted into the 7043 bp NgoMI/BlpI fragment of
pALVIN-OV-1.1-I-hLAL-dSA, thereby creating pALVIN-OVR1-I-hLAL-dSA
(see FIG. 10 for the construction schematics of
pALVIN-OVR1-I-hLAL-dSA). The construction of the retroviral vector
segment of the vector, denoted as pALVIN (aka
pAVIJCR-A395.22.3.1-KM or pALV-SIN), is described in United States
Patent Application 2008/0064862.
[0213] In addition, included is the production of LAL in accordance
with the invention using a promoter and/or vector disclosed in US
patent publication No. 2008/0064862, published Mar. 13, 2008, the
disclosure of which is incorporated in its entirety herein by
reference.
Example 2
Viral Particle Production
[0214] The G0 founder transgenic male, XLL109, carrying the hLAL
transgene in its genome, was created by using a retroviral
transgenesis method as follows. Replication-defective viral
particles carrying the pALVIN-OVR1-I-hLAL-dSA vector were produced
by transient transfection of an immortalized chicken fibroblast
cell line. These chicken fibroblast cells were simultaneously
transfected with three plasmids, pALVIN-OVR1-I-hLAL-dSA,
pCMV-gag-pol and pCMV-VSV-G. pCMV-gag-pol expresses the gag and pol
genes of RAV1 strain of the avian leukosis virus. pCMV-VSV-G
expresses the envelope protein of the vesicular stomatitis virus.
Four hours after transfection, the media was replaced with DMEM
supplemented with 10% fetal bovine serum, 100 units/mL penicillin
and 100 .mu.g/mL streptomycin. Media was harvested at 48 hours
post-transfection, filtered through a 0.45 micron filter
(Millipore) and concentrated by ultracentrifugation. Concentrated
retrovirus carrying the ALVIN-OVR1-I-hLAL-dSA transgene was
collected and used in the transduction of early stage embryos. Note
that because "p" is the notation for the plasmid form of vector,
the "p" is absent from the transgene designations once the
transgene is in the form of packaged vector or integrated
transgene.
Example 3
Embryo Transgenesis
[0215] Integration of the ALVIN-OVR1-I-hLAL-dSA expression cassette
into the genome of an embryo was achieved by transduction of early
stage embryos (Speksnijder and Ivarie, 2000). Freshly laid
fertilized White Leghorn eggs were obtained from a breeding colony.
An aperture was made in the shell to provide access to the embryo.
Seven microliters of concentrated replication deficient retrovirus
particles carrying the ALVIN-OVR1-I-hLAL-dSA expression cassette
described above were injected into the subgerminal cavity of the
embryo. Eggs were sealed with hot glue, and then incubated and
hatched under standard conditions. Progeny produced from these
injections were given individual identification markers at hatch
for identification and traceability. Blood samples from the progeny
were transgene positive when analyzed by real-time PCR for the hLAL
transgene using PCR primers specific for the hLAL coding sequence
(as described below). This gave an indication that the transgenesis
procedure was successful. The real-time PCR assay for the hLAL
transgene utilizes Taqman.RTM. chemistry (Applied Biosystems). The
forward and reverse primers were 5'-ACGACTGGCTTGCAGATGTCT-3' (SEQ
ID NO: 16) and 5'-CCCCAAATGAAGTCAAGATGCT-3' (SEQ ID NO: 17),
respectively. The Taqman.RTM. probe sequence was
5'-CCGGAATGCTCTCATGGAACACCAA-3'(SEQ ID NO: 18) and was labeled with
FAM (as the emitter) at the 5' end and Iowa Black (as the quencher)
at the 3' end. Primers, probe and 1 .mu.l of extracted DNA was
added to 30 .mu.l Taqman.RTM. Universal Master Mix (Applied
Biosystems). Control reactions included various dilutions of a
plasmid bearing the hLAL sequence and DNA from wild-type chickens
(data not shown). Standard cycling parameters were used on an
Applied Biosystems 7500 Fast Real-Time PCR System.
Example 4
Identification of G0 Founder
[0216] Semen was collected from sexually mature males and DNA was
extracted and assayed using the hLAL real-time PCR assay. The
number of transgene copies in each sample was estimated using known
standards (a plasmid bearing the hLAL gene) mixed with negative
control semen DNA. The transgene cassette DNA content in male
XLL109 was at a level that would allow transmission of the
transgene to his progeny, as estimated by real-time PCR. This
XLL109 male was the G0 transgenic founder and was bred with
non-transgenic chickens to generate the G1 hemizygotic transgenic
chickens.
Example 5
Propagation and Characterization of Hemizygotic G1 Avians
[0217] Progeny sired by the transgenic founder XLL109 were tested
for the presence of the transgene in blood cell DNA using the hLAL
real-time PCR assay. Blood was collected from 1-2 week old progeny
and DNA was extracted using a high-throughput technique (Harvey et
al., 2002). The DNA solutions were not quantified prior to the
Taqman assay to facilitate the high-throughput screen. Typically 1
.mu.l of DNA solution contains 50 to 400 ng of DNA which is
sufficient to generate a positive amplification signal. A total of
1,322 chicks sired by XLL109 were tested, and positive progeny were
re-bled and tested for confirmation. According to the PCR results,
22 progeny were positive for the ALVIN-OVR1-I-hLAL-dSA transgene.
An example of the Taqman results is shown in FIG. 11.
Example 6
Identification and Characterization of High-Expression Line
[0218] One of the G1 chickens, 1LL7466, laid eggs with
significantly higher levels of rhLAL protein in the egg white, as
compared to the other G1 chickens. Southern blot analysis was
performed on 1LL7466 and sibling G1 males to identify which sibling
males had the same integration site as the high expressing chicken.
Digests were performed with a restriction enzyme that cut only once
within the transgene (BlpI), and the Southern blots were probed
with a segment of the ovalbumin promoter or the hLAL coding
sequence (FIGS. 12A-D). The position of the 2.sup.nd restriction
site, which resides in the flanking genomic region, varies
depending on the site of integration. Thus the size of the BlpI
band detected by the OV probe or hLAL probe is unique to each line
generated.
[0219] The OV probe detected a single band of 4.1 kb in
BlpI-digested DNA from wild-type chickens, which corresponded to
the expected size of a BlpI segment within the endogenous ovalbumin
gene of the chicken genome (FIGS. 12B and 12D). A second band of
4.3 kb was detected with chicken 1LL7466, which corresponded to the
transgene band. Three additional female siblings, 1LL10409,
1LL10686 and 1LL12058 and three additional male siblings, 1LL8922,
1LL9330 and 1LL11217 displayed the 4.3 kb band, indicating that
these siblings might be of the same line (FIGS. 12B and 12D).
[0220] As expected the hLAL probe did not detect a band in DNA from
wild-type chickens as the DNA sequence of the chicken lysosomal
acid lipase gene and the coding sequence for the recombinant human
lysosomal acid lipase are sufficiently differentiated to not permit
hybridization under the conditions used in these Southern assays
(FIG. 12C). The hLAL probe detected a single band of .about.10.6 kb
in BlpI-digested genomic DNA from the same chickens that were
positive for the 4.3 kb band detected by the OV probe, indicating
that these 7 G1 chickens have the same integration site and thus
are of the same line. No other bands were detected, indicating that
1LL7466, 1LL10409, 1LL10686, 1LL12058, 1LL8922, 1LL9330 and
1LL11217 all had a single integration site.
[0221] The Southern analysis also indicated that the transgene was
integrated as the bands detected by the OV and hLAL probes were of
different sizes and greater in size than from the transgene alone.
A map showing the predicted structure of the integrated transgene
and position of BlpI sites in the flanking genomic regions is shown
in FIG. 12A.
[0222] To confirm that the transgene is intact, two steps were
taken. First, the hLAL coding sequence was isolated by PCR from
1LL7466. The PCR products were sequenced on both strands from the
hLAL start codon to the stop codon. The DNA sequence was exactly as
expected, indicating no changes in the DNA sequence of coding
regions in the transgene. Second, Southern blot analysis was
conducted using restriction enzyme ApaLI, which digests intact
transgene into 2 segments, 3.6 and 3.8 kb (FIG. 13A). Both the 3.6
and 3.8 kb bands were detected in ApaLI-digested genomic DNA from
G1s, indicating that the transgene was integrated in a fully intact
form (FIG. 13B).
Example 7
Propagation and Characterization of G2s
[0223] FIG. 14 shows the lineage of the hLAL G2s descended from a
single G0 founder, XLL109. At the G1 stage, the transgene was
characterized with regard to copy number, integrity, hLAL sequence
and integration site--and seven G1 transgenics were identified and
characterized (four chickens and three roosters). Propagation of
the G2s was accomplished by artificial insemination of
non-transgenic chickens with semen collected from the G1 sires
1LL8922, 1LL9330 and 1LL11217 (FIG. 14). Each inseminated chicken,
her eggs and subsequent progeny were housed separately from the
other progeny. Hatched progeny were tested for presence of the hLAL
transgene using the hLAL real-time PCR assay. Because G1 founders
were hemizygous with respect to the transgene, half of the progeny
were expected to be transgenic G2s. Of 610 G2 progeny analyzed to
date, 330 or 54% were transgenic.
Example 8
Genetic Analysis of the hLAL Avians
[0224] After identification of each G2 chicken by the hLAL
real-time PCR assay of blood DNA, the production line is subjected
to the following genetic assays: the hLAL gene was PCR-amplified
from blood DNA and sequenced to confirm 100% homology with the
human sequence; the transgene integration site was confirmed by
integration site PCR, as described above. The PCR sequencing and
integration site analysis was performed on: each chicken in a
<10 chicken production line; 10% of chickens (minimum 10) for
11-100 chicken production line; 5% of chickens (minimum 10) for
101-1000 chicken production line; 1% of chickens (minimum 50) for
1001-10,000 chicken production line; 0.1% of chickens (minimum 100)
for >10,001 chicken production line. Detailed records were
maintained at every step of the growing and production phase.
Example 9
Purification of hLAL from Egg White
[0225] Egg white (EW) containing LAL was solubilized at pH 6
overnight and clarified through centrifugation (or depth
filtration) with 0.2 um filtration. The EW was adjusted with 1 M
NaOAc buffer (pH 4) to pH 6.
[0226] The clarified EW was loaded onto a Phenyl-HIC column
(EW:column size=2:1) equilibrated with 20 mM phosphate/137 mM NaCl
buffer (pH 6). After the completion of loading, the column was
washed with equilibration buffer and 5 mM phosphate buffer (pH 6).
The LAL was eluted with 30% propylene glycol with 5 mM Tris buffer
(pH 7.2).
[0227] The eluted LAL fraction was adjusted to pH 5 with 1 M acid
and then loaded onto a GigaCap S column (EW:column size=10:1). The
column was equilibrated with 50 mM NaOAc buffer (pH 5). After
completion of loading, the column was washed with the equilibration
buffer. The LAL was eluted with 50 mM NaOAc/60 mM NaCl (pH 5).
[0228] The LAL fraction off the GigaCap S column was adjusted to
pH6 with 1 M Tris buffer and then loaded onto a Butyl-HIC column
(EW:column size=10:1). The column was equilibrated with 20 mM
phosphate/137 mM NaCl buffer (pH 6). After the completion of
loading, the column was washed with equilibration buffer and 5 mM
phosphate buffer (pH 6). The pure LAL was eluted with 50% propylene
glycol with 5 mM Tris buffer (pH 7.2). FIG. 15 depicts the
purification steps of hLAL from egg white.
Example 10
Carbohydrate Analysis of Transgenic Avian Derived hLAL
[0229] The oligosaccharide structures were determined for avian
derived human LAL by employing the following analysis techniques as
are well known to practitioners of ordinary skill in the art.
[0230] Two hundred micrograms were digested with trypsin and
chymotrypsin for 18 h at 37.degree. C. in 0.1 M Tris-HCl, pH 8.2,
containing 1 mM CaCl.sub.2. The digestion products were enriched
and freed of contaminants by Sep-Pak C18 cartridge column. After
enrichment, the glycopeptides were digested with 2 .mu.l of PNGaseF
(7.5 unit/ml) in 50 .mu.l of 20 mM sodium phosphate buffer, pH 7.5,
for 18 h at 37.degree. C. Released oligosaccharides were separated
from peptide and enzyme by passage through a Sep-Pak C18 cartridge
column.
[0231] The glycan fraction was dissolved in dimethylsulfoxide and
then permethylated based on the method of Anumula and Taylor
(Anumula and Taylor, 1992). The reaction was quenched by addition
of water and per-O-methylated carbohydrates were extracted with
dichloromethane. Per-O-methylated glycans were dried under a stream
of nitrogen.
[0232] MALDI/TOF-MS (Matrix assisted laser desorption ionization
time-of-flight mass spectrometry) was performed in the reflector
positive ion mode using .alpha.-dihydroxybenzoic acid (DHBA, 20
mg/mL solution in 50% methanol:water) as a matrix. All spectra were
obtained by using a Microflex LRF (Bruker).
[0233] MALDI-TOF-MS analysis and ESI MS/MS (electrospray ionization
tandem mass spectrometry) were performed on the oligosaccharides
after release from the peptide backbone and purification as is
understood in the art. Samples of the individual polysaccharide
species were also digested with certain enzymes and the digest
products were analyzed by HPLC as is understood in the art.
[0234] It is believed that there are about six N-linked
glycosylation sites present on human LAL. See, Zschenker, et al
(2005) J. Biochem., Vol 137, p 387-394, the disclosure of which is
incorporated in its entirety by reference This reference also
indicates that there may be an O-linked glycosyation site on Human
LAL. The N-linked oligosaccharide structures identified are shown
in FIG. 16.
[0235] The data revealed that many or all of these structures were
found as an N-linked Glycosylation structure in LAL produced in
accordance with the invention (FIG. 16). For example, A-n is found
attached to LAL produced in accordance with the invention. For
example, O-n is found attached to LAL produced in accordance with
the invention. For example, at least one of B-n, C-n and D-n is
found attached to LAL produced in accordance with the invention.
For example, at least one of E-n and F-n is found attached to LAL
produced in accordance with the invention. For example, at least
one of I-n and J-n is found attached to LAL produced in accordance
with the invention. For example, at least one of K-n and L-n is
found attached to LAL produced in accordance with the invention.
For example, at least one of M-n and N-n is found attached to LAL
produced in accordance with the invention. For example, G-n is
found attached to LAL produced in accordance with the invention.
For example, H-n is found attached to LAL produced in accordance
with the invention.
Example 11
N-Glycan Species of Transgenic Avian Derived LAL
[0236] Purified samples of transgenic avian derived hLAL (600
.mu.g/sample) were dialyzed using a Tube-O-Dialyzer (4.0 kDa
cut-off membrane; G BioSciences) against nanopure water at
4.degree. C. for about 24 hours to remove salts and other
contaminants. Nanopure water was replaced four times during the
entire dialysis period.
[0237] After dialysis, each of the samples was divided into three
aliquots: .about.1/4 of sample weight for neutral and amino sugars
analysis, .about.1/4 of sample weight for mannose-6-phosphate
analysis, and .about.1/2 of sample weight for oligosaccharide
profiling. The aliquot intended for neutral and amino sugars
analysis was hydrolyzed with 2 N trifluoroacetic acid (TFA) at
100.degree. C. for 4 hours and the aliquot for mannose-6-phosphate
analysis was hydrolyzed with 6.75 N TFA at 100.degree. C. for 1.5
hours. The hydrolysates were then dried under N.sub.2, redissolved
with 50 .mu.L H.sub.2O, sonicated for 7 min in ice and transferred
to an injection vial. However, the neutral and amino sugar samples
were diluted 2 times because the peaks produced from the originally
dissolved hydrolysates were too large.
[0238] A mix of standards for neutral and amino sugars, and for
mannose-6-phosphate with a known number of moles was hydrolyzed in
the same manner and at the same time as the sample. Four
concentration of the neutral and amino sugar standard mix (Fuc
& GalNAc, 0.2, 0.4, 0.8, and 1.6 nmoles per 10 .mu.L; GlcNAc,
0.5, 1.0, 2.0, and 4.0 nmoles per 10 .mu.L; Gal & Man, 0.3,
0.6, 1.2, and 2.4 nmoles per 10 .mu.L; and Glc, 0.1, 0.2, 0.4, and
0.8 nmoles per 10 .mu.L) and mannose-6-phosphate (640, 1280, 2560,
5120 picomoles per 10 .mu.L) were prepared to establish a
calibration equation. The number of moles of each sugar in the
sample was quantified by linear interpolation from the calibration
equation.
[0239] The neutral and amino sugars and mannose-6-phosphate were
analyzed by HPAEC using a Dionex ICS3000 system equipped with a
gradient pump, an electrochemical detector, and an autosampler. The
individual neutral and amino sugars, and mannose-6-phosphate were
separated by a Dionex CarboPac PA20 (3.times.150 mm) analytical
column with an amino trap. The gradient programs used eluents A,
degassed nanopure water and B, 200 mM NaOH for neutral and amino
sugars, and C, 100 mM NaOH and D, 1 M sodium acetate in 100 mM NaOH
for mannose-6-phosphate. Injection (10 .mu.L/injection) was made
every 40 minutes for neutral and amino sugar determination and
every 35 minutes for mannose-6-phosphate determination. All methods
were based on protocols described by Hardy and Townsend (Hardy, M.
R., and Townsend, R. R., "High-pH anion-exchange chromatography of
glycoprotein-derived carbohydrates", 1994, Methods Enzymol. 230:
208-225). Instrument control and data acquisition were accomplished
using Dionex chromeleon software. Results are shown in Table 1
below. The control sample is ovomucoid purified from EW.
TABLE-US-00005 TABLE 1 Monosaccharide composition of control and
LAL by HPAEC. nano- nano- Sample ID Analyte moles moles/.mu.g mole
% Control Fucose nd -- -- N-acetyl galactosamine 5.066 0.020 9.6
N-acetyl glucosamine 26.947 0.108 51.4 Galactose 3.876 0.016 7.4
Glucose nd -- -- Mannose 16.565 0.066 31.6 Mannose-6-phosphate nd
-- -- N-acetyl neuraminic acid ndm -- -- N-glycolyl neuraminic acid
ndm -- -- Transgenic Fucose nd -- -- Avian N-acetyl galactosamine
nd -- -- derived N-acetyl glucosamine 17.932 0.120 37.6 hLAL
Galactose 0.879 0.006 1.8 Glucose nd -- -- Mannose 23.290 0.155
48.8 Mannose-6-phosphate 5.642 0.038 11.8 N-acetyl neuraminic acid
ndm -- -- N-glycolyl neuraminic acid ndm -- -- nd = not detected;
ndm = not determined.
Structural Features of LAL
[0240] LAL has 6 potential sites in its amino acid sequence for
N-linked glycosylation, Asn.sup.36, Asn.sup.72, Asn.sup.101
Asn.sup.161, Asn.sup.273, and Asn.sup.321. Five of these,
Asn.sup.36, Asn.sup.101 Asn.sup.161, Asn.sup.273 and Asn.sup.321
were found to be glycosylated while Asn.sup.72 was unglycosylated
or substantially unglycosylated (substantially unglycosylated means
in a mixture of LAL molecules, fewer Asn.sup.72 are glycosylated
than any of Asn.sup.36, Asn.sup.101 Asn.sup.161, Asn.sup.273 and
Asn.sup.321). Accordingly, one aspect of the invention is LAL
(e.g., human LAL) which is unglycosylated and/or substantially
unglycosylated at Asn.sup.72, and production and use of such LAL.
However, LAL having a glycosylated Asn.sup.72 is within the scope
of the invention. The N-glycan structures primarily consist of a
mixture of bi-, tri- and tetraantennary structures with
N-acetylglucosamine, mannose and mannose-6-phosphate (M6P) as the
major sugars. Each site appears to have a favored set of structures
(Table 2 and FIG. 17) which is one aspect of the invention. For
example, M6P-modified N-glycans reside at least at Asn.sup.101
Asn.sup.161 and Asn.sup.273. The non-phosphorylated structures are
typical of N-glycans found on endogenous egg white proteins. No
O-linked glycans were detected as determined by lack of
N-acetylgalactosamine (GalNac). No sialic acid was detected which
is consistent with previously determined N-glycan structures of
other endogenous and exogenous proteins produced in accordance with
the invention. The invention includes LAL glycosylated with one or
more of the oligosaccharide structures disclosed herein.
TABLE-US-00006 TABLE 2 Site residence of LAL glycan structures as
determined by LC/MS of glycopeptides. Site Glycan structure
Asn.sup.36 GlcNAc4Man3GlcNAc2 Hex1GlcNAc4Man3GlcNAc2 Asn.sup.72
None detected Asn.sup.101 Phos2Man7GlcNAc2 Asn.sup.161
Phos1Man6GlcNAc2 GlcNAc1Phos1Man6GlcNAc2 Man3GlcNAc2
GlcNAc2Man3GlcNAc2 GlcNAc3Man3GlcNAc2 GlcNAc4Man3GlcNAc2
Hex1GlcNAc4Man3GlcNAc2 Asn.sup.273 Man7GlcNAc2 Man8GlcNAc2
Man9GlcNAc2 Phos1Man8GlcNAc2 Phos1Man9GlcNAc2 Asn.sup.321
GlcNAc2Man3GlcNAc2 GlcNAc3Man3GlcNAc2 GlcNAc4Man3GlcNAc2
Hex1GlcNAc4Man3GlcNAc2 GlcNAc5Man3GlcNAc2 Hex1GlcNAc5Man3GlcNAc2
GlcNAc6Man3GlcNAc2 Hex1GlcNAc6Man3GlcNAc2 Hex, galactose; Phos,
phosphate; Man, mannose; GlcNAc2, N-acetylglucosamine
Methods
[0241] Monosaccharide composition, including the neutrals, amino
and M6P, was determined qualitatively and quantitatively by high pH
anion exchange chromatography-pulsed amperometric detection
(HPAEC-PAD).
[0242] The structures of the predominant glycans were determined
with data from several mass spectrometry methods (MALDI-TOF,
NSI-MS/MS and glycopeptide LC-MS).
[0243] MALDI-TOF was useful for determination of neutral N-glycans
and was able to detect phosphorylated N-glycans (FIG. 18).
NSI-MS/MS was employed to determine the nature of minor peaks in
the MALDI-TOF spectra, some of which were attributed to
phosphorylated N-glycans (FIG. 19). Efforts to improve the ability
of MALDI-TOF to detect phosphorylated N-glycans were not
fruitful.
[0244] LC/MS of glycopeptides was able to detect neutral and
phosphorylated structures and was able to determine the position of
specific structures in the amino acid sequence of LAL (data
summarized in FIG. 17 and Table 2).
[0245] To determine which peaks in the HPAEC-PAD chromatogram are
due to phosphorylated N-glycans, LAL was treated with phosphatase
and analyzed (FIG. 3). Peaks in groups C and D decreased in area
under the curve (AUC) while a peak in group A became more
prominent. Peaks in group B did not change in proportion to the
other peaks. Based on the knowledge that retention time is
proportional to the degree of charge (either due to phosphorylation
or sialylation), it is contemplated that group C is composed of
N-glycans with one phosphate (mono M6P) and group D composed of
N-glycans with two phosphates (bis-M6P).
[0246] The retention time was also affected by composition and
relative structural position of the neutral and amino
monosaccharides. Such examples include the presence of galactose,
the presence of a bisecting GlcNac and the degree of GlcNac
substitution. Such factors contribute to the multiplicity of peaks
in the HPAEC-PAD chromatogram.
Example 12
In Vitro Enzyme Activity Analysis of Transgenic Avian Derived hLAL
in Egg White
[0247] Activity of Lysosomal Acid Lipase in egg white was
determined using the fluorogenic substrate
4-methylumbelliferyl-oleate assay essentially as described in Yan
et al. (2006), American Journal of Pathology, Vol. 169, No. 3, p
916-926, the disclosure of which is incorporated in its entirety
herein by reference.
[0248] A stock solution of 4-methylumbelliferyl oleate (4-MUO) was
prepared consisting of 2.5 mM 4-MUO in 4% Triton X-100. The assay
was performed in a microtiter plate each well containing 62.5 .mu.l
of 0.2 M Sodium Citrate (pH 5.5) in 0.01% Tween80, 12.5 .mu.l of
egg white sample and 25 .mu.l of the 2.5 mM 4-MUO. Change in
fluorescence was monitored for 30 minutes at 37.degree. C. using a
Bio-Tek Synergy HT fluorometric microplate reader (excitation 360
nm and emission 460 nm). Prior to assay, egg white containing the
hLAL was diluted to an enzyme concentration that resulted in the
reaction continuing linearly for at least 30 minutes. The reaction
was stopped with 50 .mu.l of 0.75 M Tris-HCl, pH 8.0 and the
endpoint fluorescence signal was measured in the same plate reader
used above (excitation 360 nm and emission 460 nm).
[0249] Units of activity were determined using 4-methylumbelliferyl
as a standard. One unit (U) is defined as the amount of enzyme
which results in the formation of 1 umole of
4-methylumbelliferyl/min under the assay conditions described
above. Non-hLAL containing egg white was used as a negative
control.
[0250] Egg white samples which were positive for hLAL contained
between 1 U and 100 U of activity per ml egg white. Egg white from
21 G1 chickens was analyzed. Egg white from 10 of the chickens
tested positive for hLAL activity.
Example 13
In Vitro Analysis of Transgenic Avian Derived LAL
[0251] The ability of LAL produced in the oviduct cells of
transgenic avians (referred to herein as "SBC-102," "avian derived
LAL," "LAL," or "hLAL") to bind to cells and be internalized to the
lysosomal compartment, was examined in vitro using macrophage and
fibroblast cells. When incubated with macrophage cells,
fluorescently-labeled SBC-102 was found to localize to the
lysosome. This effect could be attenuated by using a mannose
polysaccharide competitor, implicating the
N-acetylglucosamine/mannose (GlcNAc/mannose) receptor as a
mechanism of recognition and uptake by these cells. SBC-102
increased the cell-associated LAL activity in both LAL-deficient
human fibroblasts and normal murine fibroblasts after incubation in
vitro, indicating that exposure to SBC-102 can result in
substantial replacement of deficient enzymatic activity.
[0252] Mannose-6-phosphate (M6P) is present in the oligosaccharide
structures of SBC-102 which have been shown to be involved in the
delivery of lysosomal enzymes to a wide variety of cells types via
the ubiquitous M6P receptor.
[0253] LAL was purified from the egg white of transgenic hens.
Oregon Green NHS was obtained from Invitrogen.TM. (#0-10241). The
rat alveolar macrophage line, NR8383, and the mouse fibroblast
line, NIH-3T3, were obtained from ATCC. LAL-deficient Wolman's
fibroblasts were obtained from Coriell Institute for Medical
Research and LysoTracker.RTM. Red was obtained from
Invitrogen.TM..
[0254] Enzyme Labeling:
[0255] 4 mg of transgenic avian derived LAL in PBS was labeled with
Oregon Green, according to the manufacturer's recommendations and
reaction was subsequently dialyzed against PBS then
concentrated.
[0256] Macrophage Uptake:
[0257] Fluorescently-labeled transgenic avian derived LAL (5
.mu.g/mL) and LysoTracker.RTM. Red were incubated with NR8383 cells
for 2 hours. Cells were examined by co-focal fluorescence
microscopy using a sequential scanning mode at 488 nm and then 514
nm.
[0258] Competitive Inhibition with Mannan:
[0259] Fluorescently-labeled SBC-102 (5 ug/mL) and mannan were
incubated with NR8383 cells for 2 hours. Cells were trypsinized and
LAL uptake measured by florescence-activated cell sorting using
median fluorescence intensity as the endpoint.
[0260] The ability of transgenic avian derived LAL to be taken up
and subsequently incorporated into the lysosomes of target cells
was examined using the macrophage cell line, NR8383.
Fluorescently-labeled transgenic avian derived LAL and the
lysosomal marker, "LysoTracker.RTM. Red" (Invitrogen.TM.), were
incubated with cells for 2 hours. The co-localization of transgenic
avian derived LAL and lysosomal marker in the lysosomes of these
cells was subsequently examined by confocal fluorescence microscopy
using a sequential scanning mode (FIG. 20). The LAL demonstrated
localization to lysosomes, which is consistent with similar in
vitro studies using rhLAL from a variety of sources.
[0261] The binding specificity of transgenic avian derived LAL to
the GlcNAc/mannose receptor has been assessed by competitive
binding assays using the macrophage cell line, NR8383 (FIG. 21).
Fluorescently-labeled (Oregon Green) transgenic avian derived LAL
at 5 .mu.g/mL and various concentrations of the mannose-containing
oligosaccharide, mannan, were co-incubated with cells for 2 hours.
The relative inhibition of transgenic avian derived LAL uptake by
mannan, as compared with no mannan control, was quantified by
fluorescence-activated cell sorting analysis using median
fluorescence intensity as the endpoint. A mannose dose dependent
inhibition in transgenic avian derived LAL binding/uptake was
observed, which is consistent with transgenic avian derived LAL:
GlcNAcR interaction.
[0262] In addition, mannose-6-phosphate mediated uptake in
fibroblast cells was demonstrated by competition experiments with
mannose-6-phosphate (results not shown).
[0263] The ability of transgenic avian derived LAL exposure to
increase LAL activity in cells has been examined using both normal
and LAL-deficient cells in vitro. Fibroblasts isolated from a
Wolman's patient and normal murine fibroblasts (NIH-3T3) were
incubated in the presence of transgenic avian derived LAL at
concentrations of either 0, 0.16 or 0.5 .mu.g/mL for 5 hours. Cells
were then washed to remove non-specific signal and cell lysates
were assayed for LAL activity using 4-MUO substrate. Endogenous
cell-associated LAL activity was lower in Wolman's fibroblasts
compared to NIH-3T3 and dose-dependent increases in activity were
observed in both cell types after incubation with transgenic avian
derived LAL (FIG. 22).
Example 14
In Vivo Analysis of Transgenic Avian Derived LAL
[0264] LAL-deficient Yoshida Rats (i.e., Homozygous) (see Kuriyama
et al. (1990), Journal of Lipid Research, vol. 31, p 1605-1611;
Nakagawa et al., (1995) Journal of Lipid Research, vol. 36, p
2212-2218; and Yoshida and Kuriyama (1990) Laboratory Animal
Science, vol. 40, p 486-489) were treated with either SBC-102 (5
mg/kg, IV) or placebo, once/week for four weeks beginning at four
weeks of age. For each administration the SBC-102 was injected into
the rat tail vein in two equal doses (2.5 mg/kg) 30 minutes apart.
Rats and aged-matched wild-type controls were examined one week
after the final dose. Analyses were done in triplicate.
[0265] Gross pathologic examination of the SBC-102 treated animals
demonstrated normalization in liver color in addition to reduction
in organ size. The SBC-102 treated rats showed essentially normal
liver histology in marked contrast to the substantial accumulation
of foamy macrophages in the vehicle-treated animals (data not
presented). Serum alanine and aspartate transferase levels, which
are elevated in LAL.sup.-/- rats, were also reduced in SBC-102
treated rats (not shown).
[0266] Mass of internal organs and tissue was determined for each
rat and the data is shown in FIG. 23. Organ size is represented as
percent of body weight determined at 8 weeks of age, in LAL.sup.-/-
rats and LAL.sup.+/+ rats after weekly administration of vehicle or
SBC-102 at 5 mg/kg for 4 weeks.
[0267] Body weight of SBC-102- or vehicle-treated Yoshida rats were
compared with wild type rats, as is shown in FIG. 24. SBC-102 (5
mg/kg) or vehicle was administered by IV injection either as a
single dose or as split doses (given within 4 hour period) to
LAL.sup.-/- rats. LAL.sup.+/+ rats are age-matched littermate
controls.
Example 15
Triglyceride Analysis
[0268] Triglyceride analysis was performed on liver and spleen
tissue from wild type, homozygous placebo and homozygous SBC-102
treated animals. The triglyceride analyses were performed using
standard methodologies (i.e., MBL International's Triglyceride
Quantification Kit Catalog #JM-K622-100) and were done in
triplicate.
TABLE-US-00007 TABLE 3 Liver and Spleen Triglyceeride levels in
wild-type and LAL deficient rats Triglyceride (ug/mg wet tissue)
Wild Type Placebo SBC-102 (n = 3) (n = 3) (n = 3) Liver 48 84 57
Spleen 3 22 4
Liver Substrate Levels
[0269] FIG. 25 shows liver cholesterol, cholesteryl ester and
triglyceride levels determined at 8 weeks of age, in WT and LAL
deficient rats after weekly administration of vehicle or SBC-102 at
5 mgkg.sup.-1 for 4 weeks.
Example 16
Dose Response Study
[0270] Based on the studies performed above, the pharmacodynamic
(PD) effects of a range of doses and dose schedules (qw and qow) of
LAL ("SBC-102") were examined in LAL.sup.-/- rats. In these
studies, SBC-102 was administered by IV injections at dosages of
0.2, 1, 3 and 5 mg/kg, qow, or 0.35, 1 and 5 mg/kg, qw, for 1
month, beginning at 4 weeks of age. Results demonstrate
improvements in body weight (BW) gain (FIG. 26), organomegaly (FIG.
27), and tissue substrate levels (FIG. 28). Serum transaminase
levels were also reduced as the SBC-102 dose increased, with levels
reaching essentially wild-type levels at the higher doses.
Example 17
Administration of Recombinant LAL in a Rat Model
[0271] The effects of repeat-dosing with recombinant human
lysosomal acid lipase (LAL) on weight, tissue triglycerides and
cholesterol, hepatomegaly, splenomegaly, lymphadenopathy,
intestinal weight, and other parameters were evaluated in LAL
Deficient Donryu rats described in Yoshida and Kuriyama (1990)
Laboratory Animal Science, vol. 40, p 486-489 (see also Kuriyama et
al. (1990) Journal of Lipid Research, vol. 31, p 1605-1611;
Nakagawa et al., (1995) Journal of Lipid Research, vol. 36, p
2212-2218), the disclosure of which is incorporated in its entirety
herein by reference.
[0272] At 4 weeks of age, Donryu rats homozygous for the LAL
deletion (LAL.sup.-/-) were assigned into groups to either be dosed
with recombinant human LAL produced in a transgenic chicken oviduct
system or a saline placebo. Wild-type, age-matched, littermate rats
were used as controls. The LAL.sup.-/- rats were dosed once a week
for four weeks (four doses total) or once every two weeks for four
weeks (two doses total) by tail-vein injection as a single dose or
in two equal doses given 30 minutes apart. Doses of LAL were 1
mg/kg or 5 mg/kg. Dosing schedule is shown in Table 4. The rats
were pretreated with diphenhydramine (5 mg/kg) to counteract
potential anaphylactic reactions, a procedure which is based on
previous experiences in animal models of enzyme replacement therapy
for the treatment of lysosomal storage disease (Shull et al. (1994)
Proceedings of the National Academy of Science, vol. 91, p. 12937;
Bielicki et al. (1999) The Journal of Biological Chemistry, 274, p.
36335; Vogler et al. (1999) Pediatric Research, 45, p. 838.), the
disclosure of which is incorporated in its entirty herein by
referernce.
[0273] FIG. 29 shows the daily progress in weight gain of rats
which were administered either 1 mg/kg of LAL per week or 5 mg/kg
of LAL per week or 5 mg/kg of LAL per two weeks. It can be seen in
the figure that there is little or no difference in therapeutic
effect between the two dose sizes and frequencies.
TABLE-US-00008 TABLE 4 Weighing and Dosing Schedule Day from Birth
Assessments/Injections Performed Day 13 WEIGHED Day 14 Day 20 Day
21 Pups Weaned Day 24 Day 25 Day 27 Day 28 First Injection for
administration once every week and once every two weeks Day 31 Day
32 Day 34 Day 35 Second Injection for administration once every
week Day 38 Day 39 Day 41 Day 42 Third Injection for administration
once every week; Second administration for once every two weeks Day
45 Day 48 Day 49 Fourth injection for administration once every
week Day 55 Day 56 Necropsy
Pathologic Examination of LAL.sup.-/- Rats Treated with Recombinant
LAL
[0274] At the termination of the study described in Example 1,
study animals were humanely euthanized and necropsied to examine
gross pathology, histopathology, and clinical chemistry. The gross
necropsy included examination of the external surface of the body,
all orifices, and the cranial, thoracic, and abdominal cavities and
their contents. Mass of internal organs and tissues were determined
for the rats and the organs and tissues were harvested and fixed in
10% neutral-buffered formalin. Following fixation, the tissues were
processed and histological slides of hematoxylin and eosin-stained
sections were prepared and evaluated.
[0275] The gross pathological examination of treated animals
analyzed showed a substantial normalization in liver size and color
as can be seen in the dissection shown in FIG. 30. Organ-to-body
weight ratios were determined and demonstrated a reduction in the
relative organ size for liver, spleen, mesenteric tissue, duodenum,
jejunum and ileum in successfully treated animals which were
dissected, as compared to the placebo treated rats (FIG. 23).
Histopathology of liver tissue from LAL of treated rats analyzed
shows essentially normal liver histology in marked contrast to the
substantial accumulation of foamy macrophages in the
placebo-treated animals (FIG. 30).
Example 18
Treatment of Wolman Disease (WD) by Administration of Recombinant
LAL
[0276] At 7 weeks of age a female patient is admitted to the
hospital because of difficulty in weight gain and poor progress
since birth. At the initial physical examination the patient weighs
3.6 kg (birth weight 3.7 kg) and is thin, with loose skin folds.
The abdomen is distended, with firm hepatomegaly of 6 cm and firm
splenomegaly of about 4 cm. Enlarged lymph nodes are noted in the
groin and muscular activity is weak.
[0277] The initial hemoglobin level is 9.2 gm, platelets 506,000,
and white blood cells 11,550. Urinalysis is normal, and bone marrow
smears reveal vacuolated lymphocytes and numerous foam cells. Serum
chemical measurements: total lipids 834 mg/100 ml, phospholipids
176 mg/100 ml, triglycerides 141 mg/100 ml, cholesterol 129 mg/100
ml, bilirubin 0.3 mg/100 ml, alkaline phosphatase 9.0 BU %, SGOT 90
units, SGPT 50 units, cholinesterase 20 units, urea nitrogen 8.3
mg, fasting sugar 45 mg/100 ml. CT scan of the abdomen shows
hepatosplenomegaly and bilateral symmetrically enlarged adrenal
glands with calcification.
[0278] The patient is surgically implanted with a venous vascular
access port for dosing. After connecting the port to an ambulatory
infusion machine, the patient is pretreated with 1 mg/kg of
diphenhydramine 20 minutes prior to LAL infusion in order to
counteract potential anaphylactic infusion reactions. The patient
is then administered LAL at 1 mg/kg over the course of 5 hours by
intravenous infusion. This therapy is repeated one time every 7
days indefinitely.
[0279] Within two weeks of administering the first dose of LAL, the
patient experiences a significant improvement in weight gain and
normalization in size of key abdominal organs as determined by
ultrasound. Laboratory results demonstrate that infusion of the LAL
restores lysosomal acid lipase activity in the patient and leads to
correction of related abnormalities.
Example 19
Treatment of Cholesteryl Ester Storage Disease (CESD) by
Administration of Recombinant LAL
[0280] A 3-year-old boy with a pruritic abdominal rash is examined
by his pediatrician. Upon abdominal examination, hepatomegaly is
noted by the physician and confirmed by ultrasound. At this point
no diagnosis is made and the patient is monitored periodically.
[0281] At age 8, he is admitted to the hospital with
gastroenteritis. Light microscopy of a liver biopsy shows increased
intracytoplasmic glycogen and small lipid droplets in hepatocytes.
Electron microscopy shows membrane-bound lipid droplets with small
electron dense granules. A working diagnosis of glycogen storage
disease type III (DeBrancher disease) is made, but skin fibroblast
Debrancher activity is normal.
[0282] At age 10, hepatomegaly persists and a second liver biopsy
is taken. Light microscopy shows altered lobular architecture of
the hepatic parenchyma with distended hepatocytes containing
cytoplasmic granules and vacuoles with mild periportal fibrosis.
Fibroblast acid lipase activity is found to be 7% of normal,
confirming the diagnosis of CESD. Plasma concentrations of total
cholesterol (TC), triglycerides (TG), low-density lipoprotein
cholesterol (LDL-C) are each above the 95th percentile for age and
sex at 7.51, 3.24 and 5.58 mmol/L, respectively, while plasma
high-density lipoprotein cholesterol (HDL-C) is below the 5th
percentile at 0.47 mmol/L; he has combined hyperlipidemia
(hypercholesterolemia, hypertriglyceridemia,
hypoalphalipoproteinemia and hyperbetalipoproteinemia).
[0283] The patient is surgically implanted with a venous vascular
access port for dosing. After connecting the port to an ambulatory
infusion machine, the patient is pretreated with 5 mg/kg of
diphenhydramine 20 minutes prior to LAL infusion in order to
counteract potential anaphylactic infusion reactions. The patient
is then administered LAL at 5 mg/kg over the course of 5 hours by
intravenous infusion. This therapy is repeated one time every 14
days indefinitely.
[0284] Within two weeks of administering the first dose of LAL, the
patient experiences a significant improvement in weight gain and
normalization in size of key organs as determined by ultrasound.
Laboratory results demonstrate that infusion of the LAL restores
lysosomal acid lipase activity in the patient and leads to
correction of related abnormalities.
Example 20
Description and Composition of the Medicinal Product
[0285] The drug substance of LAL described herein ("SBC-102") is a
recombinant human lysosomal acid lipase (rhLAL) purified from the
egg white produced from transgenic Gallus. The excipients used in
SBC-102 are similar to those used for other products for lysosomal
storage disorders (LSD) currently on the market, and have been
selected to maintain stability of the drug product.
[0286] SBC-102 is a clear, colorless, sterile liquid provided in a
clear, Type I borosilicate glass vial with a non-natural latex
(butyl), FluroTec.RTM.-coated stopper and aluminum crimp seal.
SBC-102 is provided as an aqueous solution comprised of SBC-102 (2
mg/mL), Trisodium Citrate Dihydrate (13.7 mg/mL, USP), Citric Acid
Monohydrate (1.57 mg/mL, USP), Human Serum Albumin (10 mg/mL, USP),
and Water for Injection (to final volume, USP). The pH of SBC-102
is 5.9.+-.0.2. SBC-102 contains no preservatives and vials are
intended for single use only.
TABLE-US-00009 TABLE 5 Excipients in SBC-102 (LAL) Excipent CAS
number Grade Function Trisodium Citrate 6132-04-03 USP Buffer
Dihydrate Citric Acid Monohydrate 5949-29-1 USP Buffer Human Serum
Albumin 70024-90-7 USP Stabilizer
Components of the Drug Product
TABLE-US-00010 [0287] TABLE 6 Formulation of SBC-102 Component
Concentration SBC-102 (rhLAL) 2 mg/mL* Trisodium Citrate Dihydrate
13.7 mg/mL Citric Acid Monohydrate 1.57 mg/mL Human Serum Albumin
10 mg/mL Water for Injection, QS to 1.0 mL
[0288] Each example in the above specification is provided by way
of explanation of the invention, not limitation of the invention.
In fact, it will be apparent to those skilled in the art that
various modifications, combinations, additions, deletions and
variations can be made in the present invention without departing
from the scope or spirit of the invention. For instance, features
illustrated or described as part of one embodiment can be used in
another embodiment to yield a still further embodiment. It is
intended that the present invention cover such modifications,
combinations, additions, deletions, and variations.
[0289] All documents (e.g., U.S. patents, U.S. patent applications,
publications) cited in the above specification are incorporated
herein by reference. Various modifications and variations of the
present invention will be apparent to those skilled in the art
without departing from the scope and spirit of the invention.
[0290] While this invention has been particularly shown and
described with references to example embodiments thereof, it will
be understood by those skilled in the art that various changes in
form and details may be made therein without departing from the
scope of the invention encompassed by the appended claims.
Sequence CWU 1
1
201399PRTHOMO SAPIENS 1Met Lys Met Arg Phe Leu Gly Leu Val Val Cys
Leu Val Leu Trp Thr 1 5 10 15 Leu His Ser Glu Gly Ser Gly Gly Lys
Leu Thr Ala Val Asp Pro Glu 20 25 30 Thr Asn Met Asn Val Ser Glu
Ile Ile Ser Tyr Trp Gly Phe Pro Ser 35 40 45 Glu Glu Tyr Leu Val
Glu Thr Glu Asp Gly Tyr Ile Leu Cys Leu Asn 50 55 60 Arg Ile Pro
His Gly Arg Lys Asn His Ser Asp Lys Gly Pro Lys Pro 65 70 75 80 Val
Val Phe Leu Gln His Gly Leu Leu Ala Asp Ser Ser Asn Trp Val 85 90
95 Thr Asn Leu Ala Asn Ser Ser Leu Gly Phe Ile Leu Ala Asp Ala Gly
100 105 110 Phe Asp Val Trp Met Gly Asn Ser Arg Gly Asn Thr Trp Ser
Arg Lys 115 120 125 His Lys Thr Leu Ser Val Ser Gln Asp Glu Phe Trp
Ala Phe Ser Tyr 130 135 140 Asp Glu Met Ala Lys Tyr Asp Leu Pro Ala
Ser Ile Asn Phe Ile Leu 145 150 155 160 Asn Lys Thr Gly Gln Glu Gln
Val Tyr Tyr Val Gly His Ser Gln Gly 165 170 175 Thr Thr Ile Gly Phe
Ile Ala Phe Ser Gln Ile Pro Glu Leu Ala Lys 180 185 190 Arg Ile Lys
Met Phe Phe Ala Leu Gly Pro Val Ala Ser Val Ala Phe 195 200 205 Cys
Thr Ser Pro Met Ala Lys Leu Gly Arg Leu Pro Asp His Leu Ile 210 215
220 Lys Asp Leu Phe Gly Asp Lys Glu Phe Leu Pro Gln Ser Ala Phe Leu
225 230 235 240 Lys Trp Leu Gly Thr His Val Cys Thr His Val Ile Leu
Lys Glu Leu 245 250 255 Cys Gly Asn Leu Cys Phe Leu Leu Cys Gly Phe
Asn Glu Arg Asn Leu 260 265 270 Asn Met Ser Arg Val Asp Val Tyr Thr
Thr His Ser Pro Ala Gly Thr 275 280 285 Ser Val Gln Asn Met Leu His
Trp Ser Gln Ala Val Lys Phe Gln Lys 290 295 300 Phe Gln Ala Phe Asp
Trp Gly Ser Ser Ala Lys Asn Tyr Phe His Tyr 305 310 315 320 Asn Gln
Ser Tyr Pro Pro Thr Tyr Asn Val Lys Asp Met Leu Val Pro 325 330 335
Thr Ala Val Trp Ser Gly Gly His Asp Trp Leu Ala Asp Val Tyr Asp 340
345 350 Val Asn Ile Leu Leu Thr Gln Ile Thr Asn Leu Val Phe His Glu
Ser 355 360 365 Ile Pro Glu Trp Glu His Leu Asp Phe Ile Trp Gly Leu
Asp Ala Pro 370 375 380 Trp Arg Leu Tyr Asn Lys Ile Ile Asn Leu Met
Arg Lys Tyr Gln 385 390 395 2378PRTHOMO SAPIENS 2Ser Gly Gly Lys
Leu Thr Ala Val Asp Pro Glu Thr Asn Met Asn Val 1 5 10 15 Ser Glu
Ile Ile Ser Tyr Trp Gly Phe Pro Ser Glu Glu Tyr Leu Val 20 25 30
Glu Thr Glu Asp Gly Tyr Ile Leu Cys Leu Asn Arg Ile Pro His Gly 35
40 45 Arg Lys Asn His Ser Asp Lys Gly Pro Lys Pro Val Val Phe Leu
Gln 50 55 60 His Gly Leu Leu Ala Asp Ser Ser Asn Trp Val Thr Asn
Leu Ala Asn 65 70 75 80 Ser Ser Leu Gly Phe Ile Leu Ala Asp Ala Gly
Phe Asp Val Trp Met 85 90 95 Gly Asn Ser Arg Gly Asn Thr Trp Ser
Arg Lys His Lys Thr Leu Ser 100 105 110 Val Ser Gln Asp Glu Phe Trp
Ala Phe Ser Tyr Asp Glu Met Ala Lys 115 120 125 Tyr Asp Leu Pro Ala
Ser Ile Asn Phe Ile Leu Asn Lys Thr Gly Gln 130 135 140 Glu Gln Val
Tyr Tyr Val Gly His Ser Gln Gly Thr Thr Ile Gly Phe 145 150 155 160
Ile Ala Phe Ser Gln Ile Pro Glu Leu Ala Lys Arg Ile Lys Met Phe 165
170 175 Phe Ala Leu Gly Pro Val Ala Ser Val Ala Phe Cys Thr Ser Pro
Met 180 185 190 Ala Lys Leu Gly Arg Leu Pro Asp His Leu Ile Lys Asp
Leu Phe Gly 195 200 205 Asp Lys Glu Phe Leu Pro Gln Ser Ala Phe Leu
Lys Trp Leu Gly Thr 210 215 220 His Val Cys Thr His Val Ile Leu Lys
Glu Leu Cys Gly Asn Leu Cys 225 230 235 240 Phe Leu Leu Cys Gly Phe
Asn Glu Arg Asn Leu Asn Met Ser Arg Val 245 250 255 Asp Val Tyr Thr
Thr His Ser Pro Ala Gly Thr Ser Val Gln Asn Met 260 265 270 Leu His
Trp Ser Gln Ala Val Lys Phe Gln Lys Phe Gln Ala Phe Asp 275 280 285
Trp Gly Ser Ser Ala Lys Asn Tyr Phe His Tyr Asn Gln Ser Tyr Pro 290
295 300 Pro Thr Tyr Asn Val Lys Asp Met Leu Val Pro Thr Ala Val Trp
Ser 305 310 315 320 Gly Gly His Asp Trp Leu Ala Asp Val Tyr Asp Val
Asn Ile Leu Leu 325 330 335 Thr Gln Ile Thr Asn Leu Val Phe His Glu
Ser Ile Pro Glu Trp Glu 340 345 350 His Leu Asp Phe Ile Trp Gly Leu
Asp Ala Pro Trp Arg Leu Tyr Asn 355 360 365 Lys Ile Ile Asn Leu Met
Arg Lys Tyr Gln 370 375 3376PRTHOMO SAPIENS 3Gly Lys Leu Thr Ala
Val Asp Pro Glu Thr Asn Met Asn Val Ser Glu 1 5 10 15 Ile Ile Ser
Tyr Trp Gly Phe Pro Ser Glu Glu Tyr Leu Val Glu Thr 20 25 30 Glu
Asp Gly Tyr Ile Leu Cys Leu Asn Arg Ile Pro His Gly Arg Lys 35 40
45 Asn His Ser Asp Lys Gly Pro Lys Pro Val Val Phe Leu Gln His Gly
50 55 60 Leu Leu Ala Asp Ser Ser Asn Trp Val Thr Asn Leu Ala Asn
Ser Ser 65 70 75 80 Leu Gly Phe Ile Leu Ala Asp Ala Gly Phe Asp Val
Trp Met Gly Asn 85 90 95 Ser Arg Gly Asn Thr Trp Ser Arg Lys His
Lys Thr Leu Ser Val Ser 100 105 110 Gln Asp Glu Phe Trp Ala Phe Ser
Tyr Asp Glu Met Ala Lys Tyr Asp 115 120 125 Leu Pro Ala Ser Ile Asn
Phe Ile Leu Asn Lys Thr Gly Gln Glu Gln 130 135 140 Val Tyr Tyr Val
Gly His Ser Gln Gly Thr Thr Ile Gly Phe Ile Ala 145 150 155 160 Phe
Ser Gln Ile Pro Glu Leu Ala Lys Arg Ile Lys Met Phe Phe Ala 165 170
175 Leu Gly Pro Val Ala Ser Val Ala Phe Cys Thr Ser Pro Met Ala Lys
180 185 190 Leu Gly Arg Leu Pro Asp His Leu Ile Lys Asp Leu Phe Gly
Asp Lys 195 200 205 Glu Phe Leu Pro Gln Ser Ala Phe Leu Lys Trp Leu
Gly Thr His Val 210 215 220 Cys Thr His Val Ile Leu Lys Glu Leu Cys
Gly Asn Leu Cys Phe Leu 225 230 235 240 Leu Cys Gly Phe Asn Glu Arg
Asn Leu Asn Met Ser Arg Val Asp Val 245 250 255 Tyr Thr Thr His Ser
Pro Ala Gly Thr Ser Val Gln Asn Met Leu His 260 265 270 Trp Ser Gln
Ala Val Lys Phe Gln Lys Phe Gln Ala Phe Asp Trp Gly 275 280 285 Ser
Ser Ala Lys Asn Tyr Phe His Tyr Asn Gln Ser Tyr Pro Pro Thr 290 295
300 Tyr Asn Val Lys Asp Met Leu Val Pro Thr Ala Val Trp Ser Gly Gly
305 310 315 320 His Asp Trp Leu Ala Asp Val Tyr Asp Val Asn Ile Leu
Leu Thr Gln 325 330 335 Ile Thr Asn Leu Val Phe His Glu Ser Ile Pro
Glu Trp Glu His Leu 340 345 350 Asp Phe Ile Trp Gly Leu Asp Ala Pro
Trp Arg Leu Tyr Asn Lys Ile 355 360 365 Ile Asn Leu Met Arg Lys Tyr
Gln 370 375 4373PRTHOMO SAPIENS 4Thr Ala Val Asp Pro Glu Thr Asn
Met Asn Val Ser Glu Ile Ile Ser 1 5 10 15 Tyr Trp Gly Phe Pro Ser
Glu Glu Tyr Leu Val Glu Thr Glu Asp Gly 20 25 30 Tyr Ile Leu Cys
Leu Asn Arg Ile Pro His Gly Arg Lys Asn His Ser 35 40 45 Asp Lys
Gly Pro Lys Pro Val Val Phe Leu Gln His Gly Leu Leu Ala 50 55 60
Asp Ser Ser Asn Trp Val Thr Asn Leu Ala Asn Ser Ser Leu Gly Phe 65
70 75 80 Ile Leu Ala Asp Ala Gly Phe Asp Val Trp Met Gly Asn Ser
Arg Gly 85 90 95 Asn Thr Trp Ser Arg Lys His Lys Thr Leu Ser Val
Ser Gln Asp Glu 100 105 110 Phe Trp Ala Phe Ser Tyr Asp Glu Met Ala
Lys Tyr Asp Leu Pro Ala 115 120 125 Ser Ile Asn Phe Ile Leu Asn Lys
Thr Gly Gln Glu Gln Val Tyr Tyr 130 135 140 Val Gly His Ser Gln Gly
Thr Thr Ile Gly Phe Ile Ala Phe Ser Gln 145 150 155 160 Ile Pro Glu
Leu Ala Lys Arg Ile Lys Met Phe Phe Ala Leu Gly Pro 165 170 175 Val
Ala Ser Val Ala Phe Cys Thr Ser Pro Met Ala Lys Leu Gly Arg 180 185
190 Leu Pro Asp His Leu Ile Lys Asp Leu Phe Gly Asp Lys Glu Phe Leu
195 200 205 Pro Gln Ser Ala Phe Leu Lys Trp Leu Gly Thr His Val Cys
Thr His 210 215 220 Val Ile Leu Lys Glu Leu Cys Gly Asn Leu Cys Phe
Leu Leu Cys Gly 225 230 235 240 Phe Asn Glu Arg Asn Leu Asn Met Ser
Arg Val Asp Val Tyr Thr Thr 245 250 255 His Ser Pro Ala Gly Thr Ser
Val Gln Asn Met Leu His Trp Ser Gln 260 265 270 Ala Val Lys Phe Gln
Lys Phe Gln Ala Phe Asp Trp Gly Ser Ser Ala 275 280 285 Lys Asn Tyr
Phe His Tyr Asn Gln Ser Tyr Pro Pro Thr Tyr Asn Val 290 295 300 Lys
Asp Met Leu Val Pro Thr Ala Val Trp Ser Gly Gly His Asp Trp 305 310
315 320 Leu Ala Asp Val Tyr Asp Val Asn Ile Leu Leu Thr Gln Ile Thr
Asn 325 330 335 Leu Val Phe His Glu Ser Ile Pro Glu Trp Glu His Leu
Asp Phe Ile 340 345 350 Trp Gly Leu Asp Ala Pro Trp Arg Leu Tyr Asn
Lys Ile Ile Asn Leu 355 360 365 Met Arg Lys Tyr Gln 370
51150DNAHOMO SAPIENS 5atgaaaatgc ggttcttggg gttggtggtc tgtttggttc
tctggaccct gcattccgag 60gggtccggag ggaaactgac agctgtggat cctgaaacaa
acatgaatgt cagtgaaatt 120atctcttact ggggattccc tagtgaggaa
tacctagttg agacagaaga tggatatatt 180ctgtgcctta accgaattcc
tcatgggagg aagaaccatt ctgacaaagg tcccaaacca 240gttgtcttcc
tgcaacatgg cttgctggca gattctagta actgggtcac aaaccttgcc
300aacagcagcc tgggcttcat tcttgctgat gctggttttg acgtgtggat
gggcaacagc 360agaggaaata cctggtctcg gaaacataag acactctcag
tttctcagga tgaattctgg 420gctttcagtt atgatgagat ggcaaaatat
gacctaccag cttccattaa cttcattctg 480aataagactg gccaagaaca
agtgtattat gtgggtcatt ctcaaggcac cactataggt 540tttatagcat
tttcacagat ccctgagctg gctaaaagga ttaaaatgtt ttttgccctg
600ggtcctgtgg cttccgtcgc cttctgtact agccctatgg ccaaactggg
acgactgcca 660gatcatctca ttaaggacct ctttggagac aaagaatttc
ttccccagag tgcgtttttg 720aagtggctgg gtacccacgt ttgcactcat
gtcatactga aggagctctg tggaaatctc 780tgttttcttc tgtgtggatt
taatgagaga aatttaaata tgtctagagt ggatgtgtat 840acaacacatt
ctcctgctgg aacttctgtg caaaacatgt tacactggag ccaggctgtt
900aaattccaaa agtttcaagc ctttgactgg ggaagcagtg ccaagaatta
ttttcattac 960aaccagagtt atcctcccac atacaatgtg aaggacatgc
ttgtgccgac tgcagtctgg 1020agcgggggtc acgactggct tgcagatgtc
tacgacgtca atatcttact gactcagatc 1080accaacttgg tgttccatga
gagcattccg gaatgggagc atcttgactt catttggggc 1140ctggatgccc
1150610882DNAArtificial SequencepALVIN-OVR1-I-SBC102-dSA
6ctttccccgt caagctctaa atcgggggct ccctttaggg ttccgattta gtgctttacg
60gcacctcgac cccaaaaaac ttgattaggg tgatggttca cgtagtgggc catcgccctg
120atagacggtt tttcgccctt tgacgttgga gtccacgttc tttaatagtg
gactcttgtt 180ccaaactgga acaacactca accctatctc ggtctattct
tttgatttat aagggatttt 240gccgatttcg gcctattggt taaaaaatga
gctgatttaa caaaaattta acgcgaattt 300taacaaaata ttaacgctta
caatttccat tcgccattca ggctgcgcaa ctgttgggaa 360gggcgatcgg
tgcgggcctc ttcgctatta cgccagctgg cgaaaggggg atgtgctgca
420aggcgattaa gttgggtaac gccagggttt tcccagtcac gacgttgtaa
aacgacggcc 480agtgagcgcg tattccctaa cgatcacgtc ggggtcacca
aatgaagcct tctgcttcat 540gcatgtgctc gtagtcgtca gggaatcaac
ggtccggcca tcaacccagg tgcacaccaa 600tgtggtgaat ggtcaaatgg
cgtttattgt atcgagctag gcacttaaat acaatatctc 660tgcaatgcgg
aattcagtgg ttcgtccaat ccgtccccct ccctatgcaa aagcgaaact
720actatatcct gaggggactc ctaaccgcgt acaaccgaag ccccgctttt
cgcctaaaca 780tgctattgtc ccctcagtca agccttgccc gttacaaccc
gattcgcaag ccttgccctc 840cccacattat ccgtagcatt atttcctagc
agtcatcaga gctacagaag atactctatg 900ctgtagccaa gtctacaagt
ttactattca gcgacctcct atattccgcg tgccagccga 960tcaattacca
atccaaccag ctatcacacg gaatacaaga actcgcctac gctcttcttt
1020cgggctgctt ataagcctcc tgtaattttt ttatattcct cgctcgagtc
tcttcagaat 1080ggcacagcac cgctgcagaa aaatgccagg tggactatga
actcacatcc aaaggagctt 1140gacctgatac ctgattttct tcaaacaggg
gaaacaacac aatcccacaa aacagctcag 1200agagaaacca tcactgatgg
ctacagcacc aaggtatgca atggcaatcc attcgacatt 1260catctgtgac
ctgagcaaaa tgatttatct ctccatgaat ggttgcttct ttccctcatg
1320aaaaggcaat ttccacactc acaatatgca acaaagacaa acagagaaca
attaatgtgc 1380tccttcctaa tgttaaaatt gtagtggcaa agaggagaac
aaaatctcaa gttctgagta 1440ggttttagtg attggataag aggctttgac
ctgtgagctc acctggactt catatccttt 1500tggataaaaa gtgcttttat
aactttcagg tctccgagtc tttattcatg agactgttgg 1560tttagggaca
gacccacaat gaaatgcctg gcataggaaa gggcagcaga gccttagctg
1620accttttctt gggacaagca ttgtcaaaca atgtgtgaca aaactatttg
tactgctttg 1680cacagctgtg ctgggcaggg caatccattg ccacctatcc
caggtaacct tccaactgca 1740agaagattgt tgcttactct ctctagaccc
ccaagtcaaa ccaactatgc aggtatgctg 1800acaacactat gatgacagcc
tgttctgatc aagatctcat ttgttcatgg acaatttttg 1860ttgcttgcag
ctggtcttcc attgggaaag agtgtagtat atccttctca tctgacagaa
1920aagcagaaat tctcatgctc cacacttaat ctacattgtt ttaaaccacc
ggctacttct 1980tggagaggaa aaatggcttt tataagactc acaaaacaaa
gctctgcaag tcaaatgcat 2040acaaaactgt tctgtaggtc tggaatcagg
acactatgtg gaagtcaaat agagcagctt 2100taaaaagcct ttgggatcat
tctcatctta tatttgcagc acgatactat gacagtgata 2160actgacataa
ctgcatcaat ttccttgata ttttatttgt cttaaagtac aagacataga
2220gatggacgta aagatggaca tatgactcag gtctggacag gtccgtggtc
catgtatgat 2280aaaagagatg aagggaagga gaattgagac tgtctaagaa
gggcttcagg gacgttctga 2340aggcagattt gactgaatca gatgtactgt
ccaagtctca tatgtagcaa tggaaggctg 2400atattggaga aatataaaga
aatggctgtg aactcaaagt gaccctgaac agaaaaggga 2460tatggagtta
aaataatgtc acagaactga ggtttatatg atataccatg ggctgcagag
2520ggtcagagtg ctccaccatg ggcctctctt gggctgcagg gaacttctgt
tctacacctg 2580gaacacctcc tgccctcctc cgcactgacc tcagtgtcat
cagggctgtt tctctcacat 2640tttctcactc acctctccca actaccattg
tacagcagtt gttcttacat attgctcctc 2700ctgaggtaca tctagcatcg
ttaagtcctc agacttggca aggagaatgt agatttccac 2760agtatatatg
ttttcacaaa aggaaggaga gaaacaaaag aaaatggcac tgactaaact
2820tcagctagtg gtataggaaa gtaattctgc ttaacagaga ttgcagtgat
ctctatgtat 2880gtcctgaaga attatgttgt acttttttcc cccattttta
aatcaaacag tgctttacag 2940aggtcagaat ggtttcttta ctgtttgtca
attctattat ttcaatacag aacaatagct 3000tctataactg aaatatattt
gctattgtat attatgattg tccctcgaac catgaacact 3060cctccagctg
aatttcacaa ttcctctgtc atctgccagg ccattaagtt attcatggaa
3120gatctttgag gaacactgca agttcatatc ataaacacat ttgaaattga
gtattgtttt 3180gcattgtatg gagctatgtt ttgctgtatc ctcagaataa
aagtttgtta taaagcattc 3240acacccataa aaagatagat ttaaatattc
caactatagg aaagaaagtg tgtctgctct 3300tcactctagt ctcagttggc
tccttcacat gcacgcttct ttatttctcc tattttgtca 3360agaaaataat
aggtcaagtc ttgttctcat ttatgtcctg tctagcgtgg ctcagatgca
3420cattgtacat acaagaagga tcaaatgaaa cagacttctg gtctgttact
acaaccatag 3480taataagcac actaactaat aattgctaat tatgttttcc
atctccaagg ttcccacatt 3540tttctgtttt cttaaagatc ccattatctg
gttgtaactg aagctcaatg gaacatgagc 3600aatatttccc agtcttctct
cccatccaac agtcctgatg gattagcaga acaggcagaa 3660aacacattgt
tacccagaat taaaaactaa tatttgctct ccattcaatc caaaatggac
3720ctattgaaac taaaatctaa cccaatccca
ttaaatgatt tctatggtgt caaaggtcaa 3780acttctgaag ggaacctgtg
ggtgggtcac aattcagact atatattccc cagggctcag 3840ccagtgtctg
tacatacagc tagaaagctg tattgccttt agcagtcaag ctcgaaaggt
3900aagcaactct ctggaattac cttctctcta tattagctct tacttgcacc
taaactttaa 3960aaaattaaca attattgtgc tatgtgttgt atctttaagg
gtgaagtacc tgcgtgatac 4020cccctataaa aacttctcac ctgtgtatgc
attctgcact attttattat gtgtaaaagc 4080tttgtgtttg ttttcaggag
gcttattctt tgtgcttaaa atatgttttt aatttcagaa 4140catcttatcc
tgtcgttcac tatctgatat gctttgcagt ttgcttgatt aacttctagc
4200cctacagagt gcacagagag caaaatcatg gtgttcagtg aattctgggg
agttatttta 4260atgtgaaaat tctctagaag tttaattcct gcaaagtgca
gctgctgatc actacacaag 4320ataaaaatgt ggggggtgca taaacgtata
ttcttacaat aatagataca tgtgaactta 4380tatacagaaa agaaaatgag
aaaaatgtgt gtgtgtatac tcacacacgt ggtcagtaaa 4440aacttttgag
gggtttaata cagaaaatcc aatcctgagg ccccagcact cagtacgcat
4500ataaagggct gggctctgaa ggacttctga ctttcacaga ttatataaat
ctcaggaaag 4560caactagatt catgctggct ccaaaagctg tgctttatat
aagcacactg gctatacaat 4620agttgtacag ttcagctctt tataatagaa
acagacagaa caagtataaa tcttctattg 4680gtctatgtca tgaacaagaa
ttcattcagt ggctctgttt tatagtaaac attgctattt 4740tatcatgtct
gcatttctct tctgtctgaa tgtcaccact aaaatttaac tccacagaaa
4800gtttatacta cagtacacat gcatatcttt gagcaaagca aaccatacct
gaaagtgcaa 4860tagagcagaa tatgaattac atgcgtgtct ttctcctaga
ctacatgacc ccatataaat 4920tacattcctt atctattctg ccatcaccaa
aacaaaggta aaaatacttt tgaagatcta 4980ctcatagcaa gtagtgtgca
acaaacagat atttctctac atttattttt agggaataaa 5040aataagaaat
aaaatagtca gcaagcctct gctttctcat atatctgtcc aaacctaaag
5100tttactgaaa tttgctcttt gaatttccag ttttgcaagc ctatcagatt
gtgttttaat 5160cagaggtact gaaaagtatc aatgaattct agctttcact
gaacaaaaat atgtagaggc 5220aactggcttc tgggacagtt tgctacccaa
aagacaactg aatgcaaata cataaataga 5280tttatgaata tggttttgaa
catgcacatg agaggtggat atagcaacag acacattacc 5340acagaattac
tttaaaacta cttgttaaca tttaattgcc taaaaactgc tcgtaattta
5400ctgttgtagc ctaccataga gtaccctgca tggtactatg tacagcattc
catccttaca 5460ttttcactgt tctgctgttt gctctagaca actcagagtt
caccatgaaa atgcggttct 5520tggggttggt ggtctgtttg gttctctgga
ccctgcattc cgaggggtcc ggagggaaac 5580tgacagctgt ggatccagaa
acaaacatga atgtcagtga aattatctct tactggggat 5640tccctagtga
ggaataccta gttgagacag aagatggata tattctgtgc cttaaccgaa
5700ttcctcatgg gaggaagaac cattctgaca aaggtcccaa accagttgtc
ttcctgcaac 5760atggcttgct ggcagattct agtaactggg tcacaaacct
tgccaacagc agcctgggct 5820tcattcttgc tgatgctggt tttgacgtgt
ggatgggcaa cagcagagga aatacctggt 5880ctcggaaaca taagacactc
tcagtttctc aggatgaatt ctgggctttc agttatgatg 5940agatggcaaa
atatgaccta ccagcttcca ttaacttcat tctgaataag actggccaag
6000aacaagtgta ttatgtgggt cattctcaag gcaccactat aggttttata
gcattttcac 6060agatccctga gctggctaaa aggattaaaa tgttttttgc
cctgggtcct gtggcttccg 6120tcgccttctg tactagccct atggccaaac
tgggacgact gccagatcat ctcattaagg 6180acctctttgg agacaaagaa
tttcttcccc agagtgcgtt tttgaagtgg ctgggtaccc 6240acgtttgcac
tcatgtcata ctgaaggagc tctgtggaaa tctctgtttt cttctgtgtg
6300gatttaatga gagaaattta aatatgtcta gagtggatgt gtatacaaca
cattctcctg 6360ctggaacttc tgtgcaaaac atgttacact ggagccaggc
tgttaaattc caaaagtttc 6420aagcctttga ctggggaagc agtgccaaga
attattttca ttacaaccag agttatcctc 6480ccacatacaa tgtgaaggac
atgcttgtgc cgactgcagt ctggagcggg ggtcacgact 6540ggcttgcaga
tgtctacgac gtcaatatct tactgactca gatcaccaac ttggtgttcc
6600atgagagcat tccggaatgg gagcatcttg acttcatttg gggcctggat
gccccttgga 6660ggctttataa taagattatt aatctaatga ggaaatatca
gtgattcgaa gcggccgcaa 6720gaagaaagct gaaaaactct gtcccttcca
acaagaccca gagcactgta gtatcagggg 6780taaaatgaaa agtatgttat
ctgctgcatc cagacttcat aaaagctgga gcttaatcta 6840gaaaaaaaat
cagaaagaaa ttacactgtg agaacaggtg caattcactt ttcctttaca
6900cagagtaata ctggtaactc atggatgaag gcttaaggga atgaaattgg
actcacagta 6960ctgagtcatc acactgaaaa atgcaacctg atacatcagc
agaaggttta tgggggaaaa 7020atgcagcctt ccaattaagc cagatatctg
tatgaccaag ctgctccaga attagtcact 7080caaaatctct cagattaaat
tatcaactgt caccaaccat tcctatgctg acaaggcaat 7140tgcttgttct
ctgtgttcct gatactacaa ggctcttcct gacttcctaa agatgcatta
7200taaaaatctt ataattcaca tttctcccta aactttgact caatcatggt
atgttggcaa 7260atatggtata ttactattca aattgttttc cttgtaccca
tatgtaatgg gtcttgtgaa 7320tgtgctcttt tgttccttta atcataataa
aaacatgttt aagcaaacac ttttcacttg 7380tagtatttga aggtaccgga
tctcgagccg ccttcaatgc ccccaaaacc aatccccagg 7440tttttaactc
tcccgatttt ccaagtacca tagcccgctg agagagcgcc gcggtaatgg
7500gatcccagga ccccggggaa tataagtctg agggggacgt aagcaaccct
tccttttgta 7560acagggacaa catagcccct atttccttct tagaaggaga
ggttttcccg caataggtct 7620tacacgcgga cgaaatcacc tttatgacgg
cttccatgct tgatccaccg ggcgaccgga 7680atcacgcaga gcaaccggaa
tcacgcctgg ggtggaccgc tcagtcgtcg ggcttccttc 7740ccgtcttcca
acgactctct gagttctcgg tagggtatgt tggccccctg cagtagggct
7800ccctccgacg ccactcagct tctgccctcc taagccgcag ccccctctac
tagggtcatc 7860gtccgctccc cgaataagcg agacggatga ggacaggatc
gccacgccgc ctgtggccga 7920ccactattcc ctaacgatca cgtcggggtc
accaaatgaa gccttctgct tcatgcatgt 7980gctcgtagtc gtcagggaat
caacggtccg gccatcaacc caggtgcaca ccaatgtggt 8040gaatggtcaa
atggcgttta ttgtatcgag ctaggcactt aaatacaata tctctgcaat
8100gcggaattca gtggttcgtc caatccgtgt tagacccgtc tgttgccttc
ctaacaaggc 8160acgatcatac cacgatcata ccaccttact cccaccaatc
ggcatgcacg gtgctttttc 8220tctccttata aggcatgttg ctaactcatc
gttacataag catgttgcaa gactacaaga 8280gtattgcata agactacatt
tccccctccc tatgcaaaag cgaaactact atatcctgag 8340gggactccta
accgcgtaca accgaagccc cgcttttcgc ctaaacatgc tattgtcccc
8400tcagtcaagc cttgcccgtt acaacccgat tcgcaagcct tgccctcccc
acattatccg 8460tagcattatt tcctagcagt catcagagct acagaagata
ctctatgctg tagccaagtc 8520tacaagttta ctattcagcg acctcctata
ttccgcgtgc cagccgatca attaccaatg 8580cgcgcttggc gtaatcatgg
tcatagctgt ttcctgtgtg aaattgttat ccgctcacaa 8640ttccacacaa
catacgagcc ggaagcataa agtgtaaagc ctggggtgcc taatgagtga
8700gctaactcac attaattgcg ttgcgctcac tgcccgcttt ccagtcggga
aacctgtcgt 8760gccagctgca ttaatgaatc ggccaacgcg cggggagagg
cggtttgcgt attgggcgct 8820cttccgcttc ctcgctcact gactcgctgc
gctcggtcgt tcggctgcgg cgagcggtat 8880cagctcactc aaaggcggta
atacggttat ccacagaatc aggggataac gcaggaaaga 8940acatgtgagc
aaaaggccag caaaaggcca ggaaccgtaa aaaggccgcg ttgctggcgt
9000ttttccatag gctccgcccc cctgacgagc atcacaaaaa tcgacgctca
agtcagaggt 9060ggcgaaaccc gacaggacta taaagatacc aggcgtttcc
ccctggaagc tccctcgtgc 9120gctctcctgt tccgaccctg ccgcttaccg
gatacctgtc cgcctttctc ccttcgggaa 9180gcgtggcgct ttctcatagc
tcacgctgta ggtatctcag ttcggtgtag gtcgttcgct 9240ccaagctggg
ctgtgtgcac gaaccccccg ttcagcccga ccgctgcgcc ttatccggta
9300actatcgtct tgagtccaac ccggtaagac acgacttatc gccactggca
gcagccactg 9360gtaacaggat tagcagagcg aggtatgtag gcggtgctac
agagttcttg aagtggtggc 9420ctaactacgg ctacactaga aggacagtat
ttggtatctg cgctctgctg aagccagtta 9480ccttcggaaa aagagttggt
agctcttgat ccggcaaaca aaccaccgct ggtagcggtg 9540gtttttttgt
ttgcaagcag cagattacgc gcagaaaaaa aggatctcaa gaagatcctt
9600tgatcttttc tacggggtct gacgctcagt ggaacgaaaa ctcacgttaa
gggattttgg 9660tcatgagatt atcaaaaagg atcttcacct agatcctttt
aaattaaaaa tgaagtttta 9720aatcaatcta aagtatatat gagtaaactt
ggtctgacag ttaccaatgc ttaatcagtg 9780aggcacctat ctcagcgatc
tgtctatttc gttcatccat agttgcctga ctccccgtcg 9840tgtagataac
tacgatacgg gagggcttac catctggccc cagtgctgca atgataccgc
9900gagacccacg ctcaccggct ccagatttat cagcaataaa ccagccagcc
ggaagggccg 9960agcgcagaag tggtcctgca actttatccg cctccatcca
gtctattaat tgttgccggg 10020aagctagagt aagtagttcg ccagttaata
gtttgcgcaa cgttgttgcc attgctacag 10080gcatcgtggt gtcacgctcg
tcgtttggta tggcttcatt cagctccggt tcccaacgat 10140caaggcgagt
tacatgatcc cccatgttgt gcaaaaaagc ggttagctcc ttcggtcctc
10200cgatcgttgt cagaagtaag ttggccgcag tgttatcact catggttatg
gcagcactgc 10260ataattctct tactgtcatg ccatccgtaa gatgcttttc
tgtgactggt gagtactcaa 10320ccaagtcatt ctgagaatag tgtatgcggc
gaccgagttg ctcttgcccg gcgtcaatac 10380gggataatac cgcgccacat
agcagaactt taaaagtgct catcattgga aaacgttctt 10440cggggcgaaa
actctcaagg atcttaccgc tgttgagatc cagttcgatg taacccactc
10500gtgcacccaa ctgatcttca gcatctttta ctttcaccag cgtttctggg
tgagcaaaaa 10560caggaaggca aaatgccgca aaaaagggaa taagggcgac
acggaaatgt tgaatactca 10620tactcttcct ttttcaatat tattgaagca
tttatcaggg ttattgtctc atgagcggat 10680acatatttga atgtatttag
aaaaataaac aaataggggt tccgcgcaca tttccccgaa 10740aagtgccacc
tgacgcgccc tgtagcggcg cattaagcgc ggcgggtgtg gtggttacgc
10800gcagcgtgac cgctacactt gccagcgccc tagcgcccgc tcctttcgct
ttcttccctt 10860cctttctcgc cacgttcgcc gg 1088277780DNAArtificial
SequenceProviral sequence of pALVIN-OVR1-I-SBC102-dSA 7aatgaagcct
tctgcttcat gcatgtgctc gtagtcgtca gggaatcaac ggtccggcca 60tcaacccagg
tgcacaccaa tgtggtgaat ggtcaaatgg cgtttattgt atcgagctag
120gcacttaaat acaatatctc tgcaatgcgg aattcagtgg ttcgtccaat
ccgtccccct 180ccctatgcaa aagcgaaact actatatcct gaggggactc
ctaaccgcgt acaaccgaag 240ccccgctttt cgcctaaaca tgctattgtc
ccctcagtca agccttgccc gttacaaccc 300gattcgcaag ccttgccctc
cccacattat ccgtagcatt atttcctagc agtcatcaga 360gctacagaag
atactctatg ctgtagccaa gtctacaagt ttactattca gcgacctcct
420atattccgcg tgccagccga tcaattacca atccaaccag ctatcacacg
gaatacaaga 480actcgcctac gctcttcttt cgggctgctt ataagcctcc
tgtaattttt ttatattcct 540cgctcgagtc tcttcagaat ggcacagcac
cgctgcagaa aaatgccagg tggactatga 600actcacatcc aaaggagctt
gacctgatac ctgattttct tcaaacaggg gaaacaacac 660aatcccacaa
aacagctcag agagaaacca tcactgatgg ctacagcacc aaggtatgca
720atggcaatcc attcgacatt catctgtgac ctgagcaaaa tgatttatct
ctccatgaat 780ggttgcttct ttccctcatg aaaaggcaat ttccacactc
acaatatgca acaaagacaa 840acagagaaca attaatgtgc tccttcctaa
tgttaaaatt gtagtggcaa agaggagaac 900aaaatctcaa gttctgagta
ggttttagtg attggataag aggctttgac ctgtgagctc 960acctggactt
catatccttt tggataaaaa gtgcttttat aactttcagg tctccgagtc
1020tttattcatg agactgttgg tttagggaca gacccacaat gaaatgcctg
gcataggaaa 1080gggcagcaga gccttagctg accttttctt gggacaagca
ttgtcaaaca atgtgtgaca 1140aaactatttg tactgctttg cacagctgtg
ctgggcaggg caatccattg ccacctatcc 1200caggtaacct tccaactgca
agaagattgt tgcttactct ctctagaccc ccaagtcaaa 1260ccaactatgc
aggtatgctg acaacactat gatgacagcc tgttctgatc aagatctcat
1320ttgttcatgg acaatttttg ttgcttgcag ctggtcttcc attgggaaag
agtgtagtat 1380atccttctca tctgacagaa aagcagaaat tctcatgctc
cacacttaat ctacattgtt 1440ttaaaccacc ggctacttct tggagaggaa
aaatggcttt tataagactc acaaaacaaa 1500gctctgcaag tcaaatgcat
acaaaactgt tctgtaggtc tggaatcagg acactatgtg 1560gaagtcaaat
agagcagctt taaaaagcct ttgggatcat tctcatctta tatttgcagc
1620acgatactat gacagtgata actgacataa ctgcatcaat ttccttgata
ttttatttgt 1680cttaaagtac aagacataga gatggacgta aagatggaca
tatgactcag gtctggacag 1740gtccgtggtc catgtatgat aaaagagatg
aagggaagga gaattgagac tgtctaagaa 1800gggcttcagg gacgttctga
aggcagattt gactgaatca gatgtactgt ccaagtctca 1860tatgtagcaa
tggaaggctg atattggaga aatataaaga aatggctgtg aactcaaagt
1920gaccctgaac agaaaaggga tatggagtta aaataatgtc acagaactga
ggtttatatg 1980atataccatg ggctgcagag ggtcagagtg ctccaccatg
ggcctctctt gggctgcagg 2040gaacttctgt tctacacctg gaacacctcc
tgccctcctc cgcactgacc tcagtgtcat 2100cagggctgtt tctctcacat
tttctcactc acctctccca actaccattg tacagcagtt 2160gttcttacat
attgctcctc ctgaggtaca tctagcatcg ttaagtcctc agacttggca
2220aggagaatgt agatttccac agtatatatg ttttcacaaa aggaaggaga
gaaacaaaag 2280aaaatggcac tgactaaact tcagctagtg gtataggaaa
gtaattctgc ttaacagaga 2340ttgcagtgat ctctatgtat gtcctgaaga
attatgttgt acttttttcc cccattttta 2400aatcaaacag tgctttacag
aggtcagaat ggtttcttta ctgtttgtca attctattat 2460ttcaatacag
aacaatagct tctataactg aaatatattt gctattgtat attatgattg
2520tccctcgaac catgaacact cctccagctg aatttcacaa ttcctctgtc
atctgccagg 2580ccattaagtt attcatggaa gatctttgag gaacactgca
agttcatatc ataaacacat 2640ttgaaattga gtattgtttt gcattgtatg
gagctatgtt ttgctgtatc ctcagaataa 2700aagtttgtta taaagcattc
acacccataa aaagatagat ttaaatattc caactatagg 2760aaagaaagtg
tgtctgctct tcactctagt ctcagttggc tccttcacat gcacgcttct
2820ttatttctcc tattttgtca agaaaataat aggtcaagtc ttgttctcat
ttatgtcctg 2880tctagcgtgg ctcagatgca cattgtacat acaagaagga
tcaaatgaaa cagacttctg 2940gtctgttact acaaccatag taataagcac
actaactaat aattgctaat tatgttttcc 3000atctccaagg ttcccacatt
tttctgtttt cttaaagatc ccattatctg gttgtaactg 3060aagctcaatg
gaacatgagc aatatttccc agtcttctct cccatccaac agtcctgatg
3120gattagcaga acaggcagaa aacacattgt tacccagaat taaaaactaa
tatttgctct 3180ccattcaatc caaaatggac ctattgaaac taaaatctaa
cccaatccca ttaaatgatt 3240tctatggtgt caaaggtcaa acttctgaag
ggaacctgtg ggtgggtcac aattcagact 3300atatattccc cagggctcag
ccagtgtctg tacatacagc tagaaagctg tattgccttt 3360agcagtcaag
ctcgaaaggt aagcaactct ctggaattac cttctctcta tattagctct
3420tacttgcacc taaactttaa aaaattaaca attattgtgc tatgtgttgt
atctttaagg 3480gtgaagtacc tgcgtgatac cccctataaa aacttctcac
ctgtgtatgc attctgcact 3540attttattat gtgtaaaagc tttgtgtttg
ttttcaggag gcttattctt tgtgcttaaa 3600atatgttttt aatttcagaa
catcttatcc tgtcgttcac tatctgatat gctttgcagt 3660ttgcttgatt
aacttctagc cctacagagt gcacagagag caaaatcatg gtgttcagtg
3720aattctgggg agttatttta atgtgaaaat tctctagaag tttaattcct
gcaaagtgca 3780gctgctgatc actacacaag ataaaaatgt ggggggtgca
taaacgtata ttcttacaat 3840aatagataca tgtgaactta tatacagaaa
agaaaatgag aaaaatgtgt gtgtgtatac 3900tcacacacgt ggtcagtaaa
aacttttgag gggtttaata cagaaaatcc aatcctgagg 3960ccccagcact
cagtacgcat ataaagggct gggctctgaa ggacttctga ctttcacaga
4020ttatataaat ctcaggaaag caactagatt catgctggct ccaaaagctg
tgctttatat 4080aagcacactg gctatacaat agttgtacag ttcagctctt
tataatagaa acagacagaa 4140caagtataaa tcttctattg gtctatgtca
tgaacaagaa ttcattcagt ggctctgttt 4200tatagtaaac attgctattt
tatcatgtct gcatttctct tctgtctgaa tgtcaccact 4260aaaatttaac
tccacagaaa gtttatacta cagtacacat gcatatcttt gagcaaagca
4320aaccatacct gaaagtgcaa tagagcagaa tatgaattac atgcgtgtct
ttctcctaga 4380ctacatgacc ccatataaat tacattcctt atctattctg
ccatcaccaa aacaaaggta 4440aaaatacttt tgaagatcta ctcatagcaa
gtagtgtgca acaaacagat atttctctac 4500atttattttt agggaataaa
aataagaaat aaaatagtca gcaagcctct gctttctcat 4560atatctgtcc
aaacctaaag tttactgaaa tttgctcttt gaatttccag ttttgcaagc
4620ctatcagatt gtgttttaat cagaggtact gaaaagtatc aatgaattct
agctttcact 4680gaacaaaaat atgtagaggc aactggcttc tgggacagtt
tgctacccaa aagacaactg 4740aatgcaaata cataaataga tttatgaata
tggttttgaa catgcacatg agaggtggat 4800atagcaacag acacattacc
acagaattac tttaaaacta cttgttaaca tttaattgcc 4860taaaaactgc
tcgtaattta ctgttgtagc ctaccataga gtaccctgca tggtactatg
4920tacagcattc catccttaca ttttcactgt tctgctgttt gctctagaca
actcagagtt 4980caccatgaaa atgcggttct tggggttggt ggtctgtttg
gttctctgga ccctgcattc 5040cgaggggtcc ggagggaaac tgacagctgt
ggatccagaa acaaacatga atgtcagtga 5100aattatctct tactggggat
tccctagtga ggaataccta gttgagacag aagatggata 5160tattctgtgc
cttaaccgaa ttcctcatgg gaggaagaac cattctgaca aaggtcccaa
5220accagttgtc ttcctgcaac atggcttgct ggcagattct agtaactggg
tcacaaacct 5280tgccaacagc agcctgggct tcattcttgc tgatgctggt
tttgacgtgt ggatgggcaa 5340cagcagagga aatacctggt ctcggaaaca
taagacactc tcagtttctc aggatgaatt 5400ctgggctttc agttatgatg
agatggcaaa atatgaccta ccagcttcca ttaacttcat 5460tctgaataag
actggccaag aacaagtgta ttatgtgggt cattctcaag gcaccactat
5520aggttttata gcattttcac agatccctga gctggctaaa aggattaaaa
tgttttttgc 5580cctgggtcct gtggcttccg tcgccttctg tactagccct
atggccaaac tgggacgact 5640gccagatcat ctcattaagg acctctttgg
agacaaagaa tttcttcccc agagtgcgtt 5700tttgaagtgg ctgggtaccc
acgtttgcac tcatgtcata ctgaaggagc tctgtggaaa 5760tctctgtttt
cttctgtgtg gatttaatga gagaaattta aatatgtcta gagtggatgt
5820gtatacaaca cattctcctg ctggaacttc tgtgcaaaac atgttacact
ggagccaggc 5880tgttaaattc caaaagtttc aagcctttga ctggggaagc
agtgccaaga attattttca 5940ttacaaccag agttatcctc ccacatacaa
tgtgaaggac atgcttgtgc cgactgcagt 6000ctggagcggg ggtcacgact
ggcttgcaga tgtctacgac gtcaatatct tactgactca 6060gatcaccaac
ttggtgttcc atgagagcat tccggaatgg gagcatcttg acttcatttg
6120gggcctggat gccccttgga ggctttataa taagattatt aatctaatga
ggaaatatca 6180gtgattcgaa gcggccgcaa gaagaaagct gaaaaactct
gtcccttcca acaagaccca 6240gagcactgta gtatcagggg taaaatgaaa
agtatgttat ctgctgcatc cagacttcat 6300aaaagctgga gcttaatcta
gaaaaaaaat cagaaagaaa ttacactgtg agaacaggtg 6360caattcactt
ttcctttaca cagagtaata ctggtaactc atggatgaag gcttaaggga
6420atgaaattgg actcacagta ctgagtcatc acactgaaaa atgcaacctg
atacatcagc 6480agaaggttta tgggggaaaa atgcagcctt ccaattaagc
cagatatctg tatgaccaag 6540ctgctccaga attagtcact caaaatctct
cagattaaat tatcaactgt caccaaccat 6600tcctatgctg acaaggcaat
tgcttgttct ctgtgttcct gatactacaa ggctcttcct 6660gacttcctaa
agatgcatta taaaaatctt ataattcaca tttctcccta aactttgact
6720caatcatggt atgttggcaa atatggtata ttactattca aattgttttc
cttgtaccca 6780tatgtaatgg gtcttgtgaa tgtgctcttt tgttccttta
atcataataa aaacatgttt 6840aagcaaacac ttttcacttg tagtatttga
aggtaccgga tctcgagccg ccttcaatgc 6900ccccaaaacc aatccccagg
tttttaactc tcccgatttt ccaagtacca tagcccgctg 6960agagagcgcc
gcggtaatgg gatcccagga ccccggggaa tataagtctg agggggacgt
7020aagcaaccct tccttttgta acagggacaa catagcccct atttccttct
tagaaggaga 7080ggttttcccg caataggtct tacacgcgga cgaaatcacc
tttatgacgg cttccatgct 7140tgatccaccg ggcgaccgga atcacgcaga
gcaaccggaa tcacgcctgg ggtggaccgc 7200tcagtcgtcg ggcttccttc
ccgtcttcca acgactctct gagttctcgg tagggtatgt 7260tggccccctg
cagtagggct ccctccgacg ccactcagct tctgccctcc taagccgcag
7320ccccctctac tagggtcatc gtccgctccc cgaataagcg agacggatga
ggacaggatc 7380gccacgccgc ctgtggccga ccactattcc ctaacgatca
cgtcggggtc accaaatgaa 7440gccttctgct tcatgcatgt gctcgtagtc
gtcagggaat caacggtccg gccatcaacc 7500caggtgcaca ccaatgtggt
gaatggtcaa atggcgttta ttgtatcgag ctaggcactt 7560aaatacaata
tctctgcaat gcggaattca gtggttcgtc caatccgtgt tagacccgtc
7620tgttgccttc ctaacaaggc acgatcatac cacgatcata ccaccttact
cccaccaatc 7680ggcatgcacg gtgctttttc tctccttata aggcatgttg
ctaactcatc gttacataag 7740catgttgcaa gactacaaga gtattgcata
agactacatt 7780810762DNAArtificial
SequencepALVIN-OV-1.1-I 8nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 120nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 180nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
240nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn 300nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn 360nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 420nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 480nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
540nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn 600nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn 660nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 720nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 780nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
840nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn 900nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn 960nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1020nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1080nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
1140nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn 1200nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn 1260nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1320nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1380nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
1440nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn 1500nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn 1560nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1620nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1680nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
1740nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn 1800nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn 1860nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1920nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1980nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
2040nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn 2100nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn 2160nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 2220nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 2280nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
2340nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn 2400nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn 2460nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 2520nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 2580nnnnnnnnnn
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
2640nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
nnnnnnnnnn 2700nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnttcga
agcggccgca agaagaaagc 2760tgaaaaactc tgtcccttcc aacaagaccc
agagcactgt agtatcaggg gtaaaatgaa 2820aagtatgtta tctgctgcat
ccagacttca taaaagctgg agcttaatct agaaaaaaaa 2880tcagaaagaa
attacactgt gagaacaggt gcaattcact tttcctttac acagagtaat
2940actggtaact catggatgaa ggcttaaggg aatgaaattg gactcacagt
actgagtcat 3000cacactgaaa aatgcaacct gatacatcag cagaaggttt
atgggggaaa aatgcagcct 3060tccaattaag ccagatatct gtatgaccaa
gctgctccag aattagtcac tcaaaatctc 3120tcagattaaa ttatcaactg
tcaccaacca ttcctatgct gacaaggcaa ttgcttgttc 3180tctgtgttcc
tgatactaca aggctcttcc tgacttccta aagatgcatt ataaaaatct
3240tataattcac atttctccct aaactttgac tcaatcatgg tatgttggca
aatatggtat 3300attactattc aaattgtttt ccttgtaccc atatgtaatg
ggtcttgtga atgtgctctt 3360ttgttccttt aatcataata aaaacatgtt
taagcaaaca cttttcactt gtagtatttg 3420aaggtaccgg atctcgagcc
gccttcaatg cccccaaaac caatccccag gtttttaact 3480ctcccgattt
tccaagtacc atagcccgct gagagagcgc cgcggtaatg ggatcccagg
3540accccgggga atataagtct gagggggacg taagcaaccc ttccttttgt
aacagggaca 3600acatagcccc tatttccttc ttagaaggag aggttttccc
gcaataggtc ttacacgcgg 3660acgaaatcac ctttatgacg gcttccatgc
ttgatccacc gggcgaccgg aatcacgcag 3720agcaaccgga atcacgcctg
gggtggaccg ctcagtcgtc gggcttcctt cccgtcttcc 3780aacgactctc
tgagttctcg gtagggtatg ttggccccct gcagtagggc tccctccgac
3840gccactcagc ttctgccctc ctaagccgca gccccctcta ctagggtcat
cgtccgctcc 3900ccgaataagc gagacggatg aggacaggat cgccacgccg
cctgtggccg accactattc 3960cctaacgatc acgtcggggt caccaaatga
agccttctgc ttcatgcatg tgctcgtagt 4020cgtcagggaa tcaacggtcc
ggccatcaac ccaggtgcac accaatgtgg tgaatggtca 4080aatggcgttt
attgtatcga gctaggcact taaatacaat atctctgcaa tgcggaattc
4140agtggttcgt ccaatccgtg ttagacccgt ctgttgcctt cctaacaagg
cacgatcata 4200ccacgatcat accaccttac tcccaccaat cggcatgcac
ggtgcttttt ctctccttat 4260aaggcatgtt gctaactcat cgttacataa
gcatgttgca agactacaag agtattgcat 4320aagactacat ttccccctcc
ctatgcaaaa gcgaaactac tatatcctga ggggactcct 4380aaccgcgtac
aaccgaagcc ccgcttttcg cctaaacatg ctattgtccc ctcagtcaag
4440ccttgcccgt tacaacccga ttcgcaagcc ttgccctccc cacattatcc
gtagcattat 4500ttcctagcag tcatcagagc tacagaagat actctatgct
gtagccaagt ctacaagttt 4560actattcagc gacctcctat attccgcgtg
ccagccgatc aattaccaat gcgcgcttgg 4620cgtaatcatg gtcatagctg
tttcctgtgt gaaattgtta tccgctcaca attccacaca 4680acatacgagc
cggaagcata aagtgtaaag cctggggtgc ctaatgagtg agctaactca
4740cattaattgc gttgcgctca ctgcccgctt tccagtcggg aaacctgtcg
tgccagctgc 4800attaatgaat cggccaacgc gcggggagag gcggtttgcg
tattgggcgc tcttccgctt 4860cctcgctcac tgactcgctg cgctcggtcg
ttcggctgcg gcgagcggta tcagctcact 4920caaaggcggt aatacggtta
tccacagaat caggggataa cgcaggaaag aacatgtgag 4980caaaaggcca
gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata
5040ggctccgccc ccctgacgag catcacaaaa atcgacgctc aagtcagagg
tggcgaaacc 5100cgacaggact ataaagatac caggcgtttc cccctggaag
ctccctcgtg cgctctcctg 5160ttccgaccct gccgcttacc ggatacctgt
ccgcctttct cccttcggga agcgtggcgc 5220tttctcatag ctcacgctgt
aggtatctca gttcggtgta ggtcgttcgc tccaagctgg 5280gctgtgtgca
cgaacccccc gttcagcccg accgctgcgc cttatccggt aactatcgtc
5340ttgagtccaa cccggtaaga cacgacttat cgccactggc agcagccact
ggtaacagga 5400ttagcagagc gaggtatgta ggcggtgcta cagagttctt
gaagtggtgg cctaactacg 5460gctacactag aaggacagta tttggtatct
gcgctctgct gaagccagtt accttcggaa 5520aaagagttgg tagctcttga
tccggcaaac aaaccaccgc tggtagcggt ggtttttttg 5580tttgcaagca
gcagattacg cgcagaaaaa aaggatctca agaagatcct ttgatctttt
5640ctacggggtc tgacgctcag tggaacgaaa actcacgtta agggattttg
gtcatgagat 5700tatcaaaaag gatcttcacc tagatccttt taaattaaaa
atgaagtttt aaatcaatct 5760aaagtatata tgagtaaact tggtctgaca
gttaccaatg cttaatcagt gaggcaccta 5820tctcagcgat ctgtctattt
cgttcatcca tagttgcctg actccccgtc gtgtagataa 5880ctacgatacg
ggagggctta ccatctggcc ccagtgctgc aatgataccg cgagacccac
5940gctcaccggc tccagattta tcagcaataa accagccagc cggaagggcc
gagcgcagaa 6000gtggtcctgc aactttatcc gcctccatcc agtctattaa
ttgttgccgg gaagctagag 6060taagtagttc gccagttaat agtttgcgca
acgttgttgc cattgctaca ggcatcgtgg 6120tgtcacgctc gtcgtttggt
atggcttcat tcagctccgg ttcccaacga tcaaggcgag 6180ttacatgatc
ccccatgttg tgcaaaaaag cggttagctc cttcggtcct ccgatcgttg
6240tcagaagtaa gttggccgca gtgttatcac tcatggttat ggcagcactg
cataattctc 6300ttactgtcat gccatccgta agatgctttt ctgtgactgg
tgagtactca accaagtcat 6360tctgagaata gtgtatgcgg cgaccgagtt
gctcttgccc ggcgtcaata cgggataata 6420ccgcgccaca tagcagaact
ttaaaagtgc tcatcattgg aaaacgttct tcggggcgaa 6480aactctcaag
gatcttaccg ctgttgagat ccagttcgat gtaacccact cgtgcaccca
6540actgatcttc agcatctttt actttcacca gcgtttctgg gtgagcaaaa
acaggaaggc 6600aaaatgccgc aaaaaaggga ataagggcga cacggaaatg
ttgaatactc atactcttcc 6660tttttcaata ttattgaagc atttatcagg
gttattgtct catgagcgga tacatatttg 6720aatgtattta gaaaaataaa
caaatagggg ttccgcgcac atttccccga aaagtgccac 6780ctgacgcgcc
ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga
6840ccgctacact tgccagcgcc ctagcgcccg ctcctttcgc tttcttccct
tcctttctcg 6900ccacgttcgc cggctttccc cgtcaagctc taaatcgggg
gctcccttta gggttccgat 6960ttagtgcttt acggcacctc gaccccaaaa
aacttgatta gggtgatggt tcacgtagtg 7020ggccatcgcc ctgatagacg
gtttttcgcc ctttgacgtt ggagtccacg ttctttaata 7080gtggactctt
gttccaaact ggaacaacac tcaaccctat ctcggtctat tcttttgatt
7140tataagggat tttgccgatt tcggcctatt ggttaaaaaa tgagctgatt
taacaaaaat 7200ttaacgcgaa ttttaacaaa atattaacgc ttacaatttc
cattcgccat tcaggctgcg 7260caactgttgg gaagggcgat cggtgcgggc
ctcttcgcta ttacgccagc tggcgaaagg 7320gggatgtgct gcaaggcgat
taagttgggt aacgccaggg ttttcccagt cacgacgttg 7380taaaacgacg
gccagtgagc gcgtattccc taacgatcac gtcggggtca ccaaatgaag
7440ccttctgctt catgcatgtg ctcgtagtcg tcagggaatc aacggtccgg
ccatcaaccc 7500aggtgcacac caatgtggtg aatggtcaaa tggcgtttat
tgtatcgagc taggcactta 7560aatacaatat ctctgcaatg cggaattcag
tggttcgtcc aatccgtccc cctccctatg 7620caaaagcgaa actactatat
cctgagggga ctcctaaccg cgtacaaccg aagccccgct 7680tttcgcctaa
acatgctatt gtcccctcag tcaagccttg cccgttacaa cccgattcgc
7740aagccttgcc ctccccacat tatccgtagc attatttcct agcagtcatc
agagctacag 7800aagatactct atgctgtagc caagtctaca agtttactat
tcagcgacct cctatattcc 7860gcgtgccagc cgatcaatta ccaatccaac
cagctatcac acggaataca agaactcgcc 7920tacgctcttc tttcgggctg
cttataagcc tcctgtaatt tttttatatt cctcgttaag 7980tcctcagact
tggcaaggag aatgtagatt tccacagtat atatgttttc acaaaaggaa
8040ggagagaaac aaaagaaaat ggcactgact aaacttcagc tagtggtata
ggaaagtaat 8100tctgcttaac agagattgca gtgatctcta tgtatgtcct
gaagaattat gttgtacttt 8160tttcccccat ttttaaatca aacagtgctt
tacagaggtc agaatggttt ctttactgtt 8220tgtcaattct attatttcaa
tacagaacaa tagcttctat aactgaaata tatttgctat 8280tgtatattat
gattgtccct cgaaccatga acactcctcc agctgaattt cacaattcct
8340ctgtcatctg ccaggccatt aagttattca tggaagatct ttgaggaaca
ctgcaagttc 8400atatcataaa cacatttgaa attgagtatt gttttgcatt
gtatggagct atgttttgct 8460gtatcctcag aataaaagtt tgttataaag
cattcacacc cataaaaaga tagatttaaa 8520tattccaact ataggaaaga
aagtgtgtct gctcttcact ctagtctcag ttggctcctt 8580cacatgcacg
cttctttatt tctcctattt tgtcaagaaa ataataggtc aagtcttgtt
8640ctcatttatg tcctgtctag cgtggctcag atgcacattg tacatacaag
aaggatcaaa 8700tgaaacagac ttctggtctg ttactacaac catagtaata
agcacactaa ctaataattg 8760ctaattatgt tttccatctc caaggttccc
acatttttct gttttcttaa agatcccatt 8820atctggttgt aactgaagct
caatggaaca tgagcaatat ttcccagtct tctctcccat 8880ccaacagtcc
tgatggatta gcagaacagg cagaaaacac attgttaccc agaattaaaa
8940actaatattt gctctccatt caatccaaaa tggacctatt gaaactaaaa
tctaacccaa 9000tcccattaaa tgatttctat ggtgtcaaag gtcaaacttc
tgaagggaac ctgtgggtgg 9060gtcacaattc agactatata ttccccaggg
ctcagccagt gtctgtacat acagctagaa 9120agctgtattg cctttagcag
tcaagctcga aaggtaagca actctctgga attaccttct 9180ctctatatta
gctcttactt gcacctaaac tttaaaaaat taacaattat tgtgctatgt
9240gttgtatctt taagggtgaa gtacctgcgt gataccccct ataaaaactt
ctcacctgtg 9300tatgcattct gcactatttt attatgtgta aaagctttgt
gtttgttttc aggaggctta 9360ttctttgtgc ttaaaatatg tttttaattt
cagaacatct tatcctgtcg ttcactatct 9420gatatgcttt gcagtttgct
tgattaactt ctagccctac agagtgcaca gagagcaaaa 9480tcatggtgtt
cagtgaattc tggggagtta ttttaatgtg aaaattctct agaagtttaa
9540ttcctgcaaa gtgcagctgc tgatcactac acaagataaa aatgtggggg
gtgcataaac 9600gtatattctt acaataatag atacatgtga acttatatac
agaaaagaaa atgagaaaaa 9660tgtgtgtgtg tatactcaca cacgtggtca
gtaaaaactt ttgaggggtt taatacagaa 9720aatccaatcc tgaggcccca
gcactcagta cgcatataaa gggctgggct ctgaaggact 9780tctgactttc
acagattata taaatctcag gaaagcaact agattcatgc tggctccaaa
9840agctgtgctt tatataagca cactggctat acaatagttg tacagttcag
ctctttataa 9900tagaaacaga cagaacaagt ataaatcttc tattggtcta
tgtcatgaac aagaattcat 9960tcagtggctc tgttttatag taaacattgc
tattttatca tgtctgcatt tctcttctgt 10020ctgaatgtca ccactaaaat
ttaactccac agaaagttta tactacagta cacatgcata 10080tctttgagca
aagcaaacca tacctgaaag tgcaatagag cagaatatga attacatgcg
10140tgtctttctc ctagactaca tgaccccata taaattacat tccttatcta
ttctgccatc 10200accaaaacaa aggtaaaaat acttttgaag atctactcat
agcaagtagt gtgcaacaaa 10260cagatatttc tctacattta tttttaggga
ataaaaataa gaaataaaat agtcagcaag 10320cctctgcttt ctcatatatc
tgtccaaacc taaagtttac tgaaatttgc tctttgaatt 10380tccagttttg
caagcctatc agattgtgtt ttaatcagag gtactgaaaa gtatcaatga
10440attctagctt tcactgaaca aaaatatgta gaggcaactg gcttctggga
cagtttgcta 10500cccaaaagac aactgaatgc aaatacataa atagatttat
gaatatggtt ttgaacatgc 10560acatgagagg tggatatagc aacagacaca
ttaccacaga attactttaa aactacttgt 10620taacatttaa ttgcctaaaa
actgctcgta atttactgtt gtagcctacc atagagtacc 10680ctgcatggta
ctatgtacag cattccatcc ttacattttc actgttctgc tgtttgctct
10740agacaactca gagttcacca tg 107629242DNAArtificial
SequenceAdaptor sequence 9cccgggttgt taacatttaa ttgcctaaaa
actgctcgta atttactgtt gtagcctacc 60atagagtacc ctgcatggta ctatgtacag
cattccatcc ttacattttc actgttctgc 120tgtttgctct agacaactca
gagttcacca tgaaaatgcg gttcttgggg ttggtggtct 180gtttggttct
ctggaccctg cattccgagg ggtccggagg gaaactgaca gctgtggatc 240ct
242101575DNAArtificial SequenceSyn SBC102 10ccattatctg gttgtaactg
aagctcaatg gaacatgagc aatatttccc agtcttctct 60cccatccaac agtcctgatg
gattagcaga acaggcagaa aacacattgt tacccagaat 120taaaaactaa
tatttgctct ccattcaatc caaaatggac ctattgaaac taaaatctaa
180cccaatccca ttaaatgatt tctatggtgt caaaggtcaa acttctgaag
ggaacctgtg 240ggtgggtcac aattcagact atatattccc cagggctcag
ccagtgtctg tacatacagc 300tagaaagctg tattgccttt agcagtcaag
ctcgaaagac aactcagagt tcaccatgaa 360aatgcggttc ttggggttgg
tggtctgttt ggttctctgg accctgcatt ccgaggggtc 420cggagggaaa
ctgacagctg tggatcctga aacaaacatg aatgtcagtg aaattatctc
480ttactgggga ttccctagtg aggaatacct agttgagaca gaagatggat
atattctgtg 540ccttaaccga attcctcatg ggaggaagaa ccattctgac
aaaggtccca aaccagttgt 600cttcctgcaa catggcttgc tggcagattc
tagtaactgg gtcacaaacc ttgccaacag 660cagcctgggc ttcattcttg
ctgatgctgg ttttgacgtg tggatgggca acagcagagg 720aaatacctgg
tctcggaaac ataagacact ctcagtttct caggatgaat tctgggcttt
780cagttatgat gagatggcaa aatatgacct accagcttcc attaacttca
ttctgaataa 840gactggccaa gaacaagtgt attatgtggg tcattctcaa
ggcaccacta taggttttat 900agcattttca cagatccctg agctggctaa
aaggattaaa atgttttttg ccctgggtcc 960tgtggcttcc gtcgccttct
gtactagccc tatggccaaa ctgggacgac tgccagatca 1020tctcattaag
gacctctttg gagacaaaga atttcttccc cagagtgcgt ttttgaagtg
1080gctgggtacc cacgtttgca ctcatgtcat actgaaggag ctctgtggaa
atctctgttt 1140tcttctgtgt ggatttaatg agagaaattt aaatatgtct
agagtggatg tgtatacaac 1200acattctcct gctggaactt ctgtgcaaaa
catgttacac tggagccagg ctgttaaatt 1260ccaaaagttt caagcctttg
actggggaag cagtgccaag aattattttc attacaacca 1320gagttatcct
cccacataca atgtgaagga catgcttgtg ccgactgcag tctggagcgg
1380gggtcacgac tggcttgcag atgtctacga cgtcaatatc ttactgactc
agatcaccaa 1440cttggtgttc catgagagca ttccggaatg ggagcatctt
gacttcattt ggggcctgga 1500tgccccttgg aggctttata ataagattat
taatctaatg aggaaatatc agtgattcga 1560agcggccgcc ccggg
1575112789DNAArtificial SequenceOVR1 promoter 11ctcgagtctc
ttcagaatgg cacagcaccg ctgcagaaaa atgccaggtg gactatgaac 60tcacatccaa
aggagcttga cctgatacct gattttcttc aaacagggga aacaacacaa
120tcccacaaaa cagctcagag agaaaccatc actgatggct acagcaccaa
ggtatgcaat 180ggcaatccat tcgacattca tctgtgacct gagcaaaatg
atttatctct ccatgaatgg 240ttgcttcttt ccctcatgaa aaggcaattt
ccacactcac aatatgcaac aaagacaaac 300agagaacaat taatgtgctc
cttcctaatg ttaaaattgt agtggcaaag aggagaacaa 360aatctcaagt
tctgagtagg ttttagtgat tggataagag gctttgacct gtgagctcac
420ctggacttca tatccttttg gataaaaagt gcttttataa ctttcaggtc
tccgagtctt 480tattcatgag actgttggtt tagggacaga cccacaatga
aatgcctggc ataggaaagg 540gcagcagagc cttagctgac cttttcttgg
gacaagcatt gtcaaacaat gtgtgacaaa 600actatttgta ctgctttgca
cagctgtgct gggcagggca atccattgcc acctatccca 660ggtaaccttc
caactgcaag aagattgttg cttactctct ctagaccccc aagtcaaacc
720aactatgcag gtatgctgac aacactatga tgacagcctg ttctgatcaa
gatctcattt 780gttcatggac aatttttgtt gcttgcagct ggtcttccat
tgggaaagag tgtagtatat 840ccttctcatc tgacagaaaa gcagaaattc
tcatgctcca cacttaatct acattgtttt 900aaaccaccgg ctacttcttg
gagaggaaaa atggctttta taagactcac aaaacaaagc 960tctgcaagtc
aaatgcatac aaaactgttc tgtaggtctg gaatcaggac actatgtgga
1020agtcaaatag agcagcttta aaaagccttt gggatcattc tcatcttata
tttgcagcac 1080gatactatga cagtgataac tgacataact gcatcaattt
ccttgatatt ttatttgtct 1140taaagtacaa gacatagaga tggacgtaaa
gatggacata tgactcaggt ctggacaggt 1200ccgtggtcca tgtatgataa
aagagatgaa gggaaggaga attgagactg tctaagaagg 1260gcttcaggga
cgttctgaag gcagatttga ctgaatcaga tgtactgtcc aagtctcata
1320tgtagcaatg gaaggctgat attggagaaa tataaagaaa tggctgtgaa
ctcaaagtga 1380ccctgaacag aaaagggata tggagttaaa ataatgtcac
agaactgagg tttatatgat 1440ataccatggg ctgcagaggg tcagagtgct
ccaccatggg cctctcttgg gctgcaggga 1500acttctgttc tacacctgga
acacctcctg ccctcctccg cactgacctc agtgtcatca 1560gggctgtttc
tctcacattt tctcactcac ctctcccaac taccattgta cagcagttgt
1620tcttacatat tgctcctcct gaggtacatc tagcatcgtt aagtcctcag
acttggcaag 1680gagaatgtag atttccacag tatatatgtt ttcacaaaag
gaaggagaga aacaaaagaa 1740aatggcactg actaaacttc agctagtggt
ataggaaagt aattctgctt aacagagatt 1800gcagtgatct ctatgtatgt
cctgaagaat tatgttgtac ttttttcccc catttttaaa 1860tcaaacagtg
ctttacagag gtcagaatgg tttctttact gtttgtcaat tctattattt
1920caatacagaa caatagcttc tataactgaa atatatttgc tattgtatat
tatgattgtc 1980cctcgaacca tgaacactcc tccagctgaa tttcacaatt
cctctgtcat ctgccaggcc 2040attaagttat tcatggaaga tctttgagga
acactgcaag ttcatatcat aaacacattt 2100gaaattgagt attgttttgc
attgtatgga gctatgtttt gctgtatcct cagaataaaa 2160gtttgttata
aagcattcac acccataaaa agatagattt
aaatattcca actataggaa 2220agaaagtgtg tctgctcttc actctagtct
cagttggctc cttcacatgc acgcttcttt 2280atttctccta ttttgtcaag
aaaataatag gtcaagtctt gttctcattt atgtcctgtc 2340tagcgtggct
cagatgcaca ttgtacatac aagaaggatc aaatgaaaca gacttctggt
2400ctgttactac aaccatagta ataagcacac taactaataa ttgctaatta
tgttttccat 2460ctccaaggtt cccacatttt tctgttttct taaagatccc
attatctggt tgtaactgaa 2520gctcaatgga acatgagcaa tatttcccag
tcttctctcc catccaacag tcctgatgga 2580ttagcagaac aggcagaaaa
cacattgtta cccagaatta aaaactaata tttgctctcc 2640attcaatcca
aaatggacct attgaaacta aaatctaacc caatcccatt aaatgatttc
2700tatggtgtca aaggtcaaac ttctgaaggg aacctgtggg tgggtcacaa
ttcagactat 2760atattcccca gggctcagcc agtgtctgt
27891220DNAArtificial SequenceSynthetic oligonucleotide
12agaaactgag agtgtcttat 201329DNAArtificial SequenceSynthetic
oligonucleotide 13tgacagctgt ggatccagaa acaaacatg
291429DNAArtificial SequenceSynthetic oligonucleotide 14gccgctcgag
cgaggaatat aaaaaaatt 291520DNAArtificial SequenceSynthetic
oligonucleotide 15tccgcgcaca tttccccgaa 201621DNAArtificial
SequenceSynthetic oligonucleotide 16acgactggct tgcagatgtc t
211722DNAArtificial SequenceSynthetic oligonucleotide 17ccccaaatga
agtcaagatg ct 221825DNAArtificial SequenceSynthetic oligonucleotide
18ccggaatgct ctcatggaac accaa 2519372PRTHOMO SAPIENS 19Ala Val Asp
Pro Glu Thr Asn Met Asn Val Ser Glu Ile Ile Ser Tyr 1 5 10 15 Trp
Gly Phe Pro Ser Glu Glu Tyr Leu Val Glu Thr Glu Asp Gly Tyr 20 25
30 Ile Leu Cys Leu Asn Arg Ile Pro His Gly Arg Lys Asn His Ser Asp
35 40 45 Lys Gly Pro Lys Pro Val Val Phe Leu Gln His Gly Leu Leu
Ala Asp 50 55 60 Ser Ser Asn Trp Val Thr Asn Leu Ala Asn Ser Ser
Leu Gly Phe Ile 65 70 75 80 Leu Ala Asp Ala Gly Phe Asp Val Trp Met
Gly Asn Ser Arg Gly Asn 85 90 95 Thr Trp Ser Arg Lys His Lys Thr
Leu Ser Val Ser Gln Asp Glu Phe 100 105 110 Trp Ala Phe Ser Tyr Asp
Glu Met Ala Lys Tyr Asp Leu Pro Ala Ser 115 120 125 Ile Asn Phe Ile
Leu Asn Lys Thr Gly Gln Glu Gln Val Tyr Tyr Val 130 135 140 Gly His
Ser Gln Gly Thr Thr Ile Gly Phe Ile Ala Phe Ser Gln Ile 145 150 155
160 Pro Glu Leu Ala Lys Arg Ile Lys Met Phe Phe Ala Leu Gly Pro Val
165 170 175 Ala Ser Val Ala Phe Cys Thr Ser Pro Met Ala Lys Leu Gly
Arg Leu 180 185 190 Pro Asp His Leu Ile Lys Asp Leu Phe Gly Asp Lys
Glu Phe Leu Pro 195 200 205 Gln Ser Ala Phe Leu Lys Trp Leu Gly Thr
His Val Cys Thr His Val 210 215 220 Ile Leu Lys Glu Leu Cys Gly Asn
Leu Cys Phe Leu Leu Cys Gly Phe 225 230 235 240 Asn Glu Arg Asn Leu
Asn Met Ser Arg Val Asp Val Tyr Thr Thr His 245 250 255 Ser Pro Ala
Gly Thr Ser Val Gln Asn Met Leu His Trp Ser Gln Ala 260 265 270 Val
Lys Phe Gln Lys Phe Gln Ala Phe Asp Trp Gly Ser Ser Ala Lys 275 280
285 Asn Tyr Phe His Tyr Asn Gln Ser Tyr Pro Pro Thr Tyr Asn Val Lys
290 295 300 Asp Met Leu Val Pro Thr Ala Val Trp Ser Gly Gly His Asp
Trp Leu 305 310 315 320 Ala Asp Val Tyr Asp Val Asn Ile Leu Leu Thr
Gln Ile Thr Asn Leu 325 330 335 Val Phe His Glu Ser Ile Pro Glu Trp
Glu His Leu Asp Phe Ile Trp 340 345 350 Gly Leu Asp Ala Pro Trp Arg
Leu Tyr Asn Lys Ile Ile Asn Leu Met 355 360 365 Arg Lys Tyr Gln 370
20399PRTHOMO SAPIENS 20Met Lys Met Arg Phe Leu Gly Leu Val Val Cys
Leu Val Leu Trp Thr 1 5 10 15 Leu His Ser Glu Gly Ser Gly Gly Lys
Leu Thr Ala Val Asp Pro Glu 20 25 30 Thr Asn Met Asn Val Ser Glu
Ile Ile Ser Tyr Trp Gly Phe Pro Ser 35 40 45 Glu Glu Tyr Leu Val
Glu Thr Glu Asp Gly Tyr Ile Leu Cys Leu Asn 50 55 60 Arg Ile Pro
His Gly Arg Lys Asn His Ser Asp Lys Gly Pro Lys Pro 65 70 75 80 Val
Val Phe Leu Gln His Gly Leu Leu Ala Asp Ser Ser Asn Trp Val 85 90
95 Thr Asn Leu Ala Asn Ser Ser Leu Gly Phe Ile Leu Ala Asp Ala Gly
100 105 110 Phe Asp Val Trp Met Gly Asn Ser Arg Gly Asn Thr Trp Ser
Arg Lys 115 120 125 His Lys Thr Leu Ser Val Ser Gln Asp Glu Phe Trp
Ala Phe Ser Tyr 130 135 140 Asp Glu Met Ala Lys Tyr Asp Leu Pro Ala
Ser Ile Asn Phe Ile Leu 145 150 155 160 Asn Lys Thr Gly Gln Glu Gln
Val Tyr Tyr Val Gly His Ser Gln Gly 165 170 175 Thr Thr Ile Gly Phe
Ile Ala Phe Ser Gln Ile Pro Glu Leu Ala Lys 180 185 190 Arg Ile Lys
Met Phe Phe Ala Leu Gly Pro Val Ala Ser Val Ala Phe 195 200 205 Cys
Thr Ser Pro Met Ala Lys Leu Gly Arg Leu Pro Asp His Leu Ile 210 215
220 Lys Asp Leu Phe Gly Asp Lys Glu Phe Leu Pro Gln Ser Ala Phe Leu
225 230 235 240 Lys Trp Leu Gly Thr His Val Cys Thr His Val Ile Leu
Lys Glu Leu 245 250 255 Cys Gly Asn Leu Cys Phe Leu Leu Cys Gly Phe
Asn Glu Arg Asn Leu 260 265 270 Asn Met Ser Arg Val Asp Val Tyr Thr
Thr His Ser Pro Ala Gly Thr 275 280 285 Ser Val Gln Asn Met Leu His
Trp Ser Gln Ala Val Lys Phe Gln Lys 290 295 300 Phe Gln Ala Phe Asp
Trp Gly Ser Ser Ala Lys Asn Tyr Phe His Tyr 305 310 315 320 Asn Gln
Ser Tyr Pro Pro Thr Tyr Asn Val Lys Asp Met Leu Val Pro 325 330 335
Thr Ala Val Trp Ser Gly Gly His Asp Trp Leu Ala Asp Val Tyr Asp 340
345 350 Val Asn Ile Leu Leu Thr Gln Ile Thr Asn Leu Val Phe His Glu
Ser 355 360 365 Ile Pro Glu Trp Glu His Leu Asp Phe Ile Trp Gly Leu
Asp Ala Pro 370 375 380 Trp Arg Leu Tyr Asn Lys Ile Ile Asn Leu Met
Arg Lys Tyr Gln 385 390 395
* * * * *